Beruflich Dokumente
Kultur Dokumente
Von E. KUSS
Herrn Professor Dr. Dr. L Trautschold, dem Organisator und Moderator dieser Konferenz,
zum ehrenden Andenken
Zusammenfassung: Es werden die grundlegenden Begriffe, Symbole und Formeln reversibler Assoziationsre-
aktionen am Beispiel von Immunreaktionen zusammenfassend und im Hinblick auf ihre Anwendung im
Bereich der Analytik dargestellt (Kapitel 1). Die Enthalpien und Entropien der Aktivierung und Reaktion
werden unter Berücksichtigung der Ergebnisse neuerer Untersuchungen gedeutet (Kapitel 2). Die gängigen,
auch in den üblichen klinisch-chemischen Laboratorien durchführbaren Verfahren zur Ermittlung physika-
lisch-chemischer Kenngrößen auch komplexer Assoziationsreaktionen werden diskutiert (Kapitel 3); zur
Auswertung der Meßdaten wird auf die kürzlich in dieser Zeitschrift erschienene Übersicht verwiesen (E.
KUSS, J. Clin. Chem. Clin. Biochem. 20, 227-234 (1982)). Die Anwendung physikalisch-chemischer Kenn-
größen in der analytischen Praxis wird an Beispielen aufgezeigt (Kapitel 4).
]
) Presented at the Kleinkonferenz „Immunologische Diagnostik" der Deutschen Gesellschaft für Klinische Chemie, Hamburg, Juni
1983. t
plex wird auf einige 0,1 nm gesch tzt. Sterische und (Gl. 2a) p, = [Pi] + [PiQj
funktionale Komplementarit t bedingen sich gegen-
seitig, da die molekularen attraktiven Kr fte nur
ber kurze Distanzen wirken (1—8). l +Σ
lf
V J^-ai
Die physikalisch chemischen Aspekte der Immunre- £*
a=l *
aktion werden auf die Analytik ausgerichtet, die der
Charakterisierung der zwei Gruppen von „Reaktan- (Gl. 2b) q, = [QJ + [Ρφ
den", „Bindungsklassen" oder „Bindungsordnun-
gen"
Pi mit den „Ordnungen" i = l, 2, ... m; l +i Σ
=l ή
Qj mit den „Ordnungen" j = l, 2, ... n; Σ Kai [Qa],
Pi P2 Pm
n
P, + Σ P,Qj = p, P2 + Σ P2Qj = p2 Pm + Σ PmQj == Pm
j-i
Abb. 1. Reaktionsmatrix.
In den Reaktionsansätzen, die als thermodynami- chungen und Ableitungen folgender Art (Beispiel
sche Systeme mit konstantem Druck und konstanter P*, markiertes Antigen; für Q*, markierte Antikör-
Temperatur betrachtet werden, können P\ und/oder per, kann Analoges definiert werden):
Qj hinsichtlich ihrer Mengen und Affinitäten regel-
mäßig oder unregelmäßig verteilt sein. Als regelmä-
ßig wird eine Verteilung bezeichnet, wenn sich die [P*] = F; [P*Q] = B; p* m [P*] + [P*Q] ;
Mengen symmetrisch um eine Menge mittlerer Affi-
nität verteilen. B B R =B
F ' T ~~ l + R ; " q
Beispiel für regelmäßige Verteilung:
a) monoklonale Antikörper; identische Molekülspezies Qj mit F freie Bindungsplätze;
Anti Pj-Aktivität B besetzte Bindungsplätze;
b) polyklonale Antikörper mit Causs- oder Sips- Verteilung der n T Gesamtzahl der eingesetzten Bindungsplätze
verschiedenen Affinitäten der verschiedenen Molekülspezies R Response, Wirkung einer bestimmten Dosis p oder q auf die
Qj mit Anti Pj-Aktivitäten (9). Verteilung des „Indikators"
r Anteil der besetzten Bindungsplätze an der Gesamtzahl der
Beispiel für unregelmäßige multimodale Verteilung: Bindungsplätze (r' s B/p).
n diskrete Antikörper-Ordnungen Qj mit Anti-Pj-Aklivitäten
(10).
wegen kann Gleichung 3 zur Deutung, Gleichung 4 rungswinkel der Reaktanden Pj und Qj. Von Protein-
zur Bestimmung der unbekannten Parameter heran- Bindungsreaktionen wird angenommen, daß sich die
gezogen werden (11, 13, 14). Aktivierungsentropie ASAkt nicht wesentlich von der
Reaktionsentropie 8 (siehe Gleichung 5) unter-
ASAi A scheidet, d.h., daß die Entropie von PjQj* der Entn>
kT R RT pie von PjQj etwa gleich ist. Die wenigen bisher vor-
(Gl. 3) k = -^e
liegenden experimentellen Befunde sind nicht ganz
einheitlich. Aus der Tatsache, daß k+i kaum tempe^
RT raturabhängig ist und zumeist nicht wesentlich unter
(Gl. 4) k = A exp e
den für diffusionskontrollierte Reaktionen zu erwar-
In k = In Aexp - -^
1 1 1 A EeXp
bt/rAemws-Gleichung tenden Werten liegt (109 l mol""^"1), wurde ge-
schlossen, daß zur Assoziation von Liganden an Pro-
k + n j oder k-uj von Gleichung l
teine keine großen Aktivierungsenergien benötigt
Planck-Wirkungsquantum 6,6 x 10~34 Js werden (13, 14); Beispiele für offenbar nicht-diffu-
Entropie der Aktivierung sionskontrollierte Assoziationsreaktion siehe z.B.
AHAki: Enthalpie der Aktivierung I.e. (6), (15). Die Aktivierungsenergie zur Dissozia-
Aexp: Präexponentialfaktor
ECxP: experimentelle Aktivierungsenergie tion steroidaler Haptene von Antikörpern lag mit
ic, T, e, R: s. Gl. l, Legende 42—63 kJ/mol (10—15 kcal/mol) deutlich unter dem
für die Dissoziation von Cortisol-Transcortin gemes-
senen Wert von 151 kJ/mol (36 kcal/mol). Für die-
Zur Ermittlung Von Aexp und Eexp werden im allge- sen Komplex ist auch eine relativ hohe Aktivie-
meinen die Werte der Reaktions-Geschwindigkeits- rungsenergie der Assoziation gemessen worden (109
konstanten k bei verschiedenen Temperaturen be- kJ/mol = 26 kcal/mol). Dagegen wird die Konfor-
stimmt. Diese liegen im >l/T/zemMS-Diagramm (In k mation eines Immunglobulins durch die Assoziation
vs. l/T) nach Gleichung 4 auf einer Geraden. In der eines stefoidalen Haptens offenbar nur geringfügig
Praxis gilt der Anstieg der Geraden als Quotient verändert (6, 16, 17).
Eexp/R und der Ordinatenabschnitt bei l/T —» 0 als
In Aexp. Da zumeist von Reaktionen mit Proteinen Zu 2): Die mit Gleichung l definierte Änderung der Gibbsschen
Standardenergie AG° gilt für Standardreaktionen. Die allgemein
nur die k-Werte eines engen Temperaturbereiches mit Fortschreiten einer Reaktion verbundene Änderung der
eingesetzt werden können, sind insbesondere die Gibbsschcn Energie AG wird durch die Gleichungen 5 und 6 fest-
durch Extrapolation gewonnenen Werte von Aexp gelegt.
mit großen Fehlern behaftet. Die ermittelten Werte
Nach Gleichung 5 wird die Negjativität von G umso
sind innerhalb des Meßbereiches und innerhalb der
größer und somit auch die Triebkraft einer Reaktion
Meßgenauigkeit konstant, d.h. anscheinend unab-
um so größer, je kleiner die Enthalpiezunahme ist
hängig von der Temperatur, wogegen die Theorie ei-
(durch größeres negatives ) und je größer die
ne Temperaturabhängigkeit der Aexp und Eexp zu-
Entropiezunahme ist (durch größeres positives
grundeliegenden molekularen Werte einschließt.
TAS); sie ist abhängig von den Ausgangs-Konzen-
Zur Deutung von Eexp und Aexp bzw. zur Bestim- trationen der Reaktionspartner (zum chemischen
mung von « und ASAkt werden die Gleichungen Potential des gebundenen Liganden, dG/dn, siehe
3 und 4 verglichen; offensichtlich entspricht die Ak- I.e. (18)).
tivierungs-Enthalpie dem Wert E exp -RT
Zur Normierung der in Gleichung 5 und Gleichung 6
und die Aktivierungs-Entropie AS A kt dem Wert R In
enthaltenen Größen AG, und 8 wurden die
(A exp Nh/RT)-R. Aus der Gleichung folgt ferner-
Standardreaktionen definiert, an deren Beginn alle
hin, daß die Geschwindigkeit einer Reaktion um so
Reaktionspartner in der Konzentration l (z.B. l
größer ist, je kleiner die Enthalpiezunahme und je
mol/1) und an deren Ende alle Reaktionspartner in
größer die Entropiezunahme beim Übergang vom
den jeweiligen Gleichgewichtskonzentrationen vor-
Grundzustand Pj + Qj oder PjQj zum Übergangszu-
liegen. Durch diese Normierung wird In · \ s= In l =
stand PjQ* der Reaktion ist.
0 und In Kf^ = In K (K == Gleichgewichtskonstante)
Ein großes positives Enthalpieglied wird als Deh- und somit Gleichung 6 zu Gleichung 7 und Glei-
nung oder Stauchung chemischer Bindungen bei chung 8, den logarithmierten Formen der Gleichung
Ausbildung des Ubergangszustandes gedeutet. Ein 1. Die zugehörigen Potentialdifferenzen werden als
großes negatives Entropieglied gilt als Ausdruck der Standardpötentiale °, ° und 8° bezeichnet.
geringen Wahrscheinlichkeit der Ausbildung präzi- Durch Differenzierung wird Gleichung 9a erhalten.
ser komplementärer Konformationen und Berüh- Gleichung 9a kann integriert werden, wenn im inter-
essierenden Bereich ΔΗ° von der Temperatur unab- Die Zahlenwerte von ΔΗ° lassen sich nach Glei-
h ngig ist. Als Folge davon erh lt man die Gleichung chung 9b aus der Temperaturabh ngigkeit der K-
9b, ein Analogon der ,4n7ien/Hs-Gleichung (GL 4). Werte ermitteln. Hiernach liegen die K-Werte im
van91 //^//-Diagramm (In K vs. l/T) auf einer Gera-
den. In der blichen Laborpraxis gilt der Anstieg der
( l. 5) AG = ΔΗ - ΤΔ5 Geraden als Quotient ΔΗ°/Κ. Da aber im strengen
Gibbs-Helmholtz-Gleichung Sinne sowohl ΔΗ° wie auch Δ8° von der Temperatur
abh ngen, sind die Voraussetzungen f r den ber-
(Gl 6) ΔΟ = RT In ^ gang von Gleichung 9a zu Gleichung 9b nicht gege-
ben und im van't Ho/jf-Diagramm ist ein nicht-linea-
rer Verlauf der K-Werte zu erwarten. In der tempe-
(GL 7) ΔΟ° = - RT In K = - RT In ±i raturabh ngigen nderung von ΔΗ° dr ckt sich
ACp aus, der Unterschied der Summen der spezifi-
schen W rmen von Reaktanden und Produkten
(Kirchoff-Salz). Die Zahlenwerte von ΔΗ (= W r-
met nung der Reaktion) lassen sich auch, und bei
Temperaturabh ngigkeit von ΔΗ richtiger, direkt im
Kalorimeter bestimmen. L t man die Reaktion im
(Gl. 9a) van't //o//-Gleichung Kalorimeter bei verschiedenen Temperaturen ablau-
fen, kann man aus der Temperaturabh ngigkeit der
W rmet nung den Wert von Δ€£ berechnen, bei li-
(Gl. 9b) In K = - ΔΗ° ^= + C nearem Verlauf als ΔΗ°/ΔΤ, sonst ber quadrati-
sche Regression (z.B. ΔΗ° = A + BT + CT2; C£ =
B + 2CT).
(GL 10) = Δθρ° /CJrc/z0//-Gleichung Die Zahlenwerte von Δ8° werden nach Gleichung 5
durch Differenzenbildung aus den Werten von ΔΟ°
und ΔΗ° berechnet oder aus dem Achsenabschnitt,
ΔΟ: nderung der G/6 s-Energie in Analogie zur Aktivierungsentropie (GL 4).
ΔΗ: nderung der Enthalpie
AS: nderung der Entropie F r konkrete Reaktionen sind die numerischen
Δ Cp: nderung der W rmekapazit t Werte der Potentiale zumindest n herungsweise ex-
Κ™: Quotient der initialen Konzentrationen der Reaktionspart- perimentell bestimmbar. Wegen der unvermeidli-
ner [ Jini
Kfin: Quotient der finalen Konzentrationen der Reaktionspartner chen Abweichung der experimentellen Bedingungen
llfin
von „Standardbedingungen" (z.B. In [H+] = 0!)
Z hler der Quotienten: kontinuierliche Multiplikation der k nnen nur „apparente" Werte ermittelt werden,
Konzentrationen der Reaktionsprodukte; st chiometrische was durch z.B. ΔΟ0/, ΔΗ0', und Δ8°' gekennzeich-
Koeffizienten als Exponenten.
Nenner der Quotienten: kontinuierliche Multiplikation der
net werden sollte; die experimentellen Bedingungen
Konzentrationen der Reaktanden; st chiometrische Koeffi- sind anzugeben (z.B. 25 °C (298,15 K); pH 7,6 lo-
zienten als Exponenten. nenst rke 0,1 mol/1) (19).
z.B. f r: 1P -l· IQ ^± 1PQ
Die Gz' foschen Potentiale der Immunreaktionen
egen bei -21 bis -63 kJ/mol (-5 bis -15 kcal/
Kir
mol). Immunreaktionen erwiesen sich zum Teil als
berwiegend Enthalpie-getrieben, zum Teil als
κKfin ~ berwiegend Entropie-getrieben; es wurden sowohl
[P]UQ]in positive wie auch negative Werte f r ΔΟ° publiziert
(4, 6, 13, 20). Auch die Frage, ob die Dispersion der
Die Zahlenwerte f r Δθ° (bzw. ΔΟ) lassen sich un- Δθ°-Werte einer „nat rlichen" Antik rperpopula-
mittelbar aus den Werten von K (bzw. von Kini und tion auf die Streuung des Enthalpie- oder des Entro-
Κίίη) errechnen (GL 6 bzw. GL 7). Theoretische pie-Gliedes zur ckzuf hren ist, bleibt offen, auch
Sch tzung ber Van der Waa/s-Interaktion///awfl- wenn zuletzt das Enthalpie-Glied als Ursache der
for-Konstanten der Assoziation von P und Q kl der Streuung von Δθ° favorisiert wurde (21). Zumin-
Gasphase mit nachfolgender Hydratation f hrt als dest an einigen Hapten-Antik rper-Paaren wurde
kleine Differenz gro er Zahlen erwartungsgem eine Enthalpie-Entropie-Kompensation nachgewie-
nur ungef hr in den Bereich der experimentell er- sen. Mit steigender Temperatur ging der Einflu des
mittelten ΔΟ° Werte (8). Enthalpie-Anteils zugunsten des Entropie-Anteils
zur ck (22).
J. Clln. Chem. Clin. Biochem. / Vol. 22,1984 / No. 12
856 KUSS: Physikalisch-chemische Aspekte reversibler A ssoziations-Reaktionen
Die Deutung von °, 8° und AC£ als Ergebnis Wasserstoff-Brücken wird eine negative Änderung
molekularer Vorgänge muß Änderungen der Reak- der Wärmekapazität erwartet. Die Umkehr derarti-
tanden und des Lösungsmittels berücksichtigen, da ger Effekte bei der Assoziation von P und Q im Be-
sich mit der Reaktion auch die Solvatationszustände reich der Kontaktregionen von P und Q, die zusätzli-
ändern (statt Formel l besser:) chen intermolekularen Wechselwirkungen zwischen
P und Q und die Energiebeiträge? durch intramole-
PI(N + m H20) + Qj(y + n H20) *=*· PiQj(m + n H2O) kulare Konformationsänderungen von P und Q er-
+ ( + y) H2o geben als Summe die meßbaren Änderungen AG°,
°, AS° und AC°. Die oben genannte Enthalpie-
Die vorliegenden Deutungen sind unvollständig, da Entropie-Kompensation könnte wie folgt verlaufen.
die thermodynamischen Potentiale die Summe aller Bei niedrigen Temperatüren wird die negative Ge-
molekularen Prozesse repräsentieren und da der samt-Enthalpie- und -Entropie-Änderung überwie-
Nachweis von Änderungen einzelner Molekülspe- gend durch die „intrinsische" Enthalpie- und Entro-
zies mit Hilfe von z.B. Röntgen- oder NMR-Spek- pie-Änderung der Komplexbildung bestimmt. Die
troskopie noch nicht abgeschlossen ist. Lediglich ei- mit steigender Temperatur zunehmende Verminde-
ne Struktur-unabhängige und somit unspezifische rung der Negativität mit Übergang zu positiven Wer-
Komponente des Entropie-Terms, eine Mischungs- ten der Gesamtpotentiale wäre eine Folge der Ent-
entropie, kann aus der Standard-Entropie-Ände- halpie- und Entropie-Änderung durch Vorgänge im
rung 5° einfach eliminiert werden. Hierdurch wer- Lösungsmittel. Aus dem gegensinnigen Einfluß der
den Werte für die „unitarische" Entropie-Änderung Enthalpie- und Entropie-Änderungen resultiert eine
ÄSU und für die entsprechend abgeleitete „unitari- im Meßbereich ungefähr konstante Änderung des
sche" Änderung des Gibbsschen Potentials AGU er- Gibbsschen Potentials.
halten, mit denen die Stabilität des Komplexes bes-
ser charakterisiert werden kann.
3. Reaktions-Geschwindigkeitskonsfanten und Re-
ASU = 5° + R In 1/[H2O] aktions-GIeichgewiditskonstanten
AGU = ° - R In 1/[H2O]T Die Berechnung von Aexp, Eexp, °, ° und AS°
(R In 1/[H20] = 33,5 J mol' K" 1 1 setzt die Kenntnis der Geschwindigkeitskonstanten
= 7,98 cal mor1 K-1 k+i, k-i und/oder die Kenntnis der Gleichgewichts-
(3, 7, 8, 12, 14, 22, 23). konstanten K = k + ]/k_] bei verschiedenen Tempe-
[H2O] = 55,6 mol/I raturen voraus. Die Größen k und K können unab-
hängig voneinander experimentell bestimmt werden,
Der Energiegewinn, der mit der Assoziationsreak- k über die Reaktionsgeschwindigkeiten, K über die
tion verbunden ist, d.h. die Negativität von AG°, Gleichgewichts-Konzentrationen. Als Quotient von
wird auf die Summation zahlreicher, im einzelnen k+i und k_i kann K auch über die Reaktionsge-
schwacher und z.T. gegensinnig wirkender Kräfte schwindigkeiten ermittelt werden. Da beide Verfah-
zurückgeführt, die aus den Wechselwirkungen ver- ren mit systematischen experimentellen Fehlern be-
schiedener Molekülgruppen resultieren, überwie- haftet sein können, empfiehlt sich der Vergleich der
gend sind dies die van der Wßöfc-Kräfte, die Wasser- nach beiden Verfahren gewonnenen Ergebnisse. Für
stoffbrücken-Bindungen und die hydrophoben eine subtilere Behandlung der Reaktionskinetik
Wechselwirkungen, d. h. die Minimierung der Expo- auch mehrwertiger und trägerfixierter Reaktions-
sition unpolarer Gruppen und die Maximierung der partner mit Unterscheidung der diffusiven und reak-
Exposition polarer und ionischer Gruppen. tiven Anteile von k und K siehe z.B. I.e. (24).
Beim Lösen unpolarer Gase in Wasser (25 °C) wird
wegen der Neuorientierung der Wassermoleküle an Reaktions-Geschwindigkeitskonstanten
den Grenzflächen (Ausbildung „eisartiger" Struktu-
Die durch Formel l definierte reversible Reaktion
ren) die negative Entropie-Änderung das Gibbsschc
setzt sich aus den Partialreaktionen nach Formel
Potential bestimmen und wegen der Ausbildung von
und l" zusammen.
Wasserstoff-Brücken wird eine positive Änderung c>
der Wärmekapazität erwartet („Schmelzen" der eis- (Formel l') P{ + Qj -^-»PiQ,
artigen Strukturen). Beim Lösen von Ionen in Was-
ser wird wegen der -Dipol-Wechselwirkung die (Formel l") PiQj -^->Pi + Qj
positive Enthalpie-Änderung das Gibbssche Poten- [ ] bedeutet im folgenden „Konzentration zur Zeit t", also nicht
tial bestimmen und wegen der Verminderung von mehr „Gleichgewichtskonzenträtion" [ ]&,.
Wird die Reaktion nach Formel gestartet, findet Reaktion mit k = 109 l
zur Zeit t0 ausschließlich die Assoziationsreaktion l
(t]/2 = = 10 9 s bei Konzentrationen von
statt (v_i = 0), deren Geschwindigkeit v+i durch k[P]o
Gleichung 11 definiert, zur Zeit t0 maximal ist. l mol/1). Im allgemeinen liegen Bestimmungen die-
ser Art außerhalb der Möglichkeiten der üblichen
Labortechnik; es werden z.B. Strömlings- und Rela-
( ,, ) v„ - - ÜB
dt
- --ßl-
dt
SSI
dt xationsmethoden notwendig (16, 27). Bei niederen
Konzentrationen und hohen Affinitäten der Reak-
tanden ist es jedoch möglich, mit den üblichen La-
bormethoden auch für die Geschwindigkeitskon-
Wird die Reaktion nach Formel l" gestartet, findet
stanten der Assoziationsreaktionen Näherungswerte
zur Zeit t0 ausschließlich die Dissoziationsreaktion
zu erhalten, selbst wenn kein „inneres Signal" der
statt (v+i = 0), deren Geschwindigkeit v_i, durch
Moleküle eine Unterscheidung von P* und P*Q er-
Gleichung 12 definiert, zur Zeit t0 maximal ist.
möglicht, sondern zu ihrer Bestimmung eine Tren-
nung dieser Molekülspezies erforderlich ist (6, 2.5).
«a«,
Wenn v+i > v-j, dann kann, zumindest in der Initial-
Zu irgendeinem Zeitpunkt zwischen t0 und täq sind phase der Reaktion, statt Gleichung 13 die Glei-
beide Geschwindigkeiten, v +1 und v_i von Null ver- chung 11 verwendet werden. Sie wird zur Gleichung
schieden und es gilt Gleichung 13 (Analytische Lö- 15 umgewandelt.
sung: I.e. (26).
(Gl. 15) = k +1 (p - [PQ]) (q - [PQ])
d[PQ] _ d[P] = d[Q]
(Gl. 13) d[PQ]
dt dt dt k+, dt =
= k+1[P] [Q] - k-,[PQ] 0
(p - (q -
Durch Integration erhält man die Gl. 16 und 17
Zur Zeit täq hat sich das kinetische Gleichgewicht der (25).
Reaktion eingestellt. Von diesem Zeitpunkt an gilt 1
Gleichung 14 a—c. • 16
16)) kk +l tt - _ p inIn PÜ ~ tPQ»
( _ [pQ])
keit der Reaktion dürften Fehler in der Versuchsan- Einklang zu bringen ist. Als diagnostisches Hilfsmit-
ordnung oder Messung als Ursache für die Abwei- tel empfiehlt sich die Transformation der Gleichung
chung von der Linearität wahrscheinlicher sein. Es l, mit i = l, j = l,
kann auch auf eine apparente Geschwindigkeitskon-
stante kapp übergegangen werden: a) nach Langmuir^Michaelis-Menten
_ qKF
B
~ l + KF
' (28)
Bäq (B,,- B,) - b) nach Scatchard
r/F = - Kr + K
Bestimung von k-1 c) nach Sips-Hill-Nernst
Da nach Voraussetzung v_j <^ v+i, muß die Rück- ln(B/(q - B)) = aln K + aln F
Assoziation P -l· Q —> PQ unterbunden werden.
Wenn dies möglich ist (kompetitive Hemmung der Aus der Lage der Meßpunkte in den Diagrammen B
Bindung von P, Adsorption von P), kann von Formel vs. F, r/F vs. r, ln(B/(q - B)) vs. F, wird auf Abwei-
l" und somit auch von Gleichung 12 ausgegangen chungen vom einfachsten Modell, i = l, j = l, K,j =
werden; Gleichung 12 wird umgeformt zu Gleichung K, geschlossen; je nach Plausibilität wird eines der
18 (siehe z.B. I.e. (6), (25), (26)). folgenden Modelle den realen Versuchsbedingungen
unterlegt (26, 29, 30).
(Gl. 18) k-, dt = -
Wenn Pi zu P oder P* wird, vereinfacht sich Glei- Bereich mit 75% der Bindungsstellen
chung 19 zu Gleichung 19b.
0,5 4,3 0,0025 bis 40 K
0,7 2,4 0,16 6
ij qj KI qi 0,8 * 1,8 0,27 3,7
(Gl. 19b) R = 1,0 0,0 alle Bindungsstellen l x K
l + Kj[F]
d.h.Kj = K
KZ qi qn
+ ...+
l + K2[F] l + K„[F] Zur Berechnung des Heterogenitäts-Index wird nach Gleichung
21 ln(r/(l - r)) gegen F aufgetragen (5/pJ-/////-Diagramm); hier-
zu muß q bereits bekannt sein, ggf. aus dem Scatchard-Diagramm
a) Wenn das System neben den Antikörper-Bin- ermittelt sein. Der Anstieg der Geraden ergibt a; zur Bedeutung
dungsplätzen („spezifische Binder") einen „Binder" der Asymptoten bei nicht-linearem Sips-/////-Graph, siehe z.B.
Qm mit niedriger Affinität und hoher Kapazität (z.B. I.e. (30); neuere Behandlung der Verteilungsfunktion siehe z.B.
I.e. (9).
„unspezifische Adsorption") enthält, dann wird
Für jedes und gilt, daß die mittlere intrinsische Assoziations-
konstante K den reziproken Wert von [P] bei Halbsättigung von q
Kn[F] -» 0 und somit K n q n /(l + Kn[F]) zur Konstan- (bzw. n x q) entspricht; dieser Wert ist im So7/c/zfl/Y/-Diagramm
ten K n q n = N unmittelbar zugänglich.
Die Wahrscheinlichkeit, daß P von einer n-wertigen Gleichung 24 kann durch Si/?s-/fi//-Afernsr-Transfor-
j mation (Gl. 21) umgewandelt werden in einen Aus-
Einheit, von deren n Bindungsstellen mit K = K alle
mit P besetzt sind, P n n Q> von einer der n Stellen ab- druck der Art
dissoziiert, ist -fach wahrscheinlicher, als daß P von
einer nQ Einheit abdissoziert, von der erst eine der n log = log (-
Stellen besetzt ist. Deswegen wird Kn zu l/n K.
Dieser Ausdruck geht für sehr kleine Werte von [P]
über in
Die Gruppe Gleichung 22 kann unter Verwendung
von Gleichung 23 zur Adair-Funktion (Gl. 24) log K + log [P]
transformiert werden (14, 30).
und für sehr große Werte von [P] über in
i=1
j , log K 4- log [P],
(G1.24) r = n
l + P diese Ausdrücke definieren Asymptoten der durch
Gleichung 24 definierten Funktion y = /(x). Sie er-
n l
• : >ldm>-Konstanten, deren molekular-physikalische Bedeu^ geben (y -» 0) Werte für K und K. Diese Werte ste-
tung vom Typ der Assoziations-Reaktion abhängt. hen in Zusammenhang mit der. empirisch gefunde-
K, x K2 . . . K) nen Funktion (Gl. 25),
j
J. Clin. Chem. Clin. Biochem. / Vol. 22, 1984 / No. 12
KUSS: Physikalisch-chemische Aspekte reversibler Assoziations-Reaktionen 861
Literatur
1. Huber, R. (1980) 10. Kim, Y. T., Werblin, Th. P. & Siskind, G. W. (1974)
Spatial structure of immunoglobulin molecules. Distribution of antibody affinities-II. Fractionation of antibo^
Klin. Wochenschr. 58, 1217-1231. dy with respect to its hapten binding affinity.
2. Tonegawa, S. (1983) Immunochemistry 77, 685—690.
Somatic generation of antibody diversity. 11. Menzinger, M. & Wolfgang, R. L. (1969)
Nature 302, 575-581. Bedeutung und Anwendung der Arrhenius^Aktivierungs-
3. Schulz, G. E. (1977) energie.
Regeln für Struktur globulärer Proteine. Angew. Chem. 81, 446—452.
Angew. Chem. 89, 24-33. 12. Sturtevant, J. M. (1977)
4. Gill, T. J., III (1973) Heat capacity and entropy changes in processes involving
Antigenic determinants on synthetic polypeptides. In: Speci- proteins (thermodynamics/hydrophobic effect/vibrational
fic Receptors of Antibodies, Antigens and Cells. 3rd Int. modes/conformations).
Convoc. Immunol., Buffalo, N.Y., 1972, pp. 136-169. Proc. Natl. Acad. Sei. USA 74, 2236-2240.
5. Twining, S. S., Lehmann, H. & Atassi, M. Z. (1980) 13. Sehon, A. H. (1971)
The antibody response to myoglobin is independent of the Hapten reactions and kinetics of interaction with antibodies.
immunized species. In: Methods in Immunology and Immunochemistry, Vol. 3
Biochem. J. 797, 681-697. (Williams, C. A. & Chase, M. W., eds.) New York, Academic
6. KUSS, E., Dinr, W., Goebel, R., Gloning, K., Hötzinger, H., Press, pp. 375-462.
Link, M. & Thoma, H. (1978) 14. Weber, G. (1975)
Steroids äs immunochemical probes. Thermodynamic and ki- Energetic of ligand binding to proteins. In: Advances in Pro-
netic data with special regard to the "bridge problems" in tein Chemistry (Anfinsen, C. B., Edsall, J. T. & Richards, F.
estrogen radioimmunoassay. In: Radioimmunoassay and re- M., eds.) Vol. 29, New York, Academic Press.
lated procedures in medicine 1977, Vol. l. International Ato- 15. Hornick, C. L. & Karush, F. (1972)
mic Energy Agency, Vienna, p. 69—89. Antibody affinity-III The role of multivalence.
7. Rupley, J. A., Gratton, E. & Careri, G. (1983) Immunochemistry 9, 325—340.
Water and globular proteins. 16. Stroupe, St. D. & Westphal, U. (1975)
Trends Biochem. Sei. 8, 18—22. Steroid-protein interactions. Stopped flow fluorescence stu^
8. Van Oss, C. J. & Neumann, A. W. (1977) dies of the interaction between steroid hormones and proge-
Comparisön between antigen-antibody binding energies. sterone-binding globulln.
'Immunol. Commun. 6, 341—354. J. Biol. Chem. 250, 8735^8739.
9. Thakur, A. K. & Delisi, Ch. (1978) 17. Hötzinger, H. (1977)
Theory of ligand binding to heterogeneous receptor popula- Untersuchungen über Steroid-Makromolekül-Wechselwir-
tions: characterization of the free-energy distribution func- kungen.
tion. In: Biopolymers, Vol. 17, 1075-1089 (John Wiley and ° Inaugural-Dissertation München,
Sons, Inc.).
Lehrstuhl für Medizinische Mikrobiologie und Immunologie (Direktor: Prof. Dr. W. Opferkuch)
der Ruhr· Universität Bochum, FRG
Summary: Conventionally prepared polyclonal antibodies have been used for a long time in biomedical re-
search and in clinical-chemical diagnosis. The hybridoma technology introduced by Köhler & Milstein ((1975)
Nature 256, 495—497), has opened the way to a new dimension in serology. It is now possible to prepare
monoclonal antibodies to any determinant on any component of biological matter. Such monoclonal and thus
specific antibodies can be obtained even against previously unknown antigens which had not been available in
purified or enriched form. Thus the dreams of immunologists and clinical scientists who were searching for
new disease-related markers, have become a reality.
The present impact and the predictable future influence of these new developments on biomedical research
and especially on clinical-chemical diagnosis, äs well äs their potential, limitations and problems, will be
critically reviewed in this paper. As an example of the potential of the new technology, recent results of tests
on the quantitation of urinary kidney-derived antigens with the help of monoclonal antibodies are presented.
With these monoclonal antibodies, which are specific for antigens in defined regions of the nephron of the
human kidney, recognition of the location and extent of primary damage at the cellular level will be possible
without invasive techniques.
Polyklonale und monoklonale Antikörper als Reagenzien in der biochemischen und klinisch-chemischen Ana-
lytik
Zusammenfassung: Konventionell hergestellte polyklonale Antikörper haben schon seit langer Zeit ihren
festen Platz als Reagenzien in der biomedizinischen Forschung und in der klinisch-chemischen Diagnostik.
Die Hybridomtechnologie mit der sich ergebenden Möglichkeit zur Herstellung monoklonaler Antikörper
gegen jede Determinante jedes denkbaren Antigenmoleküls hat das Spektrum der Anwendungsmöglichkei-
ten serologischer Techniken in unvorstellbarer Weise erweitert. So ist es jetzt möglich geworden, monoklo-
nale und damit spezifische Antikörper auch gegen Determinanten bisher unbekannter Antigene zu gewinnen,
ohne das entsprechende Antigenmolekül gereinigt oder angereichert zu haben. Die Wunschträume der Im-
munologen und klinischen Forscher, die nach neuen diagnostischen Markern, vor allem in der Tumorfor-
schung, suchten, würden greifbare Wirklichkeit.
Die vorliegende Veröffentlichung soll diese neuen Entwicklungen mit ihren - bereits heute vorhandenen und
in Zukunft absehbaren - Auswirkungen auf die biomedizinische Grundlagenforschung, vor allem aber auf
die klinische Diagnostik darstellen und ihre Möglichkeiten, Grenzen und Probleme kritisch diskutieren. Die
Möglichkeiten werden exemplarisch am Beispiel von Tests gegen Antigene der menschlichen Niere gezeigt.
In diesen Tests werden monoklonale Antikörper gegen Antigene aus genau lokalisierten Bereichen des
Nephrons eingesetzt, um die entsprechenden Antigene bei pathologischen Veränderungen im Harn von Pa-
tienten nachzuweisen. Solche Tests eröffiaen die Möglichkeit zur Erkennung von Lokalisation und Ausmaß
einer Schädigung im Nierenparenchym ohne die Anwendung invasiver Techniken.
l
), Presented at the Kleinkonferenz „Immunologische Diagnostik" der Deutschen Gesellschaft für Klinische Chemie, Hamburg, Juni
1983.
terminant like the dinitrophenyl group, artificially of solving some of the problems inherent in polyclo-
introduced into a carrier molecule, a population of nal antisera. Through in vitro fusion of sensitized B-
antibodies with different affinities and fine specifici- lymphocytes, the precursors of antibody producing
ties is induced. plasma cells, with "immortal" plasmacytoma cells,
Immunization of an animal with a substance foreign i.e. continuously dividing transformed plasma cells,
to its immune System — therefore called "immuno- it became possible to dissect the animal's polyclonal
gen" or "antigen" - produces a very specific poly- immune response into its monoclonal components
clonal cellular and humoral response. Individual and thus to prepare monoclonal antibodies.
cells of the immune System recognize antigenic "de-
terminants" or "epitopes", individual molecular The technological inventions necessary for the de-
structures on the surface of the antigenic particle. velopment of the hybridoma technology had been
Consequently, they are stimulated to produce large made a long time previously. Continuously dividing
numbers of antibodies, protein molecules comple- immortal plasmacytoma cell lines of the mouse
mentary to the corresponding epitopes. Since each were first developed by Potter (2), adapted to tissue
antigenic particle exposes an undeterminable culture conditions in 1970 by Horibata (3) and fur-
number of individual epitopes on its surface, this ther developed by others (4) including Köhler, Howe
Stimulation will result in an undeterminable number & Mustern (5).
of individual antibodies, a polyclonal antibody popu-
For selection of fused from unfused cells, mutant
lation. This antibody population is found in the se-
plasmacytoma cell lines had to be developed that are
rum of the immunized animals. deficient in an enzyme present in normal mouse
Each antibody has a binding site, a molecular struc- cells. A mutant deficient in the salvage pathway en-
ture by which it can recognize the complementary zyme hypoxanthine-guanine phosphoribosyl transfe-
structure on the antigen particle, the epitope, and rase (HGPRT) was developed by Cotton et al. (6)
bind to it. Binding of antibodies to an antigen can and by Köhler et al. (5). Hypoxanthine-guanine
have several consequences: Inhibition of biological phosphoribosyl transferase, a membrane bound en-
activities of the antigen (toxin, enzyme, bacteria, vi- zyme, allows the cell to take up hypoxanthine, a nu-
rus); complex formation (precipitation, agglutina- cleotide precursor, from the culture medium through
tion); removal or destruction of the antigen by acces- transmembrane transport and convert it into the nu-
sory biological Systems (macrophages, complement). cleotides needed for DNA synthesis (7). In general,
this pathway is not important for the celPs survival
Since the animal's immune System will be stimulated because nucleotides can equally well be acquired by
in an unpredictable way by each of the epitopes pres- de novo synthesis. If, however, the DNA de novo
ent on each of the antigens and, in additiön, by each synthesis pathway is blocked, the cells are bound to
cöntaminatioii in the antigen preparation used for make use of the external nucleotide precursor hypo-
immunization, high purity of the antigen is one of the xanthine. In the hypoxanthine-aminopterine-thymi-
most important preconditions for the preparation of dine (HAT) selection medium developed by Linie-
specific antisera. Very often it is difficult or impossi- field in 1964 (8), the de novo synthesis pathway is
ble to obtain highly purified antigens. Sometimes, äs blocked by aminopterine and only cells with an in-
is the case with membrane integrated antigens, puri- tact hypoxanthine-guanine phosphoribosyl transfe-
fication of the antigen is not possible without de- rase salvage pathway enzyme can survive. Unfused
struction of its native structure. Preparation of anti- hypoxanthine-guanine phosphoribosyl transferase
sera specific for subunits of complex biological mole- deficient plasmacytoma cells, although immortal in
cules like enzymes is equally difficult since the native principle, cannot survive under these conditions.
biological structure is often preserved only in the in- Unfused lymphocytes, mortal in vitro, will only sur-
tegrated native molecule. The preparation of antibo- vive a few days although their hypoxanthine-guanine
dies to previously unknown biological molecules was phosphoribosyl transferase enzyme is fully active.
not possible at all through conventional immuniza- Only hybrids between the hypoxanthine-guanine
tion procedures. phosphoribosyl transferase deficient plasmacytoma
cells and normal mouse lymphocytes will survive in
vitro. Thus, by means of fusion, two genetic factors
can be combined in one cell: the immortality and
The Hybridoma Technology capability for unlimited growth of the plasmacytoma
The hybridoma technology has opened a new dimen- cell and the capacity to produce one individual mo-
sion in the field of immunology and provided a way noclonal antibody of the plasma cell.
Originally K hler & Milstein used Sendai virus s the placed by normal culture medium and the cell sam-
fusing agent (1). Later, however, polyethyleneglyc- ples can be further processed. The rapidly growing
ol (PEG), a fusiogen found by plant cytologists, was hybrid cells, called hybridomas, secrete monoclonal
adapted for fusion because of its higher fusion rate antibodies into the culture fluid. Their specificities
and easier application (9, 10). In practice, fusion is can be tested by suitable tests.
done by mixing, in the presence of the fusing agent, •t
the spieen lymphocytes of an immunized mouse with Details of the fusion protocols and mouse myeloma
mouse plasmacytoma cells harvested from in vitro cell lines available for fusion have been published in
culture. Fusion takes place randomly within a few various technical papers (11—15). The principle is
minutes. After removal of the fusing agent the cells depicted in figure 1.
are distributed into the wells of culture plates and
fed with HAT selective medium. After 1—2 weeks Immunization procedures vary greatly from l bora-
unfused plasmacytoma and spieen cells s well s in- tory to laboratory. In our experience, a long term
ter-plasmacytoma and inter-lymphocyte fusion pro- hyperimmunization procedure with p to 12 injec-
ducts will have died, and rapid cell growth will be tions of the antigen mixture in complete Freund's ad-
observed only in those wells that contained at least juvent has led to promising results for the production
one hybrid cell in the cell mixture seeded after fu- of monoclonal antibodies to epitopes of tissue com-
sion. After 2—3 weeks the selective medium is re- ponents so far unknown.
^ —-
Polycional Plasmocytoma
antiserum cells
Hybridomos
*
|Ββ ι IQ « ι ie„
^iLsJ
Moss production of monoclonal antibodies
U ·.
Fig. 1. Schematic presentation of preparation of monoclonal antibodies to membrane antigens. Taken from:* Falkenberg et al.(68).
Production and Purification of Monoclonal Antibo- dies elicited against each of the epitopes of a multi-
dies epitope-antigen, it might not show the desired epi-
Monoclonal antibodies excreted into tissue culture tope specificity and affinity which makes it suitable
fluid by hybridoma cells can be detected by suitable for a certain test (e.g. RIA, ELISA, Immunofluores-
techniques. In most cases, antibody concentration in cence, etc.). Recently (21, 22) it was reported that
culture fluid is high enough (10—50 mg/1) for rou- monoplonal antibodies might exhibit a kind of "as-
tine tests such äs RIA, ELISA, indirect immunofluo- say-specificity", indicating that a given monoclonal
rescence, staining with peroxidase-labelled antibo- antibody might perform excellently in one assay but
dies, autoradiography. Those hybrid cell samples give poor or negative results in another. Therefore,
that secrete a monoclonal antibody of desired speci- large screening programs have to be performed to
ficity have to be checked for monoclonality. The identify those monoclonal antibodies that exhibit the
probability of monoclonality depends on the set-up desired specificity and sufficient affinity for their an-
of the experiment and especially on the frequency of tigen(s).
wells with cell growth and can be calculated accord- In our experience, there is no problem in testing mo-
ingly (16, 17). However, in most cases, cloning will noclonal antibodies, even those of low affinity, with
be necessary, either by limiting dilution or on soft techniques in which one of the reaction partners is
agar. Mass production of monoclonal antibodies is fixed to a solid phase (e.g. solid phase RIA, ELISA,
then possible either from cell culture supernatant or Immunofluorescence, Immunoperoxidase).
from ascitic fluid of hybridoma tumour bearing mice.
For purification of monoclonal antibodies several Further problems might arise from the "cross-reac-
methods can be applied: tivity" of monoclonal antibodies (23). The binding
- affinity chromatography on protein A columns site of a monoclonal antibody is complementary to a
(18) (applicable only to monoclonal antibodies of three dimensional molecular structure on the antigen
some IgG-subclasses) molecule, the epitope. On protein molecules such
structures might be determined by the primary se-
— immunospecific affinity chromatography on anti- quence of a few amino acids or by a steric configura-
gen columns or on antimouse-Ig-columns: Care- tion of several closely or distantly located amino acid
ful selection of the dissociating agent is important residues. Since the molecular area forming such epi-
to prevent irreversible damage to the antibody topes is rather small, the same or similarly construct-
molecules ed molecular areas might be present on other related
- conventional biöchemical techiüques such äs ion or non-related proteins. This "blurred vision" of the
exchange and gel permeation chromatography. monoclonal antibodies causes considerable problems
The HPLC technique has recently been applied for their use. Although these considerations are also
successfully to monoclonal antibody purification valid for each of the antibodies that form a polyclo-
(19, 20). nal antiserum, these problems are not encountered
because all the antibodies of the serum react with
one target antigen for which a high specificity is thus
obtained. It might be necessary in the future to com-
Problems with Monoclonal Antibodies bine several monoclonal antibodies to form artificial
antisera-like oligoclonal mixtures.
However, it has turned out to be rather difficult to
obtain monoclonal antibodies of high purity. Mono- Due to the individual structure in the constant (class
clonal antibodies in ascitic fluid are contaminated and subclass specific sequences) and variable (idio-
with normal mouse seriim proteins, iiicluding normal typic sequences) regions each monoclonal antibody
mouse IgG's which cannot always be removed by the is a distinct Individuum and has to be treated äs such.
purification prpcedüres rnentioned above. Monoclo- Techniques and procedures developed for the biö-
nal antibodies in tissue culture fluid are free of other chemical and immunochemical manipulation of an-
mouse proteins. They are, however, heavily contam- tibodies from conventionally prepared polyclonal
inated with proteins from horse serum or from foetal antisera cannot always be applied to these "capri-
calf serum (e.g. 10 g of monoclonal antibodies in cious primadonnas" of monoclonal antibodies. Di-
5000 g of horse serum proteins). gestion with proteases to produce Fab-fragments or
The affinity and specificity of monoclonal antibodies conjugation with marker molecules do not always
are not always adequate. Since each monoclonal work äs expected and cause problems in the prepara-
antibody is just one of the total popuiation of antibo- tion of derivatives of monoclonal antibodies (24).
Application of Monoclonal Antibodies Instead of Predictions from the economic sector point to the
Conventional Sera development of a 2 billion dollar industry world wide
by 1990 (25). At this time a 50% replacement of
Monoclonal antibodies have many advantages over
polyclonal antibodies by monoclonal antibodies in
conventional polyclonal antisera. Nearly everything
diagnostic tests is forecasted (26).
that has been done with antisera might be done bet-
ter with monoclonal antibodies. The most important In the fbrst instance, development 'was aimed at re-
advantages and disadvantages of working with mo- placing polyclonal antisera by monoclonal antibo-
noclonal antibodies are summarized below: dies. By this approach new and better reagents for
research and clinical-analytical purposes were deve-
loped. However, the high costs of the technique and
the unavoidable large screening programmes result-
Advantages
ed in sales prices often prohibitive for the reduced
— No pure antigen needed: total cells, unfractionat- budget of the university research worker. In many
ed cell extracts or partially enriched fractions can cases it is questionable whether a cheap polyclonal
be used antiserum should be replaced by an expensive mo-
— Purification of antigens on immunosorbent co- noclonal antibody.
lumns possible There are, however, problems in which monoclonal
— Unlimited supply of each monoclonal antibody antibodies due to their specificity and biochemical
homogeneity have definite advantages over polyclo-
— High reproducibility over unlimited periods of nal antisera. Since monoclonal antibodies are specif-
time ic for individual antigenic epitopes, tests for haptens
— Worldwide standardization possible for the first and peptide hormones built on monoclonal antibo-
time dies might be better and more specific than conven-
tional tests applying absorbed polyclonal antisera. If
— Useful for all kinds of binding techniques, espe- a hybridoma producing an antibody with the desired
cially in solid phase Systems properties has been found, production of the mono-
— Localization of individual membrane determi- clonal antibody is always simpler and cheaper than
nants on the cell (topography) the production of polyclonal antisera which each
have to be rendered specific by tedious absorption
— during cell cycle and cell differentiation
procedures. Hormones that exhibit partial structural
— in relation to other membrane antigens identities or homologies in their peptide chains, e.g,
— Localization of individual determinants of an an- thyrotropin, follitropin, humaii chorionic gonado-
tigen (external or internal part of the antigen) tropin and lutropin, are examples of this approach.
In tests for the quantitation of such hormones in
— Determination of the shed (physiological condi- body fluids monoclonal antibodies will compete with
tion) or solubilized (pathological condition) anti- absorbed polyclonal antisera on the market.
gen or of antigen fragments in extracellular fluids
For the determination of haptens like digoxin and
structurally related compounds and breakdown pro-
ducts thereof, monoclonal antibodies might be better
Disadvantages than polyclonal antisera (27). In this case, high affin-
- Affinity of monoclonal antibodies is often low ity of the antibodies is, however, of greatest impor^
tance for the development of suitable tests. Al-
- Precipitation often not possible though the search for a monoclonal antibody that
— Expansion of work fulfils all the conditions might be long and tedious,
the chances of finding it are better than the chanees
— High costs
of finding a polyclonal antiserum with the desired
Scientists around the world have prepared monoclo- properties.
nal antibodies against nearly every antigen one can
The evaluation of isoenzymes, microhieterogeneous
thihk of. The Information collected is immense and
forms and genetic variants of enzymes by immuno-
growing day by day.
logical techniques is another field of applicätiofi of
Industry has followed the trend. Many tests, pre- monoclonal antibodies. Polyclonal antisera might be
viously performed with conventional antisera, are äs good or better than monoclonal antibodies äs was
now on the market using monoclonal antibodies. shown with the creatine kinase MB isoenzyme. Inhi-
bition obtained with monoclonal antibodies (28) to tissues and tumours of various origins. Similar obser-
the B subunit was nearly äs high äs with polyclonal vations were made by Wagner et al. (36) who found
antibodies. that 5 monoclonal antibodies directed against the
protein moiety of the CEA molecule were helpful in
There are other isoenzymes which so far can be rec-
differentiating between 5 epitopes on CEA and/or
ognized only by electrophoretic techniques. Since
different CEA related antigens in normal and malig-
the difference in electrophoretic mobüity must have nant tissues.
a structural basis, it should be possible to prepare
monoclonal antibodies with the power to identify in- "Silent" enzymes, i.e. inactive (e.g. proteases) or in-
dividual isoenzymes. The amylase isoenzymes are activated forms or breakdown products of biologi-
examples of this kind. Differentiation between the cally active molecules are another field of applica-
pancreas-type and the saliva-type isoenzyme is pos- tion of monoclonal antibodies. Monoclonal antibo-
sible by electrophoretic mobility, not by polyclonal dies to phenylalanine hydroxylase have been pre-
antisera (29). In this case monoclonal antibodies will pared in our laboratory (37) in order to differentiate
be useful reagents. between various genetic variants of the enzyme and
thus provide a means of classifying the hereditary
Several groups have prepared monoclonal antibo- disease phenylketonuria.
dies against prostatic acid phosphatase (PAP). Mo-
noclonal antibodies seem to have advantages over Modulation of enzyme activity by antibodies is a well
polyclonal antisera in test Systems, since some of the known phenomenon. With monoclonal antibodies, it
monoclonal antibodies do not cross-react with non- is now possible to draw conclusions concerning the
prostatic acid phosphatases (30). A "tandem" assay molecular site involved in enzyme activity regulation
using two monoclonal antibodies specific for two ep- and modulation by antibodies. The activation of a
itopes of the prostatic acid phosphatase molecule defective enzyme, ß-galactosidase of E. coli carrying
was found to be specific exclusively for the prostatic Z-gene point mutations, by individual monoclonal
enzyme and useful for prostatic acid phosphatase antibodies has been reported recently (38) and indi-
measurement (31). The properties of monoclonal cates that a "single hit" modification of protein con-
versus polyclonal antibodies to prostatic acid phos- formation is possible. In our University, Hessova et
phatase in histochemical staining are compared in a al. (39) have prepared monoclonal antibodies to the
recent publication by Shevchuk et al. (32). Most car- oligomeric enzyme phosphorylase kinase which al-
cinomas were positive with a goat antiserum, fewer lows characterization of the function of the a- and
with a rabbit antiserum, and only about 50% were subunits. Whereas most of the monoclonal antibo-
positive with the monoclonal antibodies. This might dies inhibited the AI or the Aa or both activities,
reflect the heterogeneity of the antigens used for some were shown to activate the AO or the AI activi-
preparation of the antisera. For clinical testing, a ties. Informative relationships were observed be-
broad spectrum antiserum might be most useful. For tween the binding to a specific subunit and the en-
research purposes, however, where absolute speci- zyme activity.
ficity is needed to gäin new Information, monoclonal Monoclonal antibodies to markers of classes and
antibodies may be more useful. subclasses of human and murine immunoglobulins
have already become important tools in research, es-
In test Systems developed for carcinoembryonic anti- pecially in hybridoma research, äs well äs in clinical
gen (CEA), two site-directed monoclonal antibodies diagnosis. Problems arising from unexpected and so
are used. Since "tionspecific eross-reacting antigens far uiiexplained reactions and cross-reactions (21,
l and 2 (NCA-1 and NCA-2)" are not recognized, 22) of monoclonal antibodies specific for immuno-
such a test System based on monoclonal antibodies globulins of the IgG subclasses are being investigat-
offers advantages over conv4entional test Systems ed in a collaborative study, organized under the aus-
(33). The seiisitivity and specificity of 3 different pices of the IUIS and the WHO. During the 6th Eu-
forms of solid phase EIA using 5 different monoclo- ropean Immunology Meeting in Interlaken in Sep-
nal antibodies against 4 distinct epitopes of the CEA tember 1984, the colloquium on "Monoclonal anti-
molecule were compared by Buchegger et al. (34). In bodies to human Immunoglobulins — Specificity and
two further recent publications, the detection of application" is devoted to this question.
"epitope heterogeneity" of CEA from various ori-
gins was reported. Eshhar et al. (35) found that a se- A whole generation of new test Systems has become
ries of 50 monoclonal anti-CEA antibodies could be possible by the introduction of monoclonal antibo-
divided into four groups according to their reactivity dies: "enzyme channeling" (40) or "proximal link-
with individual epitopes in CEA preparations from age" (41) immunometric assay s in which a measur-
able Substrate turnover is observed only when two Monoclonal Antibodies to Lymphocyte Differentia-
monoclonal antibodies, each specific for one individ- tion Antigens
ual epitope of the same particle, and each labelled One of the most important developments in this field
vvith another enzyme react with the antigen. The concerns the recognition of subsets of the lymphoid
"sandwich ELISA" with two monoclonal antibodies
cell population in human blood (43). A series of mo-
directed against two different epitopes of the anti- noclonal antibodies has been prepared, each direct-
gen, one bound to the solid phase ("catcher") the ed against a differentiation antigen by which a cer-
other labelled with a marker enzyme ("indicator") tain T-cell type is characterized. Thus, the detenni-
can be done in a "one step" mode: the antigen-con-
nation of total T-cell, T-suppressor- and T-helper
taining specimen and the enzyme labelled monoclo-
cell counts in blood has nöw become possible. Mo-
nal "indicator" antibody can be added to the solid
noclonal antibodies together with the new fluores-
phase bound "catcher" in a mixture. This saves time
cence-activated cell sorting and counting technique
and costs in the clinical laboratory.
(44) will in future enable the haematologists to ob-
tain Information on the cellular immune Status of a
In this context a paper published 1980 by Kohen et patient. Such diagnostic tools might in future enable
al. (42) should be mentioned. In this paper the au- the clinician to draw conclusions on the state of a
thors reported that a monoclonal antibody directed disease and help him to decide oii appropriate thera·^
against the dinitrophenyl (DNP) hapten exhibited peutic measures. In urology these new reagents al-
quasi-enzymatic properties if the DNP-group was ready have diagnostic äs well äs therapeutic conse-
conjugated covalently through an ester bond with quences, e.g. in kidney transplantation. Determina-
the fluoresceht compound 7-hydroxy-coumarin tion of helper to süppressor T-cell ratio might help to
(DNP-CU). The antibody-enhanced esterolysis of predict the survival of a transplant in a recipient (45,
DNP-CU results from the interaction of the labile 46). The süccessful treatment of rejection episodes
ester with a nucleophilic group in a proper position in kidney transplant recipients with monoclonal anti-
within the antibody combining site. T-cell antibodies has been reported recently (47).
Cosimi et al. (48) treated cadaver doriof renal allo-
graft recipients at the time of diagnosis of acute re-
jection with monoclonal OKT3 antibody (reactive
with all mature peripheral blood T-cells). In all 8
Exploitation of the Advantage of the Hybridoma cases loss of essentiälly all detectable peripheral
Technology: Tissue Antigens blood OKT3-reactive cells was observed within 5
minutes of i. v. iiifüsion ofr 1—5 mg of OKT3 anti-
Most of these applications of monoclonal antibodies
body, and the established rojectiön episodes were
are not of great interest to immunologists, since the
reversed in all cases within 2 to 7 days without any
new technology is only used instead of the conven-
treatment other than OKT3 antibody. Jönker et al.
tional forms of antibody production, exploiting only
(49) used a rhesus monkey skin allograft model to
part of the manifold advantages of the new technol-
study the effects of administration of monoclonal an-
ogy. In these developments, however, the usefulness
tibodies in detail. They found that tfie monoclonal
of the new technology has been tested and the ques-
OKT4 and OKT4A antibodies specific for T-helper-
tion answered whether the advantages compensate
cells successfully prolonged allograft survival where-
for the enormous costs of development.
as the monoclonal OKT8 antibody specific for cyto-
toxic/suppressor T cells did not.
In order to exploit all the possibilities of the hybrido-
ma technology, new approaches and strategies had It can be expected that monoclonal antibodies
to be devised. With monoclonal antibodies it is pos- against clearly defined T-cell-subpopulations will re-
sible to detect new antigens or antigenic determi- place the previously used horse anti^human-thymo-
nants which, for technical reasons, have not been ac- cyte globulin (ATG) with its unselective T cell killing
cessible betöre. Monoclonal antib.odies can be raised capacity (50).
against any determinant of a cell, a membrane frac-
tion, or a tissue extract. In very tedious and expen- Since malignaiit lymphocytes express normal äs well
sive screening procedures, those have to be selected äs disease-related antigens on their sürface, the char-
that are specific for disease-relevant tissue marker acterization of leukaemic cells, the categorization of
antigens. With these antibodies, the purification and leukaemias, and, finally, new therapeutic approaches
characterization of the corresponding antigens are have become possible with monoclonal antibodies
then possible. '
J. Clin. Chem. Clin. Biochem. / Vol. 22, 1984 / No. 12
Falkenberg, Pierard, Mai and Kantwerk: Polyclonal and monoclonal antibodies äs reagents 875
Currently, a simple test for the quantitation of T-cell 61)) and for radioimmunotherapy (RIT (61,62)) are
marker antigens on peripheral lymphocytes is under equally promising. Paul Ehrlich's view (63) of tar-
development at Boehringer Mannheim (52): In this geted antibodies used äs "Zauberkugeln" (magic
test, which can be performed in a normal clinical la- bullets) or, in modern terms äs "guided missiles"
boratory following routine procedures, T-lympho- against cancer might become reality in the near fu-
cyte antigens are determined with galactosidase la- ture.
belled monoclonal antibodies using the lymphocytes
themselves äs solid phase. By this test, the determi-
nation of T-cell subset patterns which previously was
possible only in laboratories equipped with highly Monoclonal Antibodies to Kidney Tissue Antigens
sophisticated machinery (fluorescence activated cell Diagnosis of kidney damage is generally obtained
sorter, FACS) or in tedious manual cell counting un- from the results of tests of renal glomerular or tubu-
der the fluorescence microscope, becomes available lar function. Changes in function, however, indicate
to every laboratory which is equipped with a centri- the existence of severe lesions or irreversible tissue
fuge and a photometer. necrosis. Thus, function parameters allow recogni-
tion of late phase reactions occurring during kidney
injury but they are in most cases inadequate for the
determination of minor early phase alterations. The
Monoclonal Antibodies to Tumour Antigens latter can be reversible and disappear when the ag-
The ability to prepare monoclonal antibodies to pre- gression on the tissue ends. They consist of modifica-
viously unknown biological marker molecules initial- tions at the level of the renal cell surface accompan-
ly raised many hopes in the field of tumour immu- ied by release of membrane components in the urine.
nology. Monoclonal antibodies, directed to tumour- Such early phase lesions can sometimes be recog-
specific or tumour-associated marker molecules, nized by electron microscopic examination of biopsy
were thought to offer the ultimate solution to the specimens. Most of the tests performed on urine in
cancer problem. The main obstacle to this approach use today yield Information on late phase events on-
lies in the animaPs undifferentiated immune re- ly. The recent establishment of assays for quantifica-
sponse to everything that is foreign in the sample tion of the urinary ß2-microglobulin (64) and for
used for immunization. Thus immunization with hu- measurement of the urinary alanine aminopeptidase
man tumour cells, tumour cell extracts, or fractions activity (65) has allowed recognition of early phase
alterations. The determination of other kidney-de-
thereof will yield, after fusipn, monoclonal antibo-
rived components in urine may in addition facilitate
dies directed against whatever is recognized äs for-
the localization of damage to particular sites of the
eign by the animal's immune System. Considering
nephron. In order to search for kidney-derived com-
the vast complexity of tissue antigens, monoclonal
ponents in urine we have prepared monoclonal an-
antibodies to real tumour ajitigens can be found only
tibodies against human kidney antigens (66, 67).
by chance.
These antibodies display various specificities for an-
As discussed earlier, monoclonal antibodies to well tigens in the different parts of the nephron, in blood
known tumour markers like carcinoembryonic aiiti- vessels and in the interstitia.
gen (CEA) or prostatic acid phosphatase (PAP)
Initial evidence for the presence of kidney-derived
seem to offer advantäges over conventionally pre-
antigens in urine was obtained by "Inhibition of im-
pared antisera. The literature on new tumour marker
munofluörescence staining" assays performed with
antigens detected by monoclonal antibodies is grow-
concentrated urine of patients suffering from various
ing day by day. Most of these reports have, however,
kidney diseases (68). In order to detect and quantify
to be taken with great reseryation. So far, none of
antigens in native urine, more sensitive tests had to
the new markers has become part of clinical diagnos-
developed. The sandwich ELISA was chosen be-
tic routine procedures. It is hoped that the efforts
cause it allows estimation of antigens which are not
undertaken iii many research laboratories around
available in pure form äs is the case with these kid-
the world will lead to the development of new diag-
ney-derived antigens.
nostic tools that will allow early detection and better
prognosis of cancer diseases. In several papers (53— A number of sandwich ELISA tests have been deve-
57) and monographs (58, 5-9) the new developments loped by using various combinations between solid
have been described in detail and critically reviewed. phase adsorbed "catcher" and glucose oxidase con-
The future prospects of the use of targeted monoclo- jugated "indicator" antibodies. Native urine samples
nal antibodies for radioimmunoimaging (RII (60, of patients suffering from various kinds of kidney
damage were assayed with each of these test Systems, is correlated with renal tissue damage, the normal
and the percentage of urines containing antigens ränge (mean ± 2.5 SD) of urinary antigen was deter-
were calculated. Thus the sandwich ELISA, a very mined by assaying the urine of healthy persons.
quick and easy technique, appeared to be suitable Antigen excretion in the urine of patients suffering
for the detection of antigens in native, i. e. unconcen- from various kidiiey diseases was compäred with the
trated and undialysed, urine. antigen excretion in the urine of healthy persons.
Each of the monoclonal antibodies used is specific Within the patients' group part of the individual
for one of the various epitopes of the kidney-derived values (10 to 30%) were significantly increased.
urinary antigens. Some of these epitopes can be situ- High levels of urinary antigens were observed in all
ated on the same antigen. Consequently, it is possi- cases of clinically diagnosed acute phases of renal
ble that some of the sandwich ELISA tests measure diseases (acute pyelonephritis, urosepsis). Destruc-
the same antigen(s), although each antigen was tion of renal parenchyma in cases of hydronephrosis,
bound to the various "catcher" antibodies by means nephrolithiasis, interstitial nephritis and polycystic
of a different antigenic epitope. In order to test this disease of the kidney was always accompanied by in-
hypothesis and to select those assays that allow de- creased release of antigens in urine. In addition,
tection of different urinary antigens, correlation some of the patients suffering from chronic glomeru^
analysis (Spearman) of the data were performed. lonephritis or diabetic nephropathy shöwed high uri-
The results indicated that these assays can be divided nary levels of antigens äs well, which is indicative of
into groups. Thus, all tests belonging to different tissue destruction.
groups detect:.different antigenic molecules, each These experiments have been described in detail re^
characterized by a specific combination of epitopes. cently (69—72). Some of the results obtäined are
Therefore, one assay was selected from each group shown in figures 2 and 3.
for further experiments.
In figure 2 the excretion of 7 urinary antigens (U A
Although the tests are sensitive enough to allow 1—7), each defined by a certain combination of mo-
quantification of antigens in unconcentrated urine, noclonal antibodies, is measured in urinary samples
no significant amounts of antigens were detected in of patients suffering from nephrolithiasis (fig. 2a) or
human serum. To find out whether urinary excretion pyelonephritis (fig. 2b).
) Nephrolithiasis
U r i n e UA1 UA2 UA3 UA4 UA5 UA6 UA7 -
sample disial distal proximal proximal disi+prox. dist.+ prox. part of the nephron
500%
b) Pyelonc»phritis
Urine U A 1 UA2 UA3 UA4 UA5 UA6 UA7
sample distal l distal distal proximal proximal d ist. + prox. d ist.* prox. part of the nephron
100% 500% 100% 500% 100% 500% 100% 500% 100% 500% 100% 500% 100% t f5CIO%
34/1 i^680Vo£> ?m l
/\
f
71/1 s\
115/1 \ l
^
Fig. 2. Excretion of urinary antigens (UA) derived from distal (UA1, UA2, UA3) and proximal (UA4, UA5) part of the nephron or
localized in all parts of the tubular System (UA6, UA7) in patients suffering from nephrolithiasis (fig. 2ai and pyelonephritis (fig.
2b). Antigen excretion is given äs percent of upper limit of normal ränge (100% = mean + 2.5 SD).
Fig. 4. Identification of localization of two antigenic epitopes in the same kidney slice by two directly labeled monoclonal antibodies.
a) Fluorescein labeled monoclonal antibody PMII 80 F5.
b) Rhodamine labeled monoclonal antibody PM II 29 D2.
Microphotographs were taken with an Olympus Fluorescence Microscope BH-2 using selection filters for each of the fluoro-
chromes. Magnification 160x.
The spectrum of human monoclonal antibodies ob- mune response in the immunobiology of the tumour,
tainable by fusion of cells from immunized donors is, the future potential of immortalization and dissec-
however, limited since humans cannot be immunized ;tion of such autologous immune responses is a chal-
Hke laboratory animals. On the other band, in vitro lenge äs well äs a promise for immunologists.
immunization of human lymphocytes still is a very
For the successful fusion of human lymphocytes, a
complicated procedure and has only been successful
human myeloma line, comparable in its properties to
with relatively few antigens (81). The peripheral
the mouse myeloma lines, is urgently needed. So far
blood of patients suffering from autoimmune dis-
most of the reports on successful fusions with human
eases should contain fusionable lymphocytes. The
myeloma lines have to be taken with great reserva-
immortalization of the monoclonal components of
tion and doubt (82,83). The usefulness of the availa-
the humoral autoimmune response should yield val-
ble human plasmacytoma or lymphoblastoid cells
uable Information on the antigens involved and on
line for fusion purposes was reviewed by Kozbor et
the pathomechanism of the disease. Anti-idiotypic
al. (84) and by Abrams et al. (85). In all cases, myco-
antisera to such monoclonal autoimmune antibodies
plasmal infections might cause the most severe prob-
might one day help to regulate autoimmune diseases
lems in human hybridoma technology. Therefore,
and to clear the blood of these autoantibodies
availability of mycoplasma free fusion partners (both
through extracorporal immunosorption.
lymphocytes and myeloma cells) seems to be the
For the preparaton of human monoclonal antibodies most important precondition for successful human x
to other antigens of interest, e.g. in cancer research, human fusions (86).
one is dependent on the patient's autologous im- In principle the results obtained so far seem promis-
mune response. If a patient has developed antibodies ing and should encourage other investigators to de-
to his own tumour the corresponding fusionable B velop this important field of hybridoma technology.
lymphocytes are available not only from the blood A patient's immune response against his own tumour
but also from draining lymph nodes or from the ex- should be more specific than the immune response of
cised tumour itself (intra-tumoural lymphocytes). an immunized animal can be expected to be. If not
for therapeutic, then definitely for diagnostic pur-
There is a considerable body of evidence for the
poses, human monoclonal antibodies will have a
presence of autologous immune response to various
great future potential.
types of malignant diseases. These data indicate that
most tumour patients develop an autologous humor-
al immune response to their tumour. The question
Acknowledgement
whether or not such immune responses have any im-
pact on the tumour, either enhancing or inhibiting This work was supported by grant 1/36 986 from the Stiftung
Volkswagenwerk and by grant Fa 71/10 - 4 of the DFG. The se-
tumour growth, inust at the moment remain unan- cretarial assistance of Mrs. D. Evertz, Mrs. E. Stammet and Mrs.
swered. Irrespective of the role of the patient's im- E. Berghüser is most gratefully acknowledged.
References
1. Köhler, G. & Mustern, C. (1975) 6. Cotton, R. G. H. & Milstein, C. (1973)
Continuous cultures of fused cells secreting antibody of Fusion of two immunoglobulin-producing myeloma cells.
predefined specifieity. Nature 244, 42-43.
Nature 256, 495-497. 7. Caskey, C. T. & Kruh, G. D. (1979)
2. Potter, M. & Boyce, C. R. (1962) The HPRT Locus.
Induction of plasma-cell neoplasms in strain BALB/c mice Cell 76, 1-9.
with mineral oil and mineral oil adjuvants. 8. Littlefield, J. W. (1964)
Nature 793, 1086-1087. Selection of hybrids from matings of fibroblasts in vitro and
3. Horibata, K. & Harris, A. W. (1970) their presumed recombinants.
Mouse myelomas and lymphömas in culture. Science 145, 709.
Exp. Cell, Res. 60, 61-77. 9. Pontecorvo, G. (1975)
4. Kearney, J. F., Radbruch, A., Liesegang, B. & Rajewski, K. Production of mammalian somatic cell hybrids by means of
(1979) polyethylene glycol treatment.
A new mouse myeloma cell line that has lost immunoglobulin Somat. Cell Genet. 7, 397.
expression but permits the construction of antibody-secreting 10. Gefter, M. L., Margulies, H. & Schärft M. D. (1977)
hybrid cell lines. A simple method for polyethylene glycol-promoted hybridi-
J. Immunoi. 725, 1548-1550. zation of mouse myeloma cells.
5. Köhler, G., Howe, S. C. & Milstein, C. (1976) Somat. Cell Genet. 3, 231.
Fusion between immunoglobulin-secreting and nonsecreting 11. Melchers, F., Potter, M. & Warner, N, L. (1979)
myeloma cell lines. Preface, In: Current topics in microbiology and immunology
Eur. J. Immunoi. 6, 292-295. 81» (Melchers, F., Potter, M. & Warner, N. U Eds.)> IX-
XXIII, Springer Verlag, Heidelberg.
12. Fazckas De St. Growth, S. & Scheidegger, D. (1980) 28. Würzburg, U. & Ströbel, R. (1981)
Production of monoclonal antibodies: strategy and tactics. Immunoinhibition test for creatine kinase B subunit: a com-
J. Immunol. Meth. 35, 1-21. parison of monoclonal mouse and polyclonal goat antibodies.
13. Goding, J. W. (1980) J. Clin. Chem. Clin. Biochem. 79, 543-544.
Antibody production by hybridomas. 29. Lorentz, K. (1982)
J. Immunol. Meth., Special hybridoma issue 39, 285—308. Alpha-Amylase. Eigenschaften, Analytik und klinische Be-
14. Methods for production and characterization of monoclonal deutung.
antibodies, Appendix (1980) Laboratoriums Blätter 32, 117—12?7
In: Monoclonal antibodies, Hybridomas: a new dimension in 30. Lee, C. L., Li, C. Y., Jou, Y. H., Murphy, G. P. & Chu, T. M.
biological analyses (Kenne«, R. H., McKearn, T. J. & Bech- (1982)
tol, K. B., Eds.), 363-417, Plenum Press, New York, Lon- Immunochemical characterization of prostatic acid phospha-
don. tase with monoclonal antibodies.
15. Production of antibody-producing hybridomas in the rodent Ann. N.Y. Acad. Sei. 390, 52-61.
Systems (1981) 31. Davies, S. N. & Gochman, N. (1983)
Appendix, In: Research Monographs in Immunology, Mo- Evaluation of a monoclonal antibody-based immunoradio-
noclonal antibodies and T-cell hybridomas, perspectives and metric assay for prostatic acid phosphatase.
technical advances (Hämmerling, G. J., Hämmerling, U. & Am. J. Clin. Pathol. 79, 114-119.
Kearney, J. F., Eds.), Vol. 3, 563-587, Eisevier North-HoI- 32. Shevchuk, M. M., Romas, N. A., Ying, G. N. P., Tannen-
land, Amsterdam. baum, M. & Olsson, C. A. (1983)
16. Coller, H. A. & Coller, B. S. (1983) Acid phosphatase localization in prostatie carcinoma. A com-
Statistical analysis of repetitive subcloning by the limiting di- parison of monoclonal antibody to heteroantisera.
lution technique with a view toward ensuring hybridoma mo- Cancer 52, 1642-1646.
noclonality. 33. Hedin, A., Carlsson, L., Berglund, A. & Hammarstroem, S.
Hybridoma 2, 91-96. (1983)
17. De Blas, A. L., Ratnaparkhi, M. V. & Mosimann, J. E. A monoclonal antibody-enzyme immunoassay for serum car-
(1983) cinoembryonic antigen with increased specificity for carcino-
Estimation of the number of monoclonal hybridomas in a mas.
cell-fusion experiment, In: Methods in Enzymology (Colo- Proc. Nat. Acad. Sei. USA 80, 3470-3474.
wick, S. P. & Kaplan, N., Eds.), Vol. 92 Immunochemical 34. Buchegger, F. & Mach, J. P. (1983)
Techniques, Part E. Monoclonal antibodies and general im- Different Solid-Phase Enzyme Immunoassays Using Five
munoassay methods (Langone, J. J. & van Vunakis, H., Eds.) Monoclonal Antibodies Reacting with Distinct Epitopes of
36—39, Academic Press, New York. Carcinoembryonic Antigen, In: Immunoenzymatic Tech-
niques (Avrameas, S., Druet, P., Mässeyeff, R. & Feldmann,
18. Ey, P. L., Prowse, S. J. & Jenkin, C. R. (1978)
G., Eds.), Developments in Immunology, Vol. 18, 385-394,
Isolation of pure IgGj, IgG2a and IgG2b immunoglobulins Eisevier Science Publishers, Amsterdam, New York, Oxford.
from mouse serum using protein A-sepharose. 35. Eshar, Z., Ben-Izhak, R., Ariel, N. & Arnon, R. (1984)
Immunochemistry 75, 429—436. Differences among individual CEA preparations and carcino-
19. The Application of High Performance Ion Exchange Chro- mas of different origins äs detected by monoclonal anti-^CEA
matography in Hybridoma Technology (1983) antibodies. In: Protides of the biological fluids, proceedings
Review, Technical Review Series, Pharmacia Fine Chemicals. of the 3 Ist Colloquium 1983 (Peeters, H., Ed.), pp. 929-932.
20. Hill, E. A., Penney, R. I. & Anderton, B. A. (1982) Pergamon Press Oxford New York.
Protein HPLC-Fast Purification of Immunoglobulin G-type 36. Wagener, C, Joy Yang, Y. H., Crawford, F. G. & Shivel, J.
Mouse Monoclonal Antibodies by FPLC Ion Exchange Chro- E. (1983)
matography, Poster C101 presented at 14th Int. Symp. on Monoclonal antibodies for Carcinoembryonic antigen and re^
Chromatography, London. lated afitigens äs a model system: a systematic approach for
21. Haaijman, J. J., Deen, C, Kröse, C. J. M., Zijlstra, J. J., the determination of epitopes specificities of monoclonal an-
Coolen, J. & Radi, J. (1984) tibodies.
Monoclonal antibodies in immunocytology, A jungle füll of J. Immunol. 230, 2308-2315.
pitfalls. 37. Bartholome, K. & Falkenberg, F. W.
Immunol. Today 5, 56—58. Preparation and characterization of monoclonal antibodies
22. Jefferis, R. & Ling, N. R. (1984) against phenylalanine-hydroxylase, in preparation.
More pitfalls in the use of monoclonal antibodies. 38. Accolla, R. S., Cina, R., Montesoro, E. & Celada, F. (1981)
Immunol. Today 5, 127. Modification of protein eonformation induced by monoclonal
23. Lane, D. & Koprowski, H. (1982) antibodies: the ß-^galactosidase model, In: Protides of the bio-
Molecular recognition and the future of monoclonal antibo- logical fluids, proceedings of the 28th colloquium 1980 (Peet-
dies. ers, H., Ed.), 489-492, Pergamon Press, Oxford, New York.
Nature 296, 200-203. 39. Hessova, Z., Thieleczek, R., Varsanyi, M., Falkenberg, F. W.
24. Milstein, C. (1982) & Heilmeyer, L. M. G., jr. Monoclonal antibodies to rabbit
Monoclonal Antibodies from Hybrid Myelomas: theoretical skeletal muscle phosphorylase-kinase: Probes for study of
aspects and some general comments, In: Monoclonal antibo- subunit function.
dies in clinical medicine (McMichael, A. J. & Fabre, J. W., Submitted for publication.
Eds.), pp. 3-16. Academic Press, London. 40. Ullman, E. F., Gibbons, I., Litmari, D., Weng, L. & DiNello,
25. Business Week (May 19, 1981), 147. R. (1983)
26. Jefferis, R. (1983) Highly Sensitive Enzyme Channeling Immunoassay for Mac-
Monoclonal antibodies and British industry. TOO little and romoleeules, In: Immunoenzymatic Techniques (Avrameas,
too late? S., Druet, P., Mässeyeff, R. & Feldmann, G., Eds.), Develop-
Immunol. Today 4, 128—130. ments in Immunology, Vol. 18, 247-256, Eisevier Science
27. Haber, E. (1982) Publishers, Amsterdam, New York, Oxford.
Monoclonal antibodies to drugs: new diagnostic and thera- 41. Sevier, E. D., David, G. S., Martinic, J., Desmond, W. J.,
peutic tools, In: Monoclonal antibodies in clinical medicine . Bartholomew, R. M. & Wang, R. (1981)
(McMichael, A. J. & Fabre, J. W., Eds.), pp. 177^500. Aca- Monoclonal antibodies in clinical immunology
demic Press, London. Clin. Chern. 27, 7797-1806.
42. Konen, F., Kim, J. B., Lindner, H. R., Eshhar, Z. & Green, 58. McMichael, A. J. & Fabre, J. W. (Eds.) (1982)
B. (1980) Monoclonal Antibodies in Clinical Medicine, Academic
Monoclonal immunoglobulin G augments hydrolysis of an es- Press, New York.
ter of the homologous hapten 59. Mitchel, M. S. & Oettgen, H. F. (1982)
FEBS Letters 111, 427-431. Progress in Cancer Research and Therapy, Hybridomas in
43. Reinherz, E. L., Kung, P. C, Goldstein, G. & Schlossman, S. Cancer Diagnosis and Treatment, Vol. 21, Raven Press, New
F. (1979) York.
Separation of functional subsets of human T cells by a mo- 60. Mach, J. P., Buchegger, F., Forni, M., Ritchard, J., Berche,
noclonal antibody. C., Lumbroso, J. D., Schreyer, M., Giardet, C, Accolla, R. S.
Proc. Nat. Acad. Sei. USA 76, 4061. & Carrel, S. (1981)
44. Herzenberg, L. A. & Herzenberg, L. A. (1978) Use of radiolabelled monoclonal anti-CEA antibodies for the
Analysis and Separation using the fluorescence activated cell detection of human carcinomas by external photoscanning
sorter (FACS), In: Handbook of experimental immunology and tomo-scintigraphy.
(Weir, D. M., Ed.), Chapter 22, Blackweil Scientific PubL, Immunol. Today 2, 239.
Oxford. 61. Burchiel, S. W. & Rhodes, B. A. (1983)
45. Cosimi, A. B., Colvin, R. B., Winn, H. J., Rubin, R., Gold- Radioimmunoimaging and Radioimmunotherapy, Eisevier,
stein, G., Kung, P. C., Hoffman, R. A., Hansen, W. P. & New York.
Rüssel, P. S. (1981) 62. Thorpe, P. E., Edwards, D. C., Davis, A. J. S. & ROSS, W. C.
Immunologie monitoring with monoclonai antibodies to hu- J. (1982)
man T-cell subsets. Monoclonal antibody-toxin conjugates: Aiming the magic
Transplant Proc. 77, 1589. bullet, In: Monoclonal Antibodies in Clinical Medicine
46. Platt, J. L., LeBien, T. W. & Michael, A. F. (1982) (McMichael, A. J. & Fabre, J. W., Eds.), pp. 167-201. Aca-
Interstitial mononuclear cell populations in renal graut rejec- demic Press, New York.
tion. J. Exp. Med. 755, 17. 63. Ehrlich, P. (1913)
47. Cosimi, A. B., Colvin, R. B., Burton, R. C., Rubin, R. H., Chemotherapy, Proc. 17th Int. Congr. Med. (1913) 1914 In:
Goldstein, G., Kung, P. C., Hansen, W. P., Delmonico, F. L. The collected papers of Paul Ehrlich (1960) (Himmelweit, F.,
& Russell, P. S. (1981) Ed.) Vol. III, 510, Pergamon Press, Oxford.
Use of monoclonai antibodies to T-cell subsets for immuno- 64. Merle, L. J., Reidenberg, M. M., Camacho, M. T., Jones, B.
logic monitoring and treatment in recipients of renal allo R. & Dreyer, D. E. (1980)
grafts. N. Eng. J. Med. 305, 308-314. Renafinjury in patients with rheumatoid arthritis treated with
gold.
48. Cosimi, A. B., Burton, R. C. & Colvin, R. B. (1981)
Clin. Pharmacol. Ther. 8, 28, 216-222.
Treatment of acute renal allograft rejection with OKT3 mo- 65. Mondorf, A. W., Scherberich, J. E., Falkenberg, F. W.,
noclonal antibody. Sachse, H. J., Gauhl, C & Schoeppe, W. (1983)
Transplant 52, 535-539. Brush Border Enzymes and Drug Nephrotoxicity, In: Acute
49. Jonker, M., Goldstein, G. & Bainer, H. (1983) Renal Failure, Correlation between Morphology and Func-
Effects of in vitro administration of monoclonal antibodies tion (Solez, K. & Whelton, A., Eds.), 281-298, Marcel Dek-
specific for human T cell subpopulations on the immune Sys- ker Inc. New York.
tem in a rhesus monkey model. 66. Falkenberg, F. W., Müller, E., Riffelmann, H. D., Behrendt,
Transpiant 35, 521-526. B. & Waks, T. (1981)
50. Cosimi, A. B. (1981) The production of monoclonal antibodies against glomerular
The clinical value of antilymphocyte antibodies. and other antigens of the human nephron.
Transplant. Proc. 75, 462-468. Renal Physiology 4, 150-156.
51. Ritz, J., Pesandö, J. M., Notis-McConarty, J., Clavell, L. A.,
67. Falkenberg, F. W., Riffelmann, H. D., Müller, E., Ganten-
Sallen, S. E. & Schlossman, S. F. (1981) berg, W., Behrendt, B. & Waks, T. (1981)
Use of monoclonal antibodies äs diagnostic and therapeutic
Monoclonal antibodies against antigens in the human kidney,
reagents in acute lymphoblastic leukemia. In: Monoclonal antibodies and T-cell hybridomas (Hämmer-
Cancer Res. 41, 4771. ling, G. J., Hämmerling, U. & Kearney, J. F., Eds.), 148-
52. Glatz, C., Barchet, H., Schetters, H., Jungfer, H. & Albert, 155, Eisevier North-Holland, Amsterdam.
W. (1983) 68. Falkenberg, F. W., Gantenberg, W., Jürgenliemk, L, Mayer,
Determination and classification of T-lymphocytes and their M., Pierard, D., Riffelmann, H. D., Behrendt, B. & Waks, T.
subsets (T-suppressor/cytotoxic and T-helper/inducer) by the
(1983)
ELISA-methpd, Abstract, 2nd International Symposium on Developmental aspects of immunologically characterized
Immunoenzymatic Techniques, Cannes. proteins.
53. Boman, B. M. & Fathman, C. G. (1981)
Editorial: Monoclonal antibodies: The next attempt at tumor Clin. Biochem. 16, 10-16.
immunotherapy. 69. Pi6rard, D., Hermann, G., Mai, U., Hecking, E., Mondorf, A.
Mayo. Clin. Proc. 56", 641. W., Scherberich, J. E. & Falkenberg, F. W. (1983)
Sandwich-enzyme immunoassays for the quantification of
54. von Kleist, S. (1980)
Tumordiagnostik mit Hilfe tümorassoziierter Antigene. kidneyrderived antigens in urine using monoclonal antibo-
dies. In: Immunoenzymatic techniques (Avrameas, S., Druet,
Dtsch. Med. Wochenschr. 105, 1557.
55. Moon, T. D., Vessella, R. L. & Lange, P. H. (1983) P., Masseyeff, R. & Feldmann, G., Eds.), 333-336, Eisevier
Science Publishers, Amsterdam, New York, Oxford.
Monoclonal antibodies in urology.
J. Urol. 130, 584-592. 70. Kantwerk, G., Mai, U., PiSrard, D., Laskus, C. & Falken-
56. Lennox, E. S. & Sikora, K. (1982) berg, F. W. (1983)
Definition of human tumour antigens, In: Monoclonal anti- Urinary kidney derived antigens determined by monoclonal
bodies in clinical medicine (McMichael, A. J. & Fabre, J. W., antibodies - future markers for nephropathy.
Eds.), pp. 111-128. Academic Press, London. Immunobiol. 765, 290-291.
71. Piorard, D., Mai, U., Kantwerk, G., Laskus, C, Heine, C,
57. Lennpx, E. S. (1982) Hecking, E., Mondorf, A. W. & Falkenberg, F. W. (1984)
Monoclonal antibodies and tumor antigens - a perspective,
. In: Progress in Cancer Research and Therapy, Hybridomas in Monoclonal antibodies äs tools for kidney damage diagnosis.
Cancer Diagnosis Treatment (Mitchel, M. S. & Oettgen, H. In: Protides of the biological fluids, 3 Ist Coll. 1983 (Peeters,
F., Eds.), Vol. 21, pp. 5-13, Raven Press, New York. H., Ed.), pp. 1047-1050. Pergamon Press, Oxford.
72. Falkenberg, F. W., Mondorf, U., Pidrard, D, Mondorf, A. 80. Schlom, J., Wunderlich, D. & Teramoto, U. A. (1980)
W., Mai, U., Kant werk, G., Meier, U. & Rindhage, A. (1984) Generation of human monoclonal antibodies reactive with
Use of monoclonal antibodies for the Identification of cellular human mammary carcinoma cells.
fragments from proximal and distal tubular cells in the urine Proc. Nat. Acad. Sei. USA 77, 6841-6845.
of patients treated with cis-platinum. 81. Cavagnaro, J. & Osband, M. E. (1983)
Submitted for publication. Successful in vitro primary irnmunization of human peripher-
73. McKearn, T. J., Smilek, D. E. & Fitch, F. W. (1980) al blood mononuclear cells and its role in the development of
Rat-mouse hybridomas and their application to studies of the human-derived monoclonal antibodies.
major histocompatibility complex, In: Monoclonal antibo- Biofeature, 30-36.
dies, hybridomas: a new dimension in biological analyses
(Kennett, R. H., McKearn, T. J. & Bechtol, K. B., Eds.), 82. Sikora, D. & Neville, A. M. (1982)
219-234, Plenum Press, New York. Human monoclonal antibodies.
74. Galfro, G., Milstein, C. & Wright, B. (1979) Nature 300, 316-317.
Rat x rat hybrid myelomas and a monoclonal anti-Fd portion 83. Kozbor, D. & Roder, J. C. (1983)
of mouse IgG. The production of monoclonal antibodies from human lym-
Nature 277, 131-133. phocytes.
75. Bazin, H. (1982) Immunol. Today 4, 72—79.
Production of rat monoclonal antibodies with LOU rat-non 84. Kozbor, D., Dexter, D. & Roder, J. C. (1983)
secreting IR983F myeloma cell line, In: Protides of the bio- A comparative analysis of the phenotypic characteristics of
logical fluids, 29th Coll. (Peeters, H., Ed.) 615-618, Per- available fusion partners for the constrüction of human
gamon Press, Oxford, New York. hybridomas.
76. DeClerq, L., Cormont, F. & Bazin, H. (1983) Hybridoma 2, 7—16.
Rat monoclonal antibodies, III, Obtainment of rat-rat hybri-
domas with the use of the LOU IR983F non secreting fusion 85. Abrams, P. G., Knost, J. A., Clarke, G., Wilburn, S., Old-
cell line. ham, R. K. & Foon, K. A. (1983)
Hybridoma, in press. Determination of the optimal human cell lines for develop^
77. Cläre, M., 9obbold, S., Haie, G. & Waldmann, H. (1983) ment of human hybridomas
Advantages of rat monoclonal antibodies. J. Immunol. 737, 1201-1204.
Immunol. Today 4, 100-101. 86. Ziegler^Heitbrock, H. W. L., Reiter, C, Trenkmann, J. &
78. Bazin, H. (1983) Riethmüller, G. (1983)
More on rat monoclonal antibodies. Establishment of human-human B-cell hybridomas produc-
Immunol. Today 4, 274. ing monoclonal antibodies, Abstract, XV. Tagung der Gesell-
79. Levy, R., Dilley, J., Brown, S. & Bergman, Y. (1980) schaft für Immunologie, Berlin, Immunbiol. 165, 383.
Mouse x human hybridomas, In: Monoclonal antibodies, hy-
bridomas: a new dimension in biological analyses (Kennett,
R. H., McKearn, T. J. & Bechtol, K. B., Eds.), 137-153, Priv.-Doz. Dr. Frank W. Falkenberg
Plenum Press, New York. Lehrstuhl für Med. Mikrobiologie
und Immunologie
Ruhr-Universität Bochum
Postfach 102148
D-4630 Bochum l
Radioimmunoassay: An Overview1)
By A. Dwenger
Summary: The historical development, principle and theory of the radioimmunological lest are described,
together with the necessary test components, Separation techniques and experimental procedure. The empha-
sis on different areas of diagnosis that rely on radioimmunoassay is compared for two institutions.
Methods for the determination and presentation of reliability criteria are described, and the current Status of
quality control of radioimmunological methods is discussed.
Three high grade mechanized Systems and five fully mechanized or automated Systems for radioimmunologi-
cal assays are presented.
Future trends in the development of radioimmunoassay can be predicted with the aid of general growth crite-
ria.
History
They explained this delay by the binding of labelled
In 1952, Arthur Mirsky proposed that maturity onset insulin to an insulin-binding globulin fraction. Using
diabetes could be attributed not so much to a defect isotopic tracing and radiochromato-electrophoresis,
of secretion, but rather to an accelerated degrada- they showed that this globulin fraction occurred gen-
tion of insulin by "insulinase" of the liver (1). In erally in the plasma of insulin-sensitive diabetics,
order to test this hypothesis, Yalow & Berson inves- and suggested that it contained an acquired insulin
tigated the metabolism of 131I-labelled insulin, and antibody. To the immunologists in the mid fifties,
observed that it was eliminated more slowly by insu- however, this was an unacceptable concept, and the
lin-sensitive diabetics than by npn-diabetics (2). fundamental studies of Yalow & Berson were reject-
') Presented at the Kleinkonferenz „Immunologische Diagnostik44 der Deutschen Gesellschaft für Klinische Chemie, Hamburg, Juni
1983.
ed by "Science" and "Journal of Clinical Investiga- eine and veterinary medicine, and into nonmedical
tion" in 1955 (3). The work was accepted in 1956, areas concerned with the analysis of low concentra-
but only after a compromise has been reached with tions of organic compounds (fig. 1). In 1974, ra-
the editors, in which the term "insulin antibody" was dioimmunological methods were performed in about
removed from the title. In the same publication they 2000 laboratories in the USA, increasing in 1975 to
also reported that the quantity of labelled insulin more than 4000 laboratories. Meanwhile,
,·; '
the funda-
bound to a defined concentration of antibody was mental work of Yalow & Berson in 1960 (4) has be-
related to the actual insulin concentration. This ob- come a classic reference. The increase in the number
servation formed the basis for the radioimmunologi- of radioimmunological determiriations since 1975 is
cal detection of plasma insulin, and for the subse- shown in figure2 (5—8).
quent development of all radioimmunological and
related methods of Saturation and displacement
analysis. Adoption of the method was, at first, ex-
RIA-Tests
traordinarily slow. Bioassays were still the preferred
USA World-wide
methods for hormone assays. No great interest was
shown in the radioimmunological test until four 1975 52000000
years later, when Yalow & Berson described the 1976 52000000 100000000
measurement of plasma insulin without extraction 1980 100000000 200000000
(4). Slowly, it became recognized that radioimmu- 1985 >200000000 >400000000
noassay was a highly sensitive and comparatively Federal Republic of Germany
simple method, for performing assays in small sam- 1979 17000000
ples and in large sample series. 1985 39000000
Even up to the mid sixties, Yalow & Berson were
practically the only authors using this method. Five Fig. 2. Growth in the number of radioimmunological tests.
years later, however, in 1970, radioimmunoassay
had already developed into the most important and
comprehensive analytical method in the endocrino-
logical laboratory. It then spread rapidly into medi- Principle and Theory
The principle and theory of the radioimmunological
test are comparatively simple and straight forward,
and therefore offer no basis for understanding the
2001 less than satisfactory precision and accuracy of the
c
3
method that still exist today. In the radioimmunolog-
ε a) ical System (fig. 3), antigen (AG) and antibody (AB)
'δ
"•5
C3 interact reversibly to form a soluble antigen-anti-
body complex. Labelled antigen (AG*) and unla-
belled antigen compete for binding to the limited
Ό
O number of antibody binding sites. The process obeys
100
the law of mass action, so that the greater the quanti-
ty of unlabelled antigen present, the less labelled an-
tigen is bound. Since labelled antigen and unlabelled
antigen are in excess of the antibody (i. e. [AG*] and
[AG] in excess of [AB], where [] refers to the con-
c centration of valencies, rather than the molar con-
centration), the terna, Saturation analysis, is also
1960 1965 1970 1960 1965 1970 used. The concentration of unlabelled antigen is de-
rived from the extent to which it competitively inhib-
Fig. 1. Increase in the number of publications concerned with ra- its the binding of radioactive antigen tp a specific
dioimmunoassays.
a) Yalow, R. S. & Berson, S. A. (1960) J. Clin. Invest.
antibody, the method being standardized with
39, 1157. Number of times quoted: 1100 (1961- known concentrations of unlabelled antigen. To per-
1975). form this typical comparative in vitro analysis,
b) Journal of Clinical Investigation,
Diabetes,
known concentrations of antibody and labelled anti-
Journal of Clinical Endocrinology, gen are incubated at a defined teniperature with var-
Endocrinology ious concentrations of unlabell$d antigen (Standard
or sample), usually until equilibrium is reached. Free that the assay is free froin interference, it is essential
antigen is then separated from bound an t i gen, and that the Standard, the antigen used for the immuni-
the radioactivity of one or both fractions is mea- zation and the labelled antigen be very pure.
sured. If an honiogeneous antibody with equal affini-
The properties of an antiserum raised against an
ty for labelled and unlabelled antigen were used, and
hapten-carrier conjugate are predetermined by the
the reaction allowed to attain Saturation, then the
type of carrier and by the site of coupling between
Standard curve would be an hyperbola (B/Bö =
hapten and carrier, whereas the properties of an an-
f([AG] + [AG*])), which could be transformed to a
tiserum raised against a high molecular weight anti-
linear, double reciprocal or double logarithmic plot gen are rather unpredictable. Especially in the mea-
(figs. 3a and 3b). In some cases, the Standard curve surement of pharmaceuticals and their metabolites,
obeys a mathematical model, which suffices for the it must be decided whether to use an antiserum that
binding kinetics and the detection limit (Scatchard recognizes a whole family of molecules (original
plot, quadratic equation, hyperbola, logit-log trans- compound and its metabolites) or one that recog-
formation, etc.). This is not usually the case, howev- nizes only biologically active metabolites.
er, so that purely einpirical Interpolation methods
are used for curve fitting (parabola, polynomials of Qualitative and quantitative evaluation of an anti-
various degrees, smoothed spline approximation, body for use in a radioimmunoassay is based on the
etc.) (9, 10). two criteria of specificity and affinity. Specificity is
determined from cross reaction with antigen ana-
AG* ,AG*-AB logues (see also the section on Reliability), and affin-
( (B)
* ity is determined by measurement of affinity con-
A6 "AG - AB
standard/sample stants. The stability of antigen-antibody complexes is
larger for multivalent antigens, owing to the aug-
9000- 0.40- 1.0-
mented formation of an intermolecular network. In
such cases the antigen-antibody reaction is more ap-
e
propriately characterized by the overall, average af-
l 4500 -"0.20 0.5
3 finity constant, known äs the avidity constant. This
S
effect of antigen valency seems to be the main reason
for the greater sensitivity of immunological tests for
0L
proteins and polypeptides, compared with those for
c [nmol/l]
haptens.
. f(lA6*MA6])
Linearizotion To a first approximation, the sensitivity of a test, i.e.
the minimal detectable concentration, corresponds
to l/Ka or 1/Kav, where the affinity constant, Ka, for
the hapten-antibody interaction is normally in the
ränge l O6—1010 1/mol, and Kav for protein-antibody
interaction can be äs high äs 1013 1/mol (fig.4).
molecule is too small or lacks sufficient chemical dif- from 1. and 2.: [AB0] =* [Hmin]
ferentiation tö act äs an antigen, i t is coupled coval-
ently to a higher molecular weight carrier (serum al- when B/F « J : l < Ka[ABo] < Ka[H m in]
bumin possesses a large number of different reactive [Hmjn] > ^~
groups that can be exploited for this pu ose), and
the conjugate is used for immunization. To ensure Fig. 4. Detection limit - affinity constant.
tj/2 of isotope < 18.5 years 1. quantitative Separation with no effect on the anti-
gen-antibody reaction (guarantee of high, preci-
Fig. 5. Relationship between detection limit and the nuclide half sion and sensitivity),
life.
2. simple, rapid and cheap performanee (high prac-
ticability),
3. no influence by plasma components (high repro-
ducibility and comparability) (13, 14),
Tritium labelling is performed by metal-catalysed
hydrogenation of unsaturated compounds, by the 4. no unspecific effects (15, 16), and
metal-catalysed exchange of halogens or hydrogen 5. time-dependent stability of the antigen-antibody
for tritium, or by the reduction of oxidized interme- complex under the Separation conditions (me-
diates with tritiated metal hydrides. Iodine labelling chanized, sequential systems)Ä>(17, 18).
Reliability
It is the purpose of all clinical chemical investiga-
tions, including those performed by radioimmunoas-
Deiection limit say, to provide reliable analytical results äs a basis
Irin for reliable clinical diagnosis. Reliability depends on
0.20 the type and degree of incidental and systematic er-
rors, which should be monitored, identified and clas-
sified by an internal laboratory quality control sys-
0.05 tem, the long term aim being to decrease or abolish
such errors. Since radioimmunoassay is a mulfistep
procedure, the possibilities for error are correspond-
Fig. 8. Non-equilibrium radioimmunoassay (digoxin). ingly large (fig. 11).
1977 1982
1. According to Ekins (20) it is determined from the
initial slope of the Standard curve, thus represent*.
ing a special case of Ekins9 precision concept: Ac
(== precision of the measuremeiit of c) depends
on the slope and the error of the measurement of
B, i.e. ; if c = 0, the corresponding value of
Äc, i.e. Äc0, defines the detection limit.
Fig. 10. Proportions of radioimmunological determinations in the 2. Schwäres method for internal quality control.
sectors: thyroid (T), hepatitis (H), cancer (C), Digitalis
glycosides (D) and general diagnosis (G) This is based on a logit-log transformation, and
1977 = Met Path, USA (because of heteroscedasticity i. e. irregulär distri-
1982 = Medizinische Hochschule Hannover bution of variance over the Standard curve) it
uses only that part of the Standard cüfve between
Reliability can be determined with the aid of the de- 15 and 85% of the initial binding of urdabelled
fined and quantifiable reliability criteria: detection antigen (Bö). As an operatiönal definition, test
limit, specificity, precision and accuracy. Detection sensitivity is therefore 0.85 x B0 (21).
limit or sensitivity is limited essentially by the affinity 3. As a general guide fof ensuring the quality of
constänt of the antibody, and can be determined in clinical chemical results, the dection limit can be
various ways (fig. 12): taken äs B0 — 3sBo. ^
BÖ
The common influences of incidental and systematic In internal laboratory quality control, precision and
errors on the precision and accuracy of the radioim- accuracy are monitored separatetyi Nowdays, the
munoassay suggest that they are related. This is clear normal procedure for precision analysis is to deter-.
from a comparison of two methods (fig. 14) (21): mine a response-error relationship (RER), which is
method A with a wide scatter (= incidental errors, represented by the Standard deviation of replicates
poor precision, high imprecision factor) around the (usually duplicates), or their deviation frorn the av-
true value of ä, and method B with low scatter (good erage of the replicates. Taking into account the con-
precision) about an average value, b, which differs fidence ränge for antigen concentrations determined
from the true value (= systematic error). The quality from the Standard curVe, a precision profile is then
of the analytical results from the two methods can be constructed. For a symmetrical distribution of the
compared by using Ekins* equation (fig. 14). On the confidence limits, this profile then represents the de-
basis of its clinical value, method B would always be pendence of the Variation coefficient ori the antigen
preferable (21). concentratiön or the appropriate response parame-
ter, and it shows how the precision aiters over the
ränge of the Standard curve (fig. 15).
Precision profiles can be constructed for four differ-
ent levels of precision (fig. 16) (21):
60
50
p*—Precision
40
Accurate value
10
0.5
8/Bo
4. between laboratories
% CV = g · 100
3. inter-series
% CV = -~~- - 100
2. within series
% CV = · 100
1. for errors that arise from the preparation of the borative study. By identifying sources of error and
Standard curve and the curve fitting procedure, by making educative recommendations to manufac-
turers and users of kits, they have helped to bring
2. for the level of precision within the series for re-
about a considerable increase in interlaboratory pre-
plicate measurements,
cision (fig. 17). Last year, Marschner presented the
3. for the level of precision between series for the evidence for this improvement, using the example of
measurement of an internal quality control sam- thyroid stimulating hormone determination methods
ple, and in the Federal Republic of Germany (22). Also last
4. for the level of interlaboratory precision for the year, the World Health Organization presented its
measurement of external quality control samples experience of the previous five years with the
in interlaboratory collaborative investigations. "matched reagents program", which involved more
than 80 laboratories in 35 countries (23). Over the
As a means of guaranteeing the internal quality of five year period, only one hormone assay (that for
results, the type 3-level of precision is important. It luteinizing hormone) out of the seven studied
comprises the total variance of "the Standard curve, showed significantly better interlaboratory precision
the fit and the sample, and the interseries deviation. when performed with WHO reagents and protocols,
For radioimmunological methods it is found to be than when performed with non-WHO reagents. If,
between 7 and 20% when the optimal r nge of the however, one assesses the changes in interlaboratory
calibration curve is used for standardization. precision over the five year period for both WHO
and non-WHO methods, s shown in figure 18, there
Of the reliability criteria, accuracy contains the grea-
must be some doubt about the efficiency of the
test element of uncertainty, s evidenced by the dif-
World Health Organization programme.
ference between the measured and true value of the
antigen concentration. Definitive methods, which
ι
can be used to check the radioimmunological meth- α b
ods, are available for very few antigens (e.g. gas 60 -
chromatography-mass spectrometry for steroids). Π
For the majority of antigens, however, especially Γ7~Ί
6/ 7\
/,
peptide and proteo-hormones, only the "relative in- 40 - /
', //
lϊ v\X\\\\\\X\s
ΧΧΧΧΧΧΧΧΧΧΝ
νΧΧΧΧΧΧΧΧΧΧ^
^χχχχχ\χ\\χν
^XXXXXXXV^M
κΧΧΧΧΧΧΧΧΊ
iments and/or the results are compared with those
k^^^^^^^
20 -
ι
from already established (possibly performed in ref-
erence laboratories) radioimmunological methods.
In addition to work at the Institute for Clinical Bio- 1
— 1977 1978 1979 1980 1981 1977 1978 1979 1980 1981
chemistry at the University of Bonn, contributions to
improving the cornparability of results between la- Fig. 18. Developments in precision for the determination of folli-
boratories have been made in the last 10 years par- tropin (a) and lutropin (b), using the 'matched reagents
program' of the World Health Organization.
ticularly by the group of Marschner, Scriba and D WHO reagents
Wood, u$ing their own type of interlaboratory colla- 13 other
I- 40
20;
20 40 20 40 20 40
Thyrotropinlmll/U
Fig. 17. Improvement in the precision of the assay for thyroid stimulating hormone in the Federal Republic of Germany.
AR1A Becton-Dickinson Chamber with solid phase antibody, Triiodothyronine, thyroxin, oestriol, Cortisol,
regenerable digoxin, thyrotropin, Bja/folate
Automated RIA Technicon Continual flow System, air bubble principle, Triiodothyroninc, thyroxin, Cortisol, digoxin,
antibody on iron particles, human placenta lactogen
magnetic Separation
Centria Union Carbide Batch principle (manual), centrifugal Triiodothyronine, ihyroxin, thyrotropin,
analyser, bound/free Separation by ion insulin, digoxin, Cortisol, B i2/folate, human
exchange placenta lactogen, lutropin, follitropin,
ferritin, prolactin
Concept 4 Micromedic Antibody-coated vessels, washing stage, Triiodothyronine, thyroxin, thyrotropin,
lOplaceracks insulin, Cortisol, B12
Gammaflow Squibb Continuous flow system, air bubble Triiodothyronine, thyroxin, digoxin, cortisol,
principle, bound/free Separation with oestriol
regenerable ion exchanger
Kemtek 3000 Bagshawe-Kemble 15 place racks, bound/free Separation by Carcinoembryonic antigen, alpha-foeto-
filtration, measurement of filter protein, human chorionic gonadotropin,
human placenta lactogen, human somato-
tropin, triiodothyronine, thyroxin, cortisol,
oestriol
of the use of existing tests for tumour markers. It can test. Infectious diseases represent a possible new
also be anticipated that the development of tests for field of application for new tests, äs evidenced by the
newly discovered tumour antigens, such äs tissue recent development of a series of radioimmunologi-
polypeptide antigen, colon-specific antigen p and cal tests in bacteriology, parasitology and virology
pro-adrenocorticotropic hormone, will lead to an in- (tuberculosis, malaria, hepatitis). Over the last few
crease in the use of radioimmunological tests in the years, simplified versions of tests have increased
field of tumour markers. An example of market reg- their share of a growing market, e.g. preprepared
ulation by legislation is seen in the Situation that ear- reaction vessels containing appropriate quantities of
lier resulted in Abbot's monopoly of the hepatitis separately lyophilized antibody and/or labelled anti-
gen, or premeasured quantities of labelled antigen in
vessels coated with antibody. In this area, however,
one can expect little further impetus for expansion,
2000
with similar low growth rates for simplified Systems
and their competitors, and little further development
of mechanized and automated Systems. It is not yet
possible to foresee whether the use of homogeneous
assays will result in a shift of emphasis in the market.
The turnover and share of radioimmunoassays in the
1000 overall immunological analytical sector of the
market will probably stabilize in the next 3—4 years.
Deperiding on the demand for increased sensitivity,
new immunological tests, especially for small anti-
gens, will be developed äs alternatives to other
niethods. Some existing radioimmunological tests,
0L- especially those concerned with thyroid function and
1960 1970 1980
drug monitoring, have been and are being replaced
Fig. 21. Growth in the number of publication concerned with ra- by non-radioimmunoassay methods. With the spread
dioimmunoassay. of presymptomatic diagnostic screening methods,
Growth critena for radioimmunoassay. the use of the available automated Systems will in-
New radioimmunological tests crease rather than stagnate; this will perhaps lead to
New areas of application
Simplification of tests an improvement in the most notable weakness of ra-
Legislation dioimmunological methods, i. e. the comparability of
Automation results, which is so essential for positive clinical diag-
Competition
New tecihnologies nosis (37).
References
1. Mirsky, I. A. (1952) Rec. Progr. Horm. Res. 7, 437-467. 23. Sufi, S. B., Jeffcoate, S. L., Hall, P. E. & Goncharov, N.
2. ßerson, S. A., Yalow, R. S., Baumann, A., Rothschild, K. & (1982) In: Radioimmunoassay and Related Procedures in
Newerly, J. (1956) J. Clin. Invest. 35, 170-190. Medicine 1982. International Atomic Energy Agency, Vien-
3. Yalow, R. S. (1978) Science 200, 1236-1245. na 1982, pp. 555-571.
4. Yalow, R. S. & Berson, S. A. (1960) J. Clin. Invest. 39, 24. Bacon, R. R. A., Hunter, W. M. & Ratcliffe, J. G. (1982) In:
1157-1175. Radioimmunoassay and Related Pijocedures in Medicine
5. Landon, J. (1979) Antibiotics Chemother. 26, 118-128. 1982, International Atomic Energy Agency, Vienna 1982,
6. Goldsmith, S. J. (1979) Antibiotics Chemother. 26, 45-60. pp. 573-589.
7. Hall, P. E. (1979) J. Steroid Biochem. / / , 113-116. 25. Röhle, G., Voigt, U., Kruse, R., Oberdörster, W. & Breuer,
8. Schmidt, H., von Stetten, O., Kellermann, G., Patzelt, H. & H. (1982) In: Radioimmunoassay and Related Procedures in
Naegele, W. (1982) In: Radioimmunoassay and Related Medicine 1982. International Atomic Energy Agency, Vien-
Procedures in Medicine 1982. International Atomic Energy na 1982, pp. 645-652.
Agency, Vienna 1982, pp. 111-121. 26. Lauterbach, H. & Lobers, W. (1982) In: Radioimmunoassay
9. Rodgers, R. P. C. (1982) In: Radioimmunoassay and Related and Related Procedures in Medicine 1982. International
Procedures in Medicine 1982. International Atomic Energy Atomic Energy Agency, Vienna 1982, pp. 615—619.
Agency, Vienna 1982, pp. 383-409. 27. Fiori, A. M., Fiori, A. M. C. & Garcia, E. J. (1982) In: Ra-
10. Lübke, K. & Nieuweboer, B. (1978) In: Immunologische dioimmunoassay and Related Procedures in Medicine 1982.
Teste für niedermolekulare Wirkstoffe, Georg Thieme Ver- International Atomic Energy Agency, Vienna 1982, pp.
lag Stuttgart, pp. 36-42. 601-606.
11. Bolton, A. E. & Hunter, W. M. (1973) Biochem. J. 133, 28. Pilo, A., Zucchelli, G. C, Piro, M. A. & Chiesa, M. R. (1982)
529-539. In: Radioimmunoassay and Related Procedures in Medicine
12. Thorell, J. I. (1981) Clin. Chem. 27, 1969-1973. 1982. International Atomic Energy Agency, Vienna 1982,
13. Dwenger, A. & Trautschold, I. (1982) J. Clin. Chem. Clin. pp. 621-628.
Biochem. 20, 29-38. 29. Albertini, A. & Bolelli, G. (1982) In: Radioimmunoassay
14. Dwenger, A,,.Röllig, Gabriele, Bojanovski, D., Canzler, H. and Related Procedures in Medicine 1982. International
& Trautscho'lcl, I. (1982) Fresenius Z. Anal. Chem. 377, Atomic Energy Agency, Vienna 1982, pp. 629—634.
358-359. 30. Verordnung über Ausnahmen von der Eichpflkht (Eich-
15. Dwenger, A., Tost, P. & Trautschold, I. (1977) J. Clin. pflicht-Ausnahmeverordnung) vom 26. Juni 1970. Bundes-
Chem. Clin. Biochem. 75, 593-602. gesetzblatt vom 30. Juni 1970, Teil II, pp. 960^965.
16. Dwengen A. & Trautschold, I. (1978) J. Clin. Chem. Clin. 31. Marschner, L, Erhardt, F., Henner, J. & Scriba, P. C. (1975)
Biochem. 76, 587-595. Z. Klin. Chem. Klin. Biochem. 73, 481-488.
17. Dwenger, A., Friedel, R. & Trautschold, I. (1974) Z. Klin. 32. Friedel, R., Dwenger, A., Kästner, S. & Trautschold, I.
Chem. Klin. Biochem. 72, 237. (1974) Z. Klin. Chem. Klin. Biochem. 72, 45.
18. Dwenger, A., Zick, R., Friedel, R. & Trautschold, I. (1976) 33. Friedel, R., Dwenger, A., Bode, R. & Trautschold, I. (1974)
Z. Anal. Chem. 279, 108-109. Z. Klin. Chem. Klin. Biochem. 72, 237-238.
19. Brown, P. A. (1979) Antibiotics Chemother. 26, 98-104. 34. Dwenger, A., Friedel, R., Schweer, H.-H. & Trautschold, I.
20. Ekins, R. P. (1974) Br. Med. Bull. 30, 3-11. (1976) Acta Endocrinol. Suppl. 202, 31-33.
21. Schwarz, S. (1982) In: Radioimmunoassays and Related 35. Dwenger, A., Friedel, R. & Trautschold, I. (1976) Z. Anal.
Procedures in Medicine 1982. International Atomic Energy Chem. 279, 109-110.
Agency, Vienna 1982, pp. 447-524. 36. Dwenger, A. & Friedel, R. (1978) Fortschr. Med. 96, 989-
22. Marschner, L, Wood, W. G. & Scriba, P. C. (1982) In: Ra- 996.
dioimmunoassay and Related Procedures in Medicine 1982. 37. Dwenger, A. & Friedel, R. (197V9) GIT Labor-Medizin 7/79,
International Atomic Energy Agency, Vienna 1982, pp. 15-16.
591-600.
Dr. A. Dwenger
Abt. f. Klinische Biochemie
Zentrum Biochemie
Med. Hochschule Hannover
Koristanty^Gutschow-Str. 8
D-3000 Hannover 61
Enzyme-immunoassay: A Review1)
By M. Oellerich
Summary: The main principles of heterogeneous and homogeneous enzyme-immunoassays are reviewed.
Furthermore, an overview is given of enzymes currently used äs labels and methods applied for conjugate
preparation. The reliability and practicability of enzyme-immunoassays are discussed. Special consideration is
given to possible interferences, the detection limits and the mechanization of these assays. A ränge of curve-
fitting methods for evaluation of the results is listed. Future prospects for the further development of enzyme-
immunoassay and application of this technique are discussed.
called a double antibody solid phase (DASP) tech- Recently a new approach to heterogerieous enzyme-
nique. immunoassays has been described (18), in whieh the
The c o m p e t i t i v e e n z y m e - i m m u n o a s s a y (fig. enzyme label is not only covalently linked to a ligand
1.1.1) is analogous to the well known classical ra- of the type to be determined, but also to a "tag"
dioimmunoassay of Yalow & Berson (15). Labelled molecule (fig. 1.1.3). Free ligand and enzyme conju-
(E-L) and unlabelled antigens (L) compete for the gate compete for an antibody. If fthe enzyme conju-
binding sites of a limited amount of antibody (AB). gate is bound to the antibody its tag is masked so that
The Saturation of the antibody occurs simultaneous- it can no longer bind to the insolubilized receptor
ly, providing all reactants are incubated together. (RI). The amount of enzyme cpnjugäte boüiid to this
The principle of "sequential Saturation" is preferred receptor is proportional to that of the free ligand to
under certain conditions, e.g. if antigens with very be assayed. This procedure is called "antibody
low serum concentrations are to be determined (16). masking enzyme tag immunoassay (AME-
However, according to Pratt et al. this technique TI A). In a model System biotin has been used äs the
leads to reduced specificity (17). tag and avidin äs the insoluble receptor (18).
1.1.3 1.4.2
Procedures in which the sample antigen (L) is bound cumvented. In the Sandwich antibody assay (fig.
to an enzyme-labelled antibody (E-AB) added in ex- 1.5), the antibody to be determined (ABi) reacts
cess, are classified s immuno-enzymometric 'with an antigen (L) bound to the solid phase, and is
assays (fig. 1.2). The remaining, free labelled anti- detected by a second enzyme-labelled antibody (E-
body is separated in a subsequent step by binding AB2).
with antigen (L) coupled to a solid phase, which is
added in excess.
Enzyme-Labels Used in Heterogeneous Enzyme-
In a rapid one step procedure called i n h i b i t i o n e n - immunoassays
zyme-immunoassay the antigen-antibody inter-
action between solid phase-coupled antigen and an The quality of an enzyme-immunoassay depends
enzyme-labelled antibody is inhibited by free anti- very much on the purity of the antigen or hapten
gen of the sample. The enzymic activity detected on used for immunization, calibration and conjugation,
the solid phase is inversely proportional to the the specificity of the antibody and the choice of a
amount of antigen present in the sample. suitable enzyme label. Sensitive assays require a
highly purified enzyme with a high turnover number,
"S a n d w i c h " a s s a y s have been described in numer-
and a low detection limit for the reaction product
ous modifications (19). In a Variation of the sand-
wich antigen assay (fig. 1.4.1), the bound antibody (4).
(ABi) is indirectly labelled by a second enzyme-la- The enzymes listed in table 2 have proved generally
belled antibody (E-ABa), which is directed against useful. The enzymes most frequently used so far for
the first (ABi) and should not react with the anti- heterogeneous enzyme-immunoassays are horse-
body (AB) attached to the solid phase (fig. 1.4.2). radish peroxidase, alkaline phosphatase and -D-ga-
The antibodies ABi and AB should be be obtained lactosidase.
from different species. Such an indirect labelling can The determination of the enzyme activity is chiefly
also be applied to immuno-enzymometric tests (5) performed by photometry. In order to increase the
and Inhibition enzyme-immunoassays (20). The detectability of the assays, however, fluorigenic, ra-
method of indirect labelling has the advantage that dioactive and chemiluminescence-producing sub-
the same enzyme-antibody conjugate can be used in strates are also used. In a further procedure, the ac-
assays for various different antigens. Thus the often tivity of peroxidase bound to an antibody-coated
difficult direct labelling of the antibody may be cir- membrane is determined by an iodide-sensitive elec-
Tab. 2. Enzyme labels used in heterogeneous enzyme-immunoassays (from I.e. (l, 21)).
Fig. 2. Principles of homogeneous enzyme-immunoassays. All reactants are present in one reaction medium: L ligand; E-L, Ej-L
enzyme labelled ligands; M-L ligand-substituted enzyme modulator; FAD-L ligand covalently linked to flavin adenine dinu-
cleotide; S-L ligand labelled Substrate; P-L ligand labelled product; AB limited amount of antibody; ABi antibody to be
detected; AB2 succinylated antibody; ABi-E, AB2-E enzyme labelled antibodies; E2-B-AB antibody co-immobilized with
an enzyme (E2) on fine beads (B); E, EI, E2, E3 enzymes; Apo-E apoenzyme; Holo-E holoenzyme; S Substrate; RBC
erythrocyte; P, P,, P2, Q Products of enzymic reactions, i Inhibition of the "marker enzyme" (frofrn I.e. (1)).
L·"
E
2.1.2
EMIT (enzyme multiplied immunoassay technique) 2.5 PQLIA (prosthetic-groupHabel immunoassay)
2.6
2.2 ECIA (enzyme channeling immunoassay) SLFIA(substrateHabeled fluorescent immunoassay)
Theenzyme modulator mediated immunoas- phospholipids, which are coiiiponents of the erythro-
say (EMMIA) described by Ngo et al. (28) is cyte membranes and therefore may be viewed äs be-
based on the ability of a ligand-coupled enzyme ing immobilized. When IgG (ABi) forms a complex
modulator (L-M) to influence the activity of the in- with the enzyme-anti-IgG conjugate, it sterically
dicator enzyme (fig. 2.4). Ligand-substituted en- prevents an interaction between the enzyme label
zyme modulator (L-M) and ligand from the sample (E) and the Substrate (S).
compete for a limited amount of antibody (AB). If Other competitive procedures, in which coenzymes
the enzyme modulator (L-M) is bound to the anti- are used to label the ligand (35, 36), may also be
body, it cannot affect the activity of the indicator en- classified äs homogeneous enzyme^immunoassays. If
zyme. Modulators which increase or decrease the en- the ligand-coenzyme conjugate is bound to an anti-
zyme activity can be used. In assays with an inhibit- body, its cycling in a suitable enzymic cycle is pro-
ing modulator the enzyme activity is inversely pro- portionally reduced. This Inhibition is reversed by
portional to the concentration of the analyte. This unconjugated ligands in competitive binding reac-
technique has been used for determination of thyr- tions. So far, however, this assay principle has gained
oxine (29). no significance in clinical diagnosis.
A further homogeneous enzyme-immunoassay is
based on a l i g a n d - l a b e l l e d enzyme prosthetic
group (30). In the scheme of figure 2.5, ligand-flav-
in-adenine-dinucleotide conjugate (L-FAD) and li-
gand (L) from the sample compete for a limited Enzyme-Labels Used in Homogeneous Enzyme Im-
amount of antibody (AB). If the ligand-FAD conju- munoassays
gate is bound by the antibody, it can no longer com-
bine with the apoenzyme (Apo-E) to form an en- The enzymes listed in table 3 have proved generally
zymatically active holoenzyme (Holo-E). Thus the useful äs labels in homogeneous enzyme-iiiimunoas-
observed enzyme activity is directly related to the says.
concentration of the analyte (L). This principle can In the EMIT, an NAD-dependent glucose-6-phos-
be used for the determination of haptens and anti- phate dehydrogenase is mainly used. The activity of
gens (8, 30, 31). this enzyme can be easily determined photometrical-
The principle of the substrate-labelled fluores- ly or fluorimetrically. In an antigemlabelled homo-
cent immunoassay is schematically presented in geneous enzyme-inhibition immunoassay for serum
figure 2.6. In this assay a ligand (L) labelled with a proteins and an enzyme-enhancement immunoassay,
fluorigenic Substrate (S) is used. This conjugate is ß-galactosidase was used äs label and a synthetic ma-
non-fluorescent and competes with the analyte (L) cromolecular dextran-linked ö-nitrophenyl-ß-galac-
for a limited amount of antibody (AB). When the toside äs Substrate (27, 37). Litman et al. (26) em-
substrate-ligand conjugate (S-L) is bound by the ployed the enzyme pair, hexokinase and glucose-6^
antibody, it cannot be converted by an enzyme to a phosphate dehydrogenase, in an enzyme channeling
fluorescent product (P-L). The amount of conjugate immunoassay. Scavenging was achieved in this assay
available for reaction with the enzyme and the re- by phosphoglucose isomerase (EC 5.3.1.9) and
sulting fluorescence intensity are proportional to the phosphofructokinase (EC 2.7.1.11).
concentration of the analyte. Since in assays of this In various other homogeneous enzyme-immunoas-
type the enzyme does not produce an amplification says the indicator enzyme is coupled neither to the
effect and the amount of unbound substrate-labelled antigen nor to antibody (fig. 2). Horseradish peroxi-
ligand available for the enzyme depends on the ana- dase (EC 1.11.1.7) or acetylcholinesterase (acetyl-
lyte concentration, it is necessary to use a fluorigenic choline hydrolase; EC 3.1.1.7) have been used in en-
Substrate to label the ligand. Substrate-labelled fluo- zyme modulator immunoassays (28, 29). In pros-
rescent immunoassays have been described for the thetic-group-label homogeneous immunoassays
determination of haptens and antigens (32, 33). flavin adenine dinucleotide has been used äs the
prosthetic group and ghicose oxidase (EC 1.1.3.4)
A further homogeneous immunoassay has been de- from Aspergillus niger äs the holoenzyme (30, 31).
scribed by Wei et al. (34). A hypothetical scheme of For homogeneous substrate-labelled fluorescent im^
this System is shown in figure 2.7. Rabbit antihüman munoassays ß-galactosidase (ß-D-galactosidase ga-
IgG (AB2) was labelled with phospholipase C (E). lactohydrolase, EC 3.2.1.23) from Escherichia coli
The enzymatic activity of the conjugate was inhibited and a fluorigenic Substrate (e.g. ß-galactosyl-umbel-
by human IgG (ABt). The Substrates (S) used were liferone) was employed (32, 3$)·
Cross-reactions with other compounds occur if the certain models, whereas "data-based" methods can
antibody lacks specificity. The antibodies of various be applied without knowledge of the type of function
commercial assays for quantitative determinations underlying the calibration curve. The niost suitable
show a relatively high specificity (2). However, con- methods must first be ascertained for each enzyme-
siderable differences in specificity have been ob- immunoassay.
served, for example, among various commercial im- •r
munoassays for determination of theophylline (42).
Future Aspects
In the past few years enzyme-immunoassays have
Detection Limits been increasingly used, especially for the determina-
In a number of heterogeneous enzyme immunoas- tion of substances like drugs, hormones, antigens of
says the detection limits are the same äs those of ra- pathogenic organisms and antibodies.
dioimmunoassay (2). In general, the detection limits
The development of enzyme-immunoassay is cur-
of radioimmunoassays ränge from 1—500 pmol/1 or
rently still in a state of flux. Further possible sources
0.2—50 fmol/tube (4). Moreover heterogeneous en-
of improvement lie in a better standardization of the
zyme immunoassays with an extraordinarily high de-
reagents and methods, in the search of more effec-
tectability have been described. Such assays were
tive marker enzymes and better cross-linking rea-
capable of detecting even l amol/tube (10~"18 mol) of
gents. Systematic investigations are needed concern-
ornithine-6-aminotransferase (43) or 24000 mole-
ing the influence of the degree of labellirig, the site of
cules of purified mouse myeloma IgG (44).
cross linking and the natuf e of the bridge on the per-
The detectability of homogeneous enzyme-immu- formance of an assay. Alternative procedufes for the
noassays is lower than that of heterogeneous tests determination of enzyme activities, such äs fluorime-
(2). The detection limits and the lower limits of the try and calorimetry should be evaluäted.
working ränge with EMIT for various drugs and
The use of suitable monoclonal antibodies
thyroxine were 2—107 pmol/1 (2), with substrate-
could contribute to an improvement of the specificity
labelled fluorescent immunoassays for several drugs
of enzyme-immunoassays. Although it is stijl quite
and immunoglobulins the corresponding ränge was
difficult to obtain suitable high-affinity monoclonal
105-106 pmol/1 (l, 32-33), and with the enzyme
antibodies, the application of such antibodies ap-
modulator mediated immunoassay for thyroxine, 6.4
pears to be promising in the immunodiagnostic field.
x l O3 pmol/1 (29). However, the detectability of
For example, in a newly developed enzyme immu-
these assays is sufficient for the determination of
noassay for determination of thyrotropin, which is
many diagnostically relevant compounds (2).
based on the "sandwich" prineiple, monoclonal anti-
ß-thyrotropin antibodies and peroxidase labeled
E v a l u a t i o n of the results Fab' fragments of sheep antibody have been used
(41). The results obtained by this method were in
For the evaluation of the results from enzyme-im-
relatively good agreement with those determined by
munoassays Computers are increasingly used. Manu-
radioimmunoassay (tab. 5). The use of selected pairs
al procedures are lengthy and sometimes less depen-
of monoclonal antibodies could allow the develop-
dable.
ment of new heterogeneous and homogeneous assay
A ränge of available curve-fitting methods is shown principles.
in table 4. Some of these procedures are based on
Mechanization
Tab. 4. Curve fitting methods for enzyme-immunoassay (from
I.e. (2)). A far-reaching mechanization of enzyme-immu-
noassays appears to be essential. According to exist-
l. Model-based methods ing experience, the improvement of the reliability
1. l Parabolic regression
l .2 Linear regression after logit-log transformation and practicability of these assays by mechanization is
1.3 Weighted linear regression after logit-log transformation likely to be far greater than the beneficial effects of
l .4 Weighted non-linear regression after logit-log transformation mechanization on the commonly used clinicäl chemi-
2. Data-based methods
2.1 Manual curve-fit cal routine procedures. As enzyme^immußoassays
2.2 Polygonal Interpolation show non-linear calibration curves, the accuracy of
2.3 Empirie spline-interpolation these tests depends very much on the precision,
2.4 Cubic spline-interpolation
2.5 Spline approximation wfiich can be cönsiderably increased by mechaniza-
tion. . jr
Tab. 5. Comparison of the results obtaincd by enzyme-immunoassay (ELISA, Enzymun-Tcst® TSH) and radioimmunoassay (TSH-
Henning) for determination of thyrotropin (TSH) in serum samplcs from paticnts.
Furthermore, the costs of reagents and technician The mechanization of heterogeneous enzyme-immu-
time can be considerably reduced if suitable mechan- noassays may perphaps be facilitated in the future by
ization is chosen (2). A large reduction in reagent the use of aqueous two-phase Systems for Separation
costs may be achieved by adaptation of EMIT to of bound and free ligand. The principle is that free
centrifugal analysers, and of the substrate-labelled and bound antigen are distributed unevenly between
fluorescent immunoassay to the Micro-ERMA (Mi- two immiscible water-soluble phases and can subse-
cro Enzyme Reaction, Multiple Assay) System (45). quently be recovered from separate phases (47).
Because of the incubation periods, and the washing- Homogeneous enzyme immunoassays have been
and Separation Steps, it is difficult to fully to mechan- partially and fully mechanized by use of many differ-
ize the ELISA-technique. Certain Steps, such äs the ent anaiytical Systems (2). Several examples are giv-
washing procedure, the dispensation of the reagents en in tableo. Single emergency determinations of
and the photometric measurement have already drugs such äs theophylline, can be performed by
been mechanized (tab. 6). EMIT within 10-20 minutes. By using quantitative
EMIT drug assays adapted to an Eppendorf System
The performance of helerogeneous enzyme-immu- ACP 5040, for example, about 250 patient samples
noassays generally takes several hours at least. In can easily be analysed by one technical assistant per
our experience 200—300 patient samples can be as- day (2). With the ACA from Du Pont, calibration
sayed for thyroxine or hepatitis B surface antigen by curves for EMIT were stable for many weeks, pro-
one technical assistant per day using partially me- vided that the same lot of reagents was used (48).
chanized Systems. Up to 4000 samples have been an-
alysed per day with an enzyme-immunoassay for de- The development of dry chemistry Systems could
termination of antibödies against Trichinella spiralis greatly simplify the performance of enzyme-immu-
(46). noassays. In the EMIT®-st™ drug detection System
all the reactive components such äs enzyme conju-
gate, Substrate, antibody and buffer are already pres-
Tab. 6. Värious anaiytical Systems used for enzyme immunoas- ent in one vial in the dry form. The assay is carried
says. out merely by adding patient sample plus water and
taking a reading at a fixed time. Recently, reagent
Homogeneous Heterogeneous
enzyme-immunoassays strip Systems for theophylline and phenytoin have
enzyme=immunoassays
been described which are based on the prosthetic-
Centrifugal analysers ELIS A-Meßplatz Eppendorf group-label homogeneous immunoassay (31). Such
(i.e. CobasBio) reagent strip Systems may allow rapid determina-
AutoLab 5000 Abbott Quantum I tions and evaluation of the results either with the un-
ACA Du Pont Riele PMC Automatik
Eppendorf ACP 5040 GilfordEIA-PRSO aided eye or by use of reflectance spectrophotome-
ABA-100 LKB 2074 try. Further developments in this field might include
Fluorostat Titertek-Multiskan dry, solid-phase reagent Systems such äs multilayer
Optimale Enzymun-Test® System ES 22
film elements (49).
References
i. Oellerich, M. (1983) In: Methods
rd
of enzymatic analysis 28. Ngo, T. T. & Lenhoff, H. M. (1980) FEBS Lett. 776, 285-
(Bergmeyer, H. U., ed.), 3 ed., volume l, pp. 233-260, 288.
Verlag Chemie, Weinheim. 29. Finley, P. R., Williams, R. J. & Lichti, D. A. (1980) Clin.
2. Oellerich, M. (1980) J. Gin. Chem. Biochem. 18, 197-208. Chem. 26, 1723-1726.
3. Wisdom, G. B. (1976) Clin. Chem. 22, 1243-1255. 30. Morris, D. L., Eliis, P. B., Carrieo, R. J., Yeager, F. M.,
4. Schuurs, A. H. W. M. & van Weemen, B. K. (1977) Clin. Schroeder, H. R., Albarella, J. P., Boguslaski, R. C., Hornby,
Chim. Acta 81, 1—40. W. E. & Rawsori, D. (1981) Anal. Chem. 53, 658-665.
5. Borrebaeck, 'C. & Mattiasson, B. (1979) J. Solid-Phase Bio- 31. Tyhach, R. J., Rupchock, P. H., Pendergrass, J. H., Skjold, A.
ehem. 4, 57-67. C., Smith, P. J., Johnson, R. D., Albarella, J. P. & Profitt, J.
6. O'Sullivan, M. J., Bridges, J. W. & Marks, V. (1979) Ann. A. (1981) Clin. Chem. 27, 1499-1504.
Clin. Biochem. 16, 221-240. 32. Burd, J. F., Wong, R. C., Feeney, J. E., Carrieo, R. J. & Bo-
7. Schärpe, S. L., Cooreman, W. M., Blomme, W. J. & Laeke- guslaski, R. C. (1977) Clin. Chem. 23, 1402-1408.
mann, G. M. (1976) Clin. Chem. 22, 733-738. 33. Ngo, T. T., Carrico, R. J., Boguslaski, R. C. & Burd, J. F.
8. Ngo, T. T. & Lenhoff, H. M. (1981) Appl. Biochem. Biotech- (1981) J. Immunol. Meth. 42, 93-103.
nol. 6, 53-64. 34. Wei, R. & Riebe, S. (1977) Clin. Chem. 23, 1386-1388.
9. Engvall, E. & Perlmann, P. (1971) Immunochemistry 8, 35. Carrico, R. J., Christner, J. E., Boguslaski, R. C. & Yeung, K.
871-874. K. (1976) Anal. Biochem. 72, 271-282.
10. van Weemen, B. K. & Schuurs, A. H. W. M. (1971) FEBS 36. Schroeder, H. R., Carrico, R. J., Boguslaski, R. C. &
Lett. 75, 232-236. Christner, J. E. (1976) Anal. Biochem. 72, 283-292.
11. Guesdon, J. L., Thierry, R. & Avrameas, S. (1978) J. Allergy 37. Gibbons, I., Skold, C, Rowley, G. L. & Ullman, E. F. (1980)
Clin. Immunol. 61, 23-27. Anal. Biochem. 702, 167-170.
12. Östermann, T. M., Juntunen, K. O. & Gothoni, G. D. (1979) 38. Rowley, G., Rubenstein, K., Huisjen, J. & Ullman, E. (1975)
Clin. Chem. 25, 716-718. J. Biol. Chem. 250, 3759-3766.
13. AI-Bassam, M. N., O'Sullivan, M. J., Gnemmi, E., Bridges, J. 39. Deleide, G., Dona, V. & Niälvaho, R. (1979) Clin. Chim.
W. & Marks, V. (1978) Clin. Chem. 24, 1590-1594. Acta 99, 195-201.
14. AI-Bassam, M. N., O'Sullivan, M. J., Bridges, J. W. & Marks, 40. Oellerich, M. & Haindl, H., unpublished data.
V. (1979) Clin. Chem. 25, 1448-1452. 41. Wehner, R., Baier, M., Kienner, D., Lenz, H., Jungfer, H.,
15. Yalow, R. S. & Berson, S. A. (1959) Nature 184, 1648- Kleinhammer, G. & Linke, R. (1983) Lab. Med. 7, 147.
1649. 42. Oellerich, M., Hannemann, P., Külpmann, W. R., Beneking,
16. Zettner, A. & Duly, P. E. (1974) Clin. Chem. 20, 5-14. M. & Sybrecht, G. W, (1982) Internist 23, 641-646.
17. Pratt, J. J. & Woldring, M. G. (1976) Clin. Chim. Acta 68, 43. Ishikawa, E. & Kato, K. (1978) Scand. J. Immunol. 8, 43-
87-90. 55.
18. Ngo, T. T. & Lenhoff, H. M. (1981) Biochem. Biophys. Res. 44. Shalev, A., Greenberg, A. H. & McAlpine, P. J. (1980) J.
Commun. 99, 496—503. Immunol. Meth. 38, 125-139.
19. Schuurs, A. H. W. M. & van Weemen, B. K. (1979) Dt. Ges. 45. Leaback, D. H. & Creme, S. (1981) Biochem. Soc. Trans. 9,
f. Klin. Chemie e. V.-Mitteilungen 10, 22-31. 580.
20. Carlier, Y., Bout, D., Fruchart, J. C., Desreumaux, C, De- 46. Ruitenberg, E. J., Steerenberg, P. A., Brosi, B. J. M. & Buys,
wailly, P., Sezille, G. & Jaillard, J. (1978) J. Immunol. Meth. J. (1974) Bull. Wld. Hlth. Org. 57, 108-109.
27, 317-324. 47. Mattiasson, B. (1980) J. Immunol. Meth. 35, 137-146.
21. Chandler, H. M., Cox, J. C., Healey, K., Mac Gregor, A., 48. Haeckel, R. & Oellerich, M. (1980) Dt. Ges. f. Klin. Chemie
Premier, R. R. & Hurrell, J. G. R. (1982) J. Immunol. Meth. e. V.-Mitteilungen 77, 74-95.
53, 187-194. 49. Curme, H. G., Columbus, R. L., Dappen, G. M., Eder, T. W.,
22. Borrebaeck, C., Börjeson, J. & Mattiasson, B. (1978) Clin. Fellows, W. D., Figueras, J., Glover, C. P., Goffe, C. A., Hill,
Chim. Acta 86, 267-278. D. E., Lawton, W. H., Muka, E. J., Pinney, J. E., Rand, R.
23. Pratt, J. J. (1978) Clin. Chem. 24, 1869-1890. N., Sanford, K. J. & Wu, T. W. (1978) Clin. Chem. 24,
24. Rubenstein, K. E., Schneider, R. S. & Ullman, E. F. (1972) 1335-1342.
Biochem. Biophys. Res. Comm. 47, 846-851.
25. Ullman, E. F., Blakemore, J., Leute, R. K., Eimstad, W. &
Jaklitsch, A. (1975) Clin. Chem. 21, 1011. Prof. Dr. M. Oellerich
26. Litman, D. J., Hanion, T. M. & Ullman, E. F. (1980) Anal. Institut für Klinische Chemie
Biochem. 706, 223-229. Medizinische Hochschule Hannover
27. Gibbons, L, Hanion, T. M., Skold, C. N., Russell, M. E. & Koristanty-Gutschow-Straße 8
Ullman, E.'F. (1981) Clin. Chem. 27, 1602-1608. P-3000 Hannover 61 * »
Luminescence Immunoassays:
Problems and Possibilities1)
By W. G. Wood
Klinische Laboratorien, Klinik für Innere Medizin (Direktor: Prof. Dr. P. C. Scriba),
Medizinische Hochschule Lübeck
Summary: This article reviews the field of bioluminescence and chemiluminescence immunoassays, and gives
examples from past and present work in these areas. The problems of luminescence immunoassays are dis-
cussed, and include the choice of label, solid phase, immunogen/hapten-protein conjugates for immobilisation
and the stability of bio- and chemiluminescent reagents.
Examples have been given to show the stages in the development of luminescence immunoassays up to their
acceptance for routine clinical in-vitro diagnostic use.
Luminometers and commercial kits have been discussed, with regard to the present Situation in these fields
and the personal experience with two semi-mechanized luminescence analysers in routine use.
') Presented at the Kleinkonferenz „Immunologische Diagnostik" der Deutschen Gesellschaft für Klinische Chemie, Hamburg, Juni
1983.
tuellen Stand der Lumineszenzimmunassays wird die Entwicklung der Bio- und Chemilumineszenz aufge-
zeigt. Auf die praktischen Probleme bei der Entwicklung von Lumineszenzimmunassays wie Wahl des Lumi-
nogens, Herstellung und Stabilität von bio- und chemilumineszierenden Markersubstanzen, die Bedeutung
der Verwendung des geeignetsten Immunogens sowie die Festphasen-Problematik wird umfassend eingegan^
gen. Beispiele von Lumineszenzimmunassays und deren Entwicklung und Optimierung bis hin zur routinemä-
ßigen Anwendung sind beschrieben. ,f
Luminometer und kommerzielle Testbestecke werden kurz angesprochen, insbesondere die persönlichen Er-
fahrungen mit zwei teilmechanisierten Luminometern in der Routine.
Characteristics
a. Chcmiluminesccnce is commonly associated with "non-bio-
logical' 'systems.
Luminol derivatives b. It often involvcs compounds related to luminol, isoluminol and
acridine.
R * NH 2 - Luminol
R = N « N 4 X- - Diazoluminol c. An enzyme is not ncccssary for light production, although a
pseudoperoxidase is oftcn used to generate nasccnt oxygcn.
d. Active oxygen is needed (Oj or O2H-) lo initiatc chemiiumi-
nesccnce.
R2-N
Advantages
a. All molecules can be labelled (in contrast to radiolabelling) in
a given substance.
b. the chemiluminescent rcaction velocity can bc controlled (in
Isoluminol derivatives contrast to radioactivity where onc is dependent upon the half-
Hfc of the radionuclide).
R i and = H - Isoluminol
Rj R2 = (CHz)2NH2 - 2-aminoethyI-N-ethyl isoluminol c. Chemiluminescent labels arc usually vcry stable and can be
RJ Rz = (CH2)4NH2 - 4-aminobutyl-N-ethyl isoluminol storcd in Solutions containing azidc or mcrthiolatc.
RI R2 = (CFhJsNHi - 5-aminopentyl-N-ethyl isolumin-
ol Disadvantagcs
Rj R2 - 6-aminohexyl-N-ethyl isoluminol a. The efficiency of the chemiluminescent reaction is usually very
(see I.e. (22)) Iow (undcr 5% of the total energy released), although ncw
compounds with efficiencies above 30% have bcen reported
(see I.e. (16)).
b. Chemiluminescence suffcrs from the same disadvantages äs ß-
scintillation counting, i.e. signal "quench" effects.
Acridine derivatives
RI absent, Rz = H - Acridine
Tab. 2. Examples of somc organisms exhibiting bioluminescence.
RI = CHs R2 = COORa where R3 is an alcohol
e.g. a sterol - Acridinium ester
Noctiluca mlllarls a marine dinoflagellate rc-
R i == CHa R2 = N-methyl acridine — Lucigenin sponsible for marine phospho-
(9,9'-bis-(N-methylacridinium nitrate)) rescence,
Renilla reniformis the sea pansy.
Diplocardia longa
Fig. l. Some of the most commonly used chemiluminescent com- luminescent earthworms.
Octochaetus tnultiporus
pounds. Latia neretoides a freshwater limpct.
Arachnocampa luminosa the New Zcaland glow-worm.
Chaetopterus variopedatiis a marine polychaete annclid.
Hoplophorus graälorostris a deep-sea shrimp.
Parapriacanthus ransonneti a luminescent fish.
Watasenia sdntillans a luminous squid.
tenets of bioluminescence äs stated by Robert Boyle Mycena cltricolor a luminous fungus.
(1,2) are listed in table 3. Photobacterium phosphoreum a luminescenl bacterium.
Photinus pyralis the American firefly.
The most commonly used luciferin-luciferase System
is that derived from the American firefly (Photinus
sp.). The purified reagents can be purchased either
separately or äs a "ready-to-use" mixture, sold äs
ATP-monitoring reagent or a similar name by sever-
al cheinical producers. Tab. 3. Basic tenets of bioluminescent observed by Robert Boyle
(see I.e. (1), (2)) in the 17th Century.
In the bioluminescent immunoassays developed in
this laboratory (14) pyruvate kinase was chosen äs a. Light without hcat.
label, using ADP and phosphoenolpyruvate äs sub- b. Very littlc oxygcn is needed for the maximal light Output.
c. The oxygcn-dependent lighl-rcaction is reversible.
strates, the ATP being produced being monitored ki- d. The light can bc extinguishcd with chemical rcagents, c.g. tur-
netically in a luminometer attached to an integrator/ pentine oil, strong spirit of sah, weak spirit of sal ammoniak.
plotter (LKB 1250).
srvd: i^A
H
COOH
H
Characteristics
a. Associated with living organisms.
b. Consists of two main components, a luciferin (substrate) and a
luciferase (enzyme).
Phoiinus Sp. (only the D-form is biologically active) c. Often, but not always, linked with ATP or NAD(P)H depend-
ent enzymes.
d. Components usually sensitive to conventional anti-microbial
agents such äs azide or merthiolate.
OH Advantages
a. Light Output highly efficient (up to 90% of theoretical values)
b. Kinetic measurements are possible.
c. Amplification effects of ATP or NAD(P)H-producing en-
zymes can be utilised. This can lead to more sensitive immu-
noassays.
OK
Disadvantages
a. Reagents are more expensive than for chemiluminescence.
Renilla reniformis
b. The enzymes are often unstable and cannot be stored in liquid
state for long periods of time.
c. Preparation of "labels" usually complicated (for luminescence
CH,-(CH 2 ) n -CHO immünoassay purposes).
(n = 8-12)
Photobacterium Sp.
Luminescence measurement
Substance
Bioluminescence Chemiluminescence
or
species-specific antibody
labelled with
Rate Integral
dl measurement measurement
background
t
dt
Fig. 3. The two forms of luminescent measurement used in the luminescent immunoassay sytems described in this article. The reagents,
together with the concentrations used in the light-generation Step have also been included.
tion Step äs in conventional CELIA and RIA meth- The question bioluminescence or chemilumines-
ods. This partly explains the lower detection limits of cence can be answered äs follows: As the biolumi-
SPALT, ILMA and ILSA for a given antigen, when nescent System is more sensitive, it should be used
compared with conventional CELIA methods. A se- where the chemiluminescent label is not yet sensitive
cond advantage of SPALT and ILSA is the ability to enough. Bioluminescent components are more ex-
use a "universal label", in this case labelled species- pensive and less stable in solution, than are their
IgG-specific antibody, e.g. donkey anti-rabbit IgG, chemiluminescent counterparts. The cost ratio is at
which is the only tracer needed for all antibodies least 20:1 more expensive in favour of biolumines-
raised in rabbits. The label can either be chemilumi- cence. The progression from bioluminescent to
nescent, e.g. diazolümiiiol or bioluminescent, e.g. chemilummescent assays can be given using this la-
pyruvate kinase. The disadvantage of the ILSA boratory äs an example. The first luminescent immu-
methqd is that in order to use a "universal label", the noassay for serum transferrin used a pyruvate kinase
two substance^specific antibodies must come from labelled antigen (28) and was used äs the sole rou-
non-related species, e.g. mouse and rabbit. Figures tine assay for over 12 months. As the expertise with
4a-4d summarise the CELIA, SPALT and ILSA chemiluminescent Systems was improved, the assay
techniques. The choice of label for luminescence im- was substituted by a bioluminescent SPALT and
munoassay depend to a large extent upon the chemi- than a chemiluminescent SPALT, the latter being
cal expertise available. The choice of diazoluminol the current routine serum transferrin method, (see
and pyruvate kinase äs Jabels was made because of gg.4c). The only bioluminescent immunoassay
the ease of synthesis of the antibody-luminogen de- which has not yet been replaced by a chemilumines-
rivatives (23, 28, 29). Füll details of synthesis and cent one in the author's laboratory is for serum thy-
practical application are just published (24, 25, 29). rotropin levels. The reason here is that the assay,
•v
t — — — hv
--- . hv
• — Antigen
Antigen labelled with luminogen
>- - Antigen specific '*first" antibody
Antigen in sample to be measured - Luminescence-labelled species-specific "second"
antibody
.r =* 4.
—· —- -*. hv
··**· -* -»- hv
which uses the ILSA technique, has two substance- Evaluation of Luminescent Immunoassays
specific antibodies which are not optimally mätched.
The proof of the püdding is in the eating — so runs
To^ive an idea of the use of luminescent immunoas- an old English proverb; and so it is with newly deve-
say in routine in-vitro diagnosis, table 5 gives ä list of loped methods that they can only be accepted after
such assays either in routine use, or undergoing clini- they have been "standardised" against existiiig
cal evaluation in the author's laboratory. Table 6 methods. In the case of the luminescent assay,, it
shows both the advantages and disadvantages of sol- must be cömpared with RIA and other established
id-phase immunoassays. immunologicäl procedüres. As there are only a few
Tab. 5. List of luminescence immunoassays undergoing clinical trials or already in routine use in the laboratory of the author (June
1983).
+
) R — routine, CE — clinicaJ evaluation, D - development stage
*) disctd. — assay discontinued or superseded.
++
) competitive assay — see figure 4c
**) MCC - microcrystalline cellulose äs solid-phase.
Table 7 shows the assay schemes for oti-foetoprotein Figure 5 shows Standard curves for the short and
in short and long versions, the former for pregnancy long arfoetoprotein ILSA using identical reagents
control the latter for post-operative tumour control. and set up at the same time.
Table 8 shows results from radio- enzyme- and lumi-
nescence immunoassays for selected patient samples. Table 9 shows the orosomueoid assay procedure, us-
The correlation between all three assays was excel- ing commercially obtained human material (Sigma,
lent when the kit Standards were us'ed for the com- Munich, catalogue riumber G-9885) for the Standard
mercial test packs and the WHO 72/225 Standard curve. The r nge of values found in a mixed patient
for the luminescent assay. The correlation between group including outpatients and patients in the in-
RIA and ILSA on 40 samples for the regression y = tensive care unit was 0.24-^1.90 g/l, which agrees
a + bx gave the following values: r = 0.986, a = with values to be expected ("normal r nge" from
2.80, b = 0.934. The corresponding values for EIA Behringwerke, Marburg a.d. Lahn, FRG, 0.55—
and ILSA were: r = 0.996, a = -1.50, b = 0.992. 1.40 g/l, mean 0.90 g/l). The number of serum sam-
The radioimmunoassay kit was from Amersham ples measured was 45. The next stage is the compari-
(Amersham-Buchler, Brunswick, FRG) and the en- son with radial immunodiffusion in a study where 50
zyme immunoassay kit from Abbott (Abbott GmbH,
Wiesbaden-Delkenheim, FRG).
Tab. 8. Selected sefa to demoiistrate performance of the ai-foe-
toprotein ILSA.
Tab. 7. Assay scheme for the αι-foetoprotein ILSA.
1. Test for "High dose hook" effect.
+ Sera from patients with hepatomas, concentration measured
Component/Step Assay A Assay B by dilution with normal human serum foll wed by radioimmu-
noassay (Amersham RIA-kit).
Serum/sample voJume (μΐ) 20 50 Patient l - concentration in serum by RIA 112.5 Χ 106 U/l
Buffer 4L + PBS/Tween (mixed in 300 250 Light Signal of 400 x 103 U/l Standard in ILSA - 6200 mV · s
equal proportions) (μΐ) Light signal of undiluted patient sample — 8340 mV · s
Anti-ai-foetoprotein (sheep) ball l
Patient 2 - serum concentration by RIA 2560 x l O3 U/l
Incubate time (h)/temp. (°C) 2/20-24 14-20/20-24
Light signal of undiluted patient sample — 7355 mV · s
Aspirate off buffer and wash with
PBS/Tween (l ml). Aspirate and 2. Dilution of a patient with a hepatoma to demoiistrate linearity.
wash with 0.15 mpl/1 NaCl (l ml). Concentration measured by EIA (Abbott AFP-EIA kit) at a
Aspirate. 1:10 dilution (corrected) 856 x 103 U/1.
Anti-ai-foetoprotein (rabbit) (μΐ) 300 300
Dilution factor Concentration Concentration
Incubate time (h)/temp. °C 2/20-24 6/20-24 in ILSA corrected for dilution,
103 U/I 103 U/I
Wash s above
Diazoluminol-donkey 300 300 1:1 (undiluted) >200 __.
anti-rabbit-IgG (μΐ) 1:2 >200 —
Incubate time (h)/temp. (°C) 2/20-24 2/20-24 1:4 199 796
1:8 112 896
Wash s above, transfer ball to 1:16 55.6 890
measuring cuvette, add 250 μΐ 1:32 27.4 877
0.15 mol/1 NaCl, measure in 1:64 14.0 896
Luminometer. 1:128 7.11 910
+
Assay A was designed for pregnancy monitoring and Assay B Samples diluted with human serum with an αι-foetoprotein con-
for post-operative follow-up of hepatoma patients, or patients tent under 103 U/L Samples assayed in Assay B in tafele 7.
with pre-operatively elevated αι-foetoprotein levels.
The sheep anti-ai-foetoprotein was obtained from Seward Anti- 3. Serum from pregnant women (15—20th week of pregnancy).
bodies (Proma, Augsburg, FRG).
The rabbit anti-cti-foetoprotein was purchased from DAKO Patient No. RIA EIA ILSA
3
(Boehringer Ingelheim, Ingelheim, FRG) and was diluted 1:500 (103 U/l) (103 /l) (io y/i)
befpre use.
The donkey anti-rabbit-IgG (Wellcome RD-17, Wellcome, Burg- 1 79 71 69
wedel, FRG) was first purified over DEAE-Cellulose, labelled 2 70 77 67
with diazoluminol and passed over an Ultrogel A4 column (LKB, 3 75 69 78
Munich FRG) before use. The working dilution was estimated at 4 . 177 192 184
approximately 1:700 when compared with the starting material. 5 59 55 . 52
The concentration of Tween 20 in the buffers was l ml/l.
Sample Assay
volume time
(μ\] [h]
50 24
24 ^
Fig. 5. The effect of serum sample volume and assay time in an Fig. 6. Typical Standard curve for a SPALT assay for orosomu-
ILSA for m-foetoprotein. coid (αι-acid glycoprotein) in which Standards and sample
are pre-diluted 1:25 before assay. The dotted line shows
the unspecific binding, i.e. where the substance-specific
antibody has been omitted from the System. It represents
routine sera are exchanged, each party only knowing the adsorption of label to the balls and is under 0.1% in an
optimised system.
bis obtained values. This somewhat shaky compari-
son must unfortunately suffice for the moment, al-
though it is far from an acceptable solution. Figure 6
shows an orosomucoid Standard curve.
Table 10 shows the optimised gentamicin SPALT The gentamicin assay has been chosen to show the
which has replaeed its fprerunners (14,23). Figure 7 precision and accuracy (against weighed-in Stan-
shows a Standard curve and table 11 quality control dards) of solid-phase luminescence immunoassays
data. This assay is in routine use and has fulfilled the using the equipment at present available for mea-
requireinents of an independent external quality surement. All data used here was obtained from an
control programme, (INSTAND, D sseldorf, FRG). LKB-1251 luminometer.
Tab. 9. Assay scheine for the orosomucoid (aj-acid glycoprotein) Tab. 10. Assay scheine for the Gentamicin SPALT in routine
SPALT. use.
Sample/Standard 50 Sample/Standard 50
(prediluted 1:25 with buffer 4N) (μϊ) (1:450 dilution in 0.15 mol/1 NaCl) (μϊ)
Rabbit anti-human orosomucoid 250 Buffer 4L + PBS-Tween (see tab. 7) (μϊ) 200
(1:500 in buffer 4N) (ul) Anti-gentamicin (rabbit) l: 125 dilution 50
Incubate at ambieht temperature (min) 10 in buffer 4Ν(μΙ)
Tab. 11. Seiected quality-controi parameters for the gentamicin Problems with Luminescence Immunoassays
SPALT.
The problem with bioluminescent labels have been
dealt with inasmuch äs they are relatively unstable
1. Standard curve data
a. Intercept stability, data from 20 assays
and cannot be conserved with the usual anti-micro-
80% intercept - 0.893 Mg/l ± 0.103 ng/1 (CV 11.5%) bial agents such äs azide or merthiolate. Chemilumi-
65% intercept - 1.58 ng/1 ± 0.130 ^ig/l (CV 8.19%) nescent compounds, when used in liquid-phase im-
50% intercept - 2.62 §/1 ± 0.137 §/1 (CV 5.24%) munoassays suffer from the same drawbacks äs ß-
35% intercept - 5.29 fig/1 ± 0.389 Mg/1 (CV 7.35%)
20% intercept — outside the Standard curve emitting radioisotopes such äs 3H or 14C, namely
(above 16 g/I) quench effects due to serum components which ab-
b. Unspecific binding data from 20 assays —
sorb light of the same wavelengths äs that emitted by
ratio to Bö and B15. the luminescent compound. These effects ean be
Ratio Bo/UB - 22.6 ± 2.07 (CV 9.16%) minimised by using solid-phase immunoassays (26,
Ratio B, 6 /UB - 5.43 ± 0.716 (CV 13.2%) 27) or by extracting the components to be measüfed
These figures are related to the sensitivity of the luminometer and prior to assay (27).
represent the signal to noise ratios at the zero and 16 g/l Stan-
dard curve points (see tab. 12 for corresponding data for the LB The main problems encoüntered in assay develop-
950). ment in this laboratory have been of a chemical ria-
ture, especially when working with hapten SPALT
2. Intra- and inter-assay coefficients of Variation for three control
sera. Data from 20 samples (intra-) from mean of duplicates
assays. Here the structure of the immunogen is of
(inter-assay). utmost importance äs is the structure of the hapten-
protein complex coupled to the solid-phase, espe-
Intra-assay Serum IV Serum V Serum VI cially where carbodiimides are used äs coupling rea-
gents. The effect of the "bridge" between hapten
Mean (Mg/l) 2.21 7.04 0.55 and protein in tracef-binding in RIA is well known
Standard deviation (ng/l) 0.042 0.371 0.027
Coefficient of Variation (%) 1.93 5.27 4.91 (31), and figures 8 and 9 show the reactions occur-
ring with carbodiimides and the effects of immuno-
Inter-assay
gen and immobilised hapten-proteiii on the Standard
Mean(ng/l) 2.26 7.14 0.59
Standard deviation ^ig/l) 0.078 0.659 0.045 curve produced (26).
Coefficient of Variation (%) 3.46 9.23 7.62
Practical problems which can arise in luminescence
immunoassays can be demonstrated using the genti-
micin SPALT described earlier. The precision of the
assay was not only influenced by the incubation
times and wash Solutions used, but also by the state
of the solid-phase before measurement of the lumi-
nescent signal. The Coefficient of Variation obtained
- using dry balls was more than double that obtained
when the bells were kept covered with physiological
saline (dry balls coefficient of Variation (CV) 8.7%,
-600 moist balls CV = 6.9%, balls in saline CV = 4.0% -
all values being those at a concentration of 6.0 mg/1
gentamicin).
§400 Problems in using coated tubes, especially for steröid
assays, have already been published (32) with regard
to unspecific binding of tracer and with regard to the
i, 200 efficiency of adsorption of antibody depending upon
the ionic strength and pH of the coating solution
(33).
0.1
When using the ILSA technique, the substänce spe-
1 2
Gentamicin img/l) cific antibodies must come from two uarelated spe-
cies in order to be able to use a labelled antibody
Fig. 7. Gentamicin SPALT assay which has been designed to directed against the "outwards-pointing" antibody.
measure "trough" values (values directly prior to drug ad-
ministration). The area of interest covers the ränge up to
An alternative to this is to use a modified ILMA in
4 mg/1, trough values above 2 mg/1 being regarded äs too whieh the "outwards-pointing" antibody has been
high. labelled with N-hydroxysuccinimidyl-biotin. In this
R'
U
0 NH , -
.c-o-c ^ ,C-NH-m
NH
A
T 14+
l
r R-NH-C-NH-R'
.C-OH -o-c
R—N«=C=N-R'
l Infernal rearrangement
fa& 9 ?·
«V^IK^H
Ä
Warer-soluble carbodümides
CH 3
/ V-N=C= * 0
l-Ethyl-3-(3-dimethylaminopropyl)carbodiimide
Fig. 8. Reaction scheme showing the two possibilities which can occur when using carbodümides for coupling haptens to proteins. In one
case (shown here äs intcrnal rearrangement) ihe carbodiimidc becomes attached to the protein and can act äs a potent antigcn. In
such cases, antibodies are raised to the hapten äs well äs to the rearranged carbodiimide.
roglobulin ILMA. The use of N-(4-aminobutyl-N- The author's laboratory has experience with two
ethyl)isoluminol hemisuccinamide via an active ester semi-mechanized luminometers, the main features
(N-(4-aminobutyl-N-ethyl)isoluminol hemisuccin- of which are shown in table 12. Neither machine is
amide N-hydroxysuccinimide ester) allows a high able to process the raw data fully so that a manual
incorporation of luminogenic groups without loss of entry of "counts" must be made into a desk-top
solubility and immunological activity. This results in Computer with modified RIA-dat^ processing pro-
assays with lower detection limits thän for assays us- gramme. One canriot expect a laboratory with auto-
ing diazoluminol äs label. matic RIA equipment to charige över to a semi-me-
chanized luminömeter, even when the assay proce-
dure is äs easy or easier than the original RIA. In the
case of the LB 950, extensive experimenting and
Instrumentation modification was needed üiitil the accepted reliabili-
The Instrumentation for luminometry is still in the ty and precision was attained so that routine assays
early stages of development, especially where immu- were possible without the assistant having to stand
noassays are concerned. At present only semi-me- over the machine to make sure that nothing went
chanized luminometers are available, mainly with a wrong!
limited sample capacity (under 50 samples) which The LKB-1251 is built to such fine tolerances that
precludes their use for long routine series. small deviations in the cuvette diameter lead to
Tab. 12. Major features of the LKB 1251 and LB 950 luminometers.
1 . General
Capacity — no. of samples 25 300
Cuvette size (mm) 51 X 12 37 x 12 - 55 x12
Special cuvettes Yes No
No. of injectors (maximum) 3 3
Pump-type Peristaltic Syringe
Pump-speed variable No Yes
Pump-volume variable Yes Yes
Mixing possible during injection/measurement Yes No+)
Pump volume maximum ( ) ca50 350 (700++))
Repeat-dispensing possible Yes No
) There is the possibility of blowing compressed air into the measurement chamber to effect mixing of tjie reagents.
) The LB 950 in use has been modified äs follows: All syringes have been replaced by syringes with Teflon plüngers (Hamilton,
Bonaduz, CH), the volume of the syringe for injecting into the measurement chamber being increased ifrom 0.5 ml to 1.0 ml.
blockage of the transport System. This means that automatically bypassed. Similarly, liquid phase as-
only high-quality cuvettes (LKB or Sarstedt No. says of the CELIA-type also circumvent the need for
68.750) can be used. The advantage of the LB 950 is ,special cuvettes.
that high quality test tubes of diameters 11—12 mm
Commercial kit producers do not seem to have rea-
and length 37—55 mm can be used. Here again, the
lised the füll potential of luminescence immunoas-
emphasis is on the quality, äs many test tubes tried
says, and are no doubt waiting for the first firm to
had unacceptable tolerances so that only tubes from
launch itself into this field, where the "patent-densi-
Sarstedt (55 x 12mm No. 55.484) were used.
ty" is still relatively thin!
Over 4000 samples were run in parallel on both
LKB-1251 and LB 950 to test for precision and dy-
namic ränge. After optimisation of both luminome- Conclusions
ters, no difference in performance could be seen.
The LKB 1251 was used for short experimental se- This article has been intended go give a brief over-
ries, the LB 950 for longer routine luminescence im- view äs to what is happening in the field of lumines-
munoassays. In order to make luminescence immu- cence immunoassay, and is intended to stimulate the
noassays an interesting alternative to RIA the Instru- reader into action in this field! Although is is now
evident that luminescence immunoassays can replace
mentation may have to be presented in the form of
"Black Boxes" with high reliability and throughout other immunoassays in all sectors (26) the impact of
äs the main criteria. such assays will depend on their commercialisation.
Parallel to the development of robust kits, the lumi-
nometer producer must present an Instrument which
Commercial Kits has all the comforts of the present-day RIA-and
Although there are no commercial luminescence im- EIA-automatic assay and data-reduction Systems.
munoassay kits on the market at the time of writing,
it is to be expected that they will soon make their
debut. Important points to be considered are, for ex-
Acknowledgements
ample, if coated tube assays are to be produced, will
the tubes fit into all luminometers? The answer is at The author would like to thank the following for producing the
results presented here äs examples: Bettina Tode, Heidi-Susanne
present definitely no, and it is easy to see, that if co- Krausz, Sabine Kurras, Jutta Jäger, Christian Strasburger, Harald
ated ball assays were developed, that this problem is Fricke, Andre Cadow and Joachim Haritz.
References
1. Boyle, R. (1667) Phil. Trans. Roy. Soc. Lond. 2, 605-612. 14. Wood, W. G., Fricke, H , von Klitzing, L., Strasburger, C. J.
2. Boyle, R. (1672) Phil. Trans. Roy. Soc. Lond. 7,5108-5116. & Scriba, P. C. (1982) J. Clin. Chem. Clin. Biochem. 20,
3 Dubois, R. (1885) Compt. Rend. Soc. Biol, 37, 559-562. 825-831.
4. Dubois, R. (1887) Compt. Rend. Soc. Biol. 39, 564-566. 15. Hersh, L. S., Vann, W. P. & Wilhelm, S. A. (1979) Anal.
5. Totter, J. R. (1966) In: Bioluminescence in Progress (John- Biochem. 93, 267-271.
son, F. H. & Hanada, Y., eds.) Princeton University Press, 16. Gundermann, K. D. (1981) In: Bioluminescence and Chemi-
Princeton, New Jersey, pp. 22-33. luminescence - Basic Chemistry and Analytical Applica-
6. McCapra, F. (1966) Quart. Rev. Chem. Soc. 20, 485-510. tions, (DeLuca, M. A. & McElroy, W. D., eds.), Academic
7. Gundermann, K. D. (1968) In: Chemilumineszenz orga- Press, New York, pp. 17-19.
nischer Verbindungen, Ist Edition, Springer Verlag, New 17. Kasha, M., Dellinger, B. & Brown, C. (1981) o.e. (16), pp.
York, Heidelberg. 3-16.
8. Gundermann, K. D. (1973) In: Chemiluminescence and Bio- 18. Barnard, G., Collins, W. P., Konen, F. & Lindner, H. R.
luminescence, (Cormier, M. J., Hercules, D. M. & Lee, J., (1981) o.e. (16), pp. 311-317.
eds.), Plenum Press, New Yorjc, London, pp. 209-229. 19. Messen, G., Martinazzo, G., Tommasi, A., Moneti, G., Saler-
9. Harvey, E. N. (1917) J. Biol. Chem. 37, 311-336. no, R., Pazzagli, M. & Serio, M. (1982) In: Luminescent As-
10. Kato, T., Wokalek, H., Schöpf, E., Eggert, H., Ernst, M., says: Perspectives in Endocrinology and Clinical Chemistry,
Rietschel, E. Th. & Fischer, H. (1981) Klin. Wochenschr. 59, (Serio, M. & Pazzagli, M., eds.), Serono Symposia, Vol. l,
203-211. Raven Press, New York, pp. 207-214.
11. Woodhead, J. S., Simpson, J. S. A., Weeks, L, Patel, A., 20. Kishi, Y,, Goto, T., Hirata, Y., Shimomura, O. and Johnson,
Campbell, A. K., Hart, R., Richardson, A. & McCapra, F. F. H. (1966) In: Bioluminescence in Progress, (Johnson, F.
(1981) In: Monoclonal Antibodies and Developments in Im- H. & Haneda, Y., eds.), Princeton University Press, Prince-
munoassay (Albertini, A. & Ekins, R., eds.), Elsevier/North- ton, New Jersey, pp. 89-113.
Holland Biomedical Press, Amsterdam, pp. 135-145. 21. Johnson, F. H. & Haneda, Y. (1966) o.e. (20), 650 pages.
12. Pratt, J. J., Woloring, M. G, & Villerius, L. (1977) J. Immun- 22. Serio, M. & Pazzagli, M. (1982) Luminescent Assays: Pers-
ol. Meth. 27, 179-184. pectives in Endocrinology and Clinical Chemistry (Serio, M.
13. Köhen, F., Pazzagli, M., Kim, J. B., Lindner, H. R. & Bogus- & Pazzagli, M., eds.), Serono Symposia, Vol. L, Ravcn Press,
laski, R. C. (1979) FEBS Letters 104, 201-205. New York, 286 pagcs.
23. Strasburger, C. J., Fricke, H., Gadow, A., Loesch, J., Wood, 29. Gadow, A., Fricke, H., Strasburger, C. J. & Wood, W. G.
W. G. & Scriba, P. C. (1982) J. Clin. Chem. Clin. Biochem. (1984) J. Clin. Chem. Clin. Biochem. 22, 337-347.
20, 668. 30. Siekmann, L. (1978) In: Quantitative Mass Spectrometry in
24. Gadow, A. & Wood, W. G. (1983) J. Clin. Chem. Clin, Bio- Life Sciences, EIsevier/Nörth Holland, Amsterdam, Vol. II,
chem. 27, 789-797. pp. 3-16.
25. Gadow, A., Fricke, H., Wood, W. G. & Scriba, P. C. (1983) 31. Hunter, W. M. (1982) In: Radioirnrhiinoassay and Related
Acta Endocrinol. (Kbh). 103, Suppl. 256, 109. Procedures in Mediane 1982, IAEA, Vienna, pp. 3—21.
26. Wood, W. G., Fricke, H., Haritz, J., Gadow, A., Krausz, H.- 32. Strasburger, C. J., Fricke, H. & Woo<J, W. G. (1982) o.e.
S., Tode, B., Strasburger, C. J. & Scriba, P. C. (1984) J. Clin. (31), pp. 757-777.
Chem. Clin. Biochem. 22, 349-356. 33. Von Klitzing, L., Schultek, T-, Strasburger, C. J., Fricke, H.
27. Kohen, F., Kim, J. B., Lindner, H. R. & Collins, W. P. (1981) & Wood, W. G. (1982) o.e. (31), pp. 57-68.
Sterods 38, 73-88.
28. Fricke, H., Strasburger, C. J. & Wood, W. G. (1982) J. Clin. Priv. Doz. Dr. William Graham Wood
Chem. Clin. Biochem. 20, 91-94. Klinische Laboratorien
Klinik für Innere Medizin
Medizinische Hochschule Lübeck
Ratzeburger Allee 160
D-2400 Lübeck
By E. Henkel
Institut für Klinische Chemie, Abt. II, der Medizinischen Hochschule Hannover,
Zentrallabor im Krankenhaus Oststadt, Hannover
Summary: The antigen-antibody reaction itself acts äs the "marker System" in the marker-free immunological
methods. This group of analytical techniques includes radial immunodiffusion, nephelometry, turbidimetry
and nephelometric Inhibition. The Particle Counting-Immunoassay (PACIA) technique also belongs to this
group, although it employs latex particles äs markers for the intensification of the indicator reaction.
The principles of the above methods are described, and their applications in diagnosis, their detection limits
and important interfering factors are discussed. For all methods, the precision in series and from day to day is
in the ränge of 5—10%. The detection limits are l ng/1 for the PACIA technique, 10 g/l for nephelometric
Inhibition, l mg/1 for nephelometry äs an end point technique, ancJ 10 mg/1 for nephelometry äs a kinetic tech-
nique.
Commercial sources of reagents and apparatus are given in an appendix.
l
) Presented at the Kleinkonferenz „Immunologische Diagnostik" der Deutschen Gesellschaft für Klinische Chemie, Hiimburg, Juni
1983.
Tab. l. List of proteins that can at present be determined by RID difficult to obtain. This very demanding procedure is
and nephelometry.
firmly established in laboratories of scientific protein
research, where multidimensional techniques are fa-
Albumin Gc-Globulin
Antithrombin III Haemopexin voured for the characterization of proteins and for
cti-Antitrypsin Haptoglobin testing the homogeneity of protein preparations.
Apolipoprotein A-I Human-placental lactogen
Apolipoprotein B IgA
Cj-Inactivator IgD
C3c IgE
C4 IgG
(FactorVIII) IgM
(associatcd protcin) Nephelometry
Coeruloplasmin Lactoferrin
C3-Activator ß-Lipoprotein
Principle
C-reactive protein (CRP) Lysozyme
a-Foetoprotein a-Macroglobulin
In a "clear solution", particles of a certain size cause
Fibronectin Plasminogen a scattering of incident light. Usually, the wavelength
Fibrinogen Prealbumin of the scattered and incident light is the same. To a
Acidic-a i -glycoprotein Proth rombin small extent, light of longer wavelength, i. e. of lower
a:-HS-glycoprotein Retinol binding protein (RBP)
ß2-Glycoprotein I Thyroxin binding globulin (TBG) energy, is also emitted (Raman effect).
ß-SP-1-glycoprotein Transferrin
a-PA-glycoprotein Condensed monochromatic light of a certain wave-
length causes polarization of the molecules of parti-
cles in a solution. Oscillations then result in the emis-
sion of light of the same wavelength äs the excitation
light. .
Application If the particle size is in the order of 0.1 of the inci-
Radial immunodiffusion is used for the determina- dent wavelength, all particles are excited in the same
tion of specific proteins from various sources. More way, and Rayleigh scattering (5) occurs.
recent diagnostic procedures, e. g. the determination
of apolipoproteins, are also possible with the aid of
this technique. The fnethod is simple to apply and Equation
requires little space. As mentioned above, the plates
also provide more Information about the guality of COS
"
10 = Io 4
the results than can be obtained with other methods. 2
Filter
Photo-detector
Backword Forword - Amplifier
270e
Fig. 1. Light scattering by a particle (P) of size less than 0.1 . Display
Fig. 4. Schematic representatiqn of a nephelometer.
Since RID naturally involves visual inspection of the Nephelometry and türbidimetry require about 5
plate, it permits the detection of atypical precipitate times more antiserum than does radial immunodiffu-
rings and other errors. Nephelometry, on the other sion.
hand, provides no control over the presence of un-
specific reactions.
Nephelometric Inhibition Method
The methods described so far are used for the quan-
Turbidimetry
titative determination of macromolecular substances
on the basis of their antigenic properties. Low mo-
In contrast to nephelometry, turbidimetric methods lecular weight compounds, e.g. pharmaceuticals,
measure the decrease in intensity of incident light. have not antigenic properties. These haptens be-
Accordingly, a turbidimeter has a similar construc- come antigenic when they are coupled to bovine al-
tion to that of a photometer. By the preparation of bumin, and they can be used in this way for the prep-
highly pure antisera, and especially by the produc- aration of antibodies. Thus, the immunological de-
tion of clinical chemical equipment with precise tim- termination of pharmaceuticals is possible, and it is
ing facilities, turbidimetric procedures have found a performed chiefly by radioimmunological or enzy-
very wide application. meimmunological methods. If relatively high con-
centrations of pharmaceuticals are present in blood,
The decrease of light intensity corresponds to an ap- they can be determined by the nephelometric Inhibi-
parent absorbance tion technique. The nephelometric Inhibition immu-
noassay was developed at about the same time by
two independent research groups (10, 11).
I = I0 · e-1*
fTTx-Ag.Ab), ~|
UJ Agglutination * Latex-Antigen I-
[37 °C Z9min _j l
**·
•
\«
• · Maximum unagglutinated
Latex-Antigen
= Minimum antibody
Free hopten
Fig. 5. Principle of the nephelometric Inhibition technique. Fig. 6. Schematic representation of the PACIA apparatus from
TECHNICON from (13).
References
1. Mancini, G., Carbonara, A. O. & Heremans, J. F. (1965) Im- 9. Sternberg, J. C. (1977) Clin. Chem. 23, 1456-1464.
munochemistry 2, 235-254, 10. Cambiaso, C. L., Massen, P. L., Vaermari, J. P. & Heremans,
2. Fahey, J. L. & McKelvey, E. M. (1965) J. Immunoi. 94, 84- J. F. (1974) J. Immunoi. Meth. 5, 153-163.
90. 11. Gauldie, J., Sherington, E. & Sircar, P. K. (1975) Fed, Prpc.
3. Henkel, E. (1977) Krankenhausarzt 50, 939^949. 34, 104 (abstr.).
4. Laurell, C.-B. (1966) Anal. Biochem. 15, 45-52. 12. Grange, J., Roch, A. M. & Qiiash, G., p. (1977) J. Immunoi.
5. Rayleigh, Lord (1871) Phil. Mag. 41, 447. Meth. 18, 365-375.
6. Mie, G. (1908) Ann. Physik 25, 377. 13. Holy, H. W. 4. Scand. Technicon Cpngress Copenhagen
7. Hellsing, K. (1974) In: Protides of the Biological Fluids, Vol. April 1981.
27, pp. 579-583 (Peeters, H., ed.) Pergamon, Oxford.
8. Deaton, C. D., Maxwell, K. W., Smith, R. S. & Creveling, R.
L. (1976) Clin. Chem. 22, 1465-1471. Priv.-Doz. Dr. E. Henkel
Institut für Klinische Chemie Abt. II
im Zentrum für Laboratoriumsmedizin
der Med. Hochschule Hannover
Zentrallabor im Krankenhaus Oststadt
Podbielskistraße 380
D-3000 Hannover 51
Summary: The practicability, Operation time and cost of ligand binding assays are clearly more favourable
than those of the possible and sometimes highly spedfic alternatives. At the same time, however, they have
distinct weaknesses with respect to the criteria of analytical performance. For the routine determination of
individual clinical chemical parameters, which are otherwise difficult to quantify, ligand binding assays (espe-
cially in those versions that do not use radioisotopes) are markedly superior to other methods. Chromato-
graphie methods, however, offer greater advantages for the determination of profiles.
Introduction c , ., , . , , , ,
Several problems have already been touched upon
When ligand binding assays were introduced in 1960 or discussed in previous papers, but in the interests
by Yalow & Berson and by Ekins (l, 2) the epoch- of a balanced presentation repetition cannot be en-
making importance of this technique and its subse- tirely avoided. Since limitations of space make it
quent far reaching application were not foreseen. necessary to be selective, the following discussion
Owing to the esoteric nature of the procedure, it was will deal largely with the areas of endocrinological
used only by a few initiates. With the advent of its diagnosis and drug monitoring.
commercialization in 1975 the method became decision fof or ^ introduction of an
widely available, albeit chiefly in the form of the ra- ^ dure fadictated fundamentally by the
dioimmunoassay. Npwdays the technique has wide- tQ thfee tions.
spread application, it is no longer considered to be
special ör exceptional, and it can now be evaluated 1. Does the measured parameter provide an answer
dispassionately· to the clinical enquiry?
For the laboratory clinician and the clinical chemist, 2. Which method gives optimally useful clinical in-
ligand binding assays represent only one of several formation?
groups of methods. They müst therefore address 3 Does the chosen method fulfil the stated require-
themselves directly to the problem of comparing li- ments with respect to quality of analysis, time re-
gand binding with alternative methodology. Such a sponse, practicability and cost?
comparison is attempted in the present paper, and
the subject is viewed from the standpoint of those Since questions 1. and 2. are outside the remit of the
who must use these methods daily. present discussion, they will not be discussed further.
Presented at the Kleinkonferenz „Immunologische 'Diagnostik" der Deutschen Gesellschaft für Klinische Chemie, Hamburg» Juni
1983.
o"
•c
>>
>*
JZ
< Quality
o.
tä) ^ ? o S J Since the value of immunological methods from the
g
CU -^
standpoint of the clinician has been presented separ-
Gas chromato
radio-enzymic
(photometric,
j= aspects.
A cornparison of the analytical performance of the
Hormones immunoassay, gas chromatography, gas chromato-
Steroids graphy-mass spectrometry and the bioässay (tab. 3)
Iodoamino acids
Biogenic amines shows that gas chromatography-mass spectrometry
Peptide hormones. is superior on all counts, providing the analyte is
Proteohormones amenable to this procedure.
Pharmaceuticals H-
Proteins, Peptides + Tab. 3. Comparison of the analytical performance of immunoas^
(antigens, antibodies, say, gas chromatography-mass spectrometry and bioäs-
enzymes and others) say.
As shown in figure l, reputedly highly specific im- Hormone Standards from different species may pos-
munological methods may sometimes be subject to a sess the same biological activity, but different immu-
certain lack of specificity. Voelkel & Tashjian inves- ' noreactivity. Conversely, chemically different sub-
tigated calcitonin in urine (4) and found differences, stances of different biological activity may have sim-
which were sometimes very pronounced, between ilar immunochemical reactivity. Likewise, äs already
the biologically and immunologically determined mentioned, fragmentation products, metabolites or
concentrations. Such deviations frequently show no prohormones of the compound in question can lead
definite relationship to each other, so they cannot be to erroneously high values. The extent of loss by
predicted or corrected by calculation. A further ex- degradation of an analysed substance in the sample
ample is the determination of ocytocin after incuba- solution (frequently serum, which contains enzymes)
tion with pregnancy serum (fig. 2) (5). In this case, can be very different from that in the Standard solu-
the values determined radioimmunologically were tion.
much higher than those from the bioassay. A similar
These phenomena can be explained by the presence
Situation exists for angiotensin II and insulin.
of either hormone precursors or hormone cleavage
products, which have no biological activity, but pos-
sess immunological reactivity. It is known that the
binding site of an antibody recognizes antigenic de-
100000- terminants equivalent in size to only 4 amino acid
residues or 6 hexose residues (6).
Precision
Under routine conditions, the interassay precision of
immunological methods usually lies between 5 and
15%. It should be mentioned, however, that this im-
precision can be decreased by a factor of 1.5—2 un-
der favourable circumstances, e.g. in a laboratory
test study, with equivalent charges, continuity of per-
sonel and low pressure of work (7).
Series to series precision is essentially similar for me-
chanized EIA (thyroxin), mechanized RIA (cortisol)
Bioossay Immurioassay Bioassay Immunoassay
and manual RIA (thyrotropin). Only the determina-
tion of oestradiol, which involves a solvent extrac-
Fig. 1. Calcitonin concentration in urine and urine concentrate
measured by bio- or radioimmuno-assay in patients with tion, shows a distinctly higher Variation coefficient
medullary cärdnpma of the thyroid (4). (tab. 4).
Bipassoy
CV(%)
Detection limit
•2!
The maximal detection limits of different analytical
procedures are shown in figure 3, and compared with -10' 15
the normally encountered serum concentrations of
varioüs parameters. Haemoglobin is included äs the Fig. 3. Comparison of detection limits attainable for analytical
blood analyte with the highest concentration, while methods and typical concentration of various clinical
chemical analytes. Diverging from the rules of the Sys-
substances such äs triiodothyronine (T3), parathyrin, teme International d'Unites g/ml was chosen äs the unit of
aldosterone, corticotropin and oestradiol are present substance concentration, äs only this allows for a meaning-
in especially low concentrations. Most pharmaceuti- ful synopsis. For procedures marked with a star, the sub-
stance amounts detectable absolutely are given.
cals are found in the concentration ränge 10~2 to
10"1 g/l. To give a mental picture of the detection
limits that can be achieved nowdays, let us consider
l g äs equivalent to the distance between the earth
and the moon (about 400000 km); l pg than corre- the assay ränge is not homogeneous. Usually only
sponds to the dot of a letter i (0.4 mm). Such quanti- the first quarter of the reference curve has a steep
ties can be measured by GC-MS with a precision de- slope. At higher concentrations the curve becomes
cidedly better than 10%. increasingly flat. The assay ränge of 1:60 for thyro-
tropin is relatively high for a radioimmunological
Linearity method. The ränge of 1:6 for valproic acid is more
tyrjical. In contrast, the linearity and assay ränge for
Reference curves for immunological assays are non- gas chromatographic-fnass spectrophotometric
linear. This means that the distribution of errors in methods are frequently more than 1:1000.
τι(
x
Γ*· Ov O\ »-< l l OO f)
S 0 Γ** 00 O^ NO Γ*" *O C5 C7 rf *-« Tf o> «O
<ci es
Ι*£ ,
·*
-^
CO
00 CO 00 NO NO NO IO ^
"""
Ε α. ^. r'ii ΓΟ ί5 C5 *·* O· f ι C^· 00 Ό ^
Ό
C
S
\fS S
—*
t**J ON «o \o o c*i ON es t^· c*"> -yj
«β
'*"* »o
Ι
,^^.
CN
0
»O
*0
f**
Γ^ Oj C*") vO
9m
*
. ^f CO ON VT) O|
v d o o o o « o r * « o j o o o v <"* o^ oo oi r>»
i/^
^
Ή
"χ .. ^1 __ _
Ι
Λ Γ*· OO i OO ΓΟ
t to i->, rt r» oil ^ \o
l **"> O>
vO
^t| 01 04 «r» m ^
l NO oo ^t »o ^j
8 vO
·£ ON 01 es fi c**<
1
£
S l -
—
C
S r^
*>Λ
—* O O s O « o r ^ r f m v O ON Tf OO rt «O
e s » - * o o ^ * - * O N O N O ^5 fO Γ** Γ** C3
δ
ι£-1
2
t -
1 1 -i
uu ^ <! O O O O O ^ O O O l ^ l - O J
K JS E g S
.Β c
ο"!35 ?··* X ^ —- o\ r^ οι
NO
es es »o <N rt 01 vo NO co «o
Γ*
!ί vo vo
«0 ON
es p »o
«O
\o
«O
oo co σ^ -^
l|
>\ ""
D. 00 • ! f O v *^ es ioONcn*-i
S 2 O O O 01 00
*c
ce 00 -«
εu *5 Ό ^ί Ό Ον Γ*» Ό ΟΝ
ο δ
0) M Du ^
O 04 £88δ£38?
>%*o oj oo oj a\ NO ^^ ^^
Ίs
oo ON es ON
JD w 0, OJ OO CO O4 CO N O O v O f O OO vOJOVOcS
*U O vO ON r-4 vd oo r^ oo ΟΙ Γ** Os Γ*^ «Ο« Γ^ OO vO*
W .O oo r»- oo r- vo ··" l Γ*^ t"^
.sg ε3 —.
OO C7\ OO OO OO
"o
ob ε ζ
O- f-
i ^ c v j tΓΛ^ ^(Λ« r^-esNOcn—<
r ^ o o r ^ \ o o » o < o r ^ ON CD es c^ *^i ON co c^ ON r*·* *^ ON
Sc £
ι
r^ r^· ON »o r*·» oc vo Γ ^ - Ο Ν — Ο Ο Ο Ο Γ ^ - O O N C Γ-ΝΟ
c 2 r^*
o
t—l i— <
c £
Z οι
ε r ^ c—o i o o J N OT-MO N T i · · ^CM· O N O O O O I ^ " C O O * ~ ' ~ * * O N O O N O
<
^ "** H
pj^§5^^KS3ieg§
II s
^ X <
r i - O O C S N O O O O ^ O N
o c ^ - —* — e s e s e s
1-
X ^ O v V O V O O O C S r ^ · * —· es oo
o~ r-io^i-iocoM-^to
g!
00 »O
2 *—ι O O O O O O O —i o o
5 j= ^ »o r-
o ^t oj oo
OO
ί,ο ^
«0
Γ^ ·* C<">| O4
!$
o ^ ^*
oo
"^ r^ "o -^-j
i
r* ^
o
00
·
'S .c
s
l 10
oo P cn es»
!«
.Ξ i-
ft. O
o ^t
>o
O\ O\ &\
Q
IO OJ Ο» Ο4 es »oi
oo cni
!
w->
*^
|5
S δ S
^•i ^
rj-| v>
OOi *-i
^fr f^t * *·"<
l
^
O
>O
CO s ^'
S !Γΐ
•s?
^ "*"" ^
^•f
PO »o
'S K es NO
i SS G\ OO CO Ό Ό ΟΙ Γ*^· NO
o o o o o o o o 0
C ^ O O ^ C O ^ f ^ f O l OO t—<
1 s
si 1
^, US ° S|.s
ε|ε
»^ QO
_^ oo **
vrj
s z*
^ c
"1
pj o o
^f OJ CO ^ 01 ^· Γ/^ OO ON AJ
< 2 < S 5fr »O >O *O VO NO f* ON ON >·/
σ ."*"' l i l S
E Ε
Ι Ξ l «
i· g s£ tesS-
— Jo β -i ·§ _
".1Ί111
"o.?- - S T ^ ^
»l 11
"0.0:3 —
P ?? r? S « o e: o
^_ i —^
o .o
σ c β» σ "σ "ο σ c ο σ ο ι tu σ
CO t—· t3 t_> l—
of ·—i «t to oc to
'L.
ΟΓΤΓ
X T
10- 10
20- 20
x
30 30
100 samples 100 samples
40
50
i!
60
70
80
90L
5 samples 10 samples
Fig. 4. Bench work (—m) and analysis ( ) times for two gas Chromatographie methods (steroid and fatty acid profiles) and two iigand
binding assays (thyrotropin by manual radioimmunoassay, and antiepileptic agents by a fu y mechanized, homogeneous enzyme-
immunoassay).
Practicability Costs
Table 6 shows the number of ligand binding assays In view of present day financial stringencies, the
against the actual number of requested analyses. question of costs is especially important. Calculation
This ratio is always greater than two, because dupli- of the real cost in public Services is, of course, ex-
cate determinations are normally performed. It de- traordinarily difficult The figures quoted here can
pends strongly on the number of points required on only be taken äs a guide.
the reference curve, and the number of control sam- There are various reasons for this. The cost of a BAT
ples used. In addition, a series may be repeated if the (Bundes-Angestellten-Tarif, Federal Employee Ta-
initial data are of poor quality. Thus, for thyrotropin, riff) post is calculated simply äs the sum of the salary
a ratio of determinations to requested analyses of 4 and the social taxes. Figures for overheads (e.g. total
indicates that an average of four determinations administrative Services) are not included and are not
must be performed to obtain one result. Short series, available. Furthermore, Information is lacking on
e.g. valproic acid assays, show an even less favoura- operational costs, building depreciation and the in-
ble ratio. terest on capital.
The net working time, based on a 40 hour week, al-
lowing for holidays, illness, etc., is 100320 minutes
Tab. 6. Ratio of the number of analyses to the number of re- per year. This is about the same äs quoted in the
quested investigations. guidelines for the reagent producing industry. The
U U/P Method
cost of a BAT Vc appointment (1983 scale) is 47 050
German marks, which represents 0.469 mark/work-
ing minute. For a BAT Vb appointment, this figure
Diphenylhydantoin 3018 744 4.1 EIA-Cobas
Valproic acid 1950 282 6.9 EIA-Cobas becomeS 0.514 mark/working minute.
Digoxin 18240 5658 3.2 EIA-LKB
The provision of apparatus and its depreciation con-
Thyroxin 27642 9894 2.8 EIA-LKB
Triiodothyronine 25800 9917 2.6 RIA-C4 tribute markedly to the total costs.
Thyrotropin 14916 3696 4.0 RIA-man
Assuming a linear depreciation to zero over ten
years, the equipment costs per analysis ränge from
U = number of analyses 0.2 mark for the manual RIA to 106.25 marks for
P = number of requested investigations (figures for 1983) the computerized combined gas chromatography-
Cobas = CobasBio, Hoffmann-La Röche mass spectrometry.
LKB = Ultralab System 2074
C4 = Concept-4, Micromedic The total costs per analysis have been calculated
man = manual, Henning from our figures, and they are presented äs four se-
parate examples in tables 7—10. Thus, the average
cost of a mechanized enzyme-immunological deter-
mination is 5.47 marks, without taking account of
building costs and electricity, etc. For a manual RIA,
At this point we cannot ignore the fact that the care the corresponding figure is 7.34 marks. If the calcu-
and disposal of radioactive materials has become an lation is based on the guidelines for industry, the re-
increasingly diffictilt problern in recent years. Reas- sult is similar, although the figure then includes all
suring Statements that the disposal of radioactive costs. Comparison with the corresponding figures for
waste presents no problems are either euphemistic, gas chromatography (94.15 marks per analysis) or
or they are based on the non-observance of the stat- gas chromatography-mass spectrometry (214.95
utary regulations. Our institute alone produces each marks per analysis) clearly demonstrates that these
year 18 drums of solid and 8 x 60 litre cannisters of latter methods cannot be considered äs alternatives
liquid waste, which must be stored for several years for routine purposes.
in a separately appointed room of the clinic for ra- This Overall assessment shows that at present there is
dioactive decay. In comparison, the management of no reasonable alternative to the ligand binding assay
non-radioactive immunoassays is naturally free from for the measurement of individual compounds that
such problems, which is why we fundamentally pre- are otherwise difficult to analyse. Of the different
fer them. types of ligand binding assay, those that do not em-
The requirements for apparatus and space, äs well äs ploy radioisotopes are decidedly preferable. On the
the qualification of the operaior, are exorbitantly other hand, for the determination of several differ-
higher for gas chromatography-mass spectrometry ent substances simultaneously, Chromatographie
than for immunoassays. techniques are clearly superior to ligand binding as-
says.
J. Clin. Chem. Clin. Biochem, / Vol. 22,1984 / No. 12
934 Vogt: Evaluation of immunological methods
Tab. 7. The cost of one determination by mechanized enzyme- Tab. 9. Average costs of a gas Chromatographie determination.
immunoassay. One technical assistant performs 32540 One technical assistant performs 1100 assays per year.
assays per year.
Tab. 8. The cost of one determination by manual radioimmu- Tab. 10. Average cost of a gas chromatographic-mass spectro-
noassay. One technical assistant performs 12330 assays photometric determination.
per year. One technical assistant performs 800 assays per year.
References
1. Yalow, R. S. & Berson, S. A. (1960) J. Clin. Invest. 39, 6. Blake, C. C. F. (1975) Nature (London) 253, 755.
1157-1175. 7. Vogt, W. & Braun, S. L. (1980) Clin. Chem. 26,1372-1373.
2. Ekins, R. P. (1960) Clin. Chim. Acta 5, 453-459. 8. Ringversuch für Hormonbestimmungen 1/83 der Dtsch. Ges.
3. Scriba, P. C. (1983) This Symposium, not submitted. f. Klin. Chemie, Januar 1983.
4. Voelkel, E. F. & Tashjian, A. H. (1971) J. Clin. Endocrinol. 9. Alexander, N. M., Gattra, R. & Nishimoto, M. (1980) Clin.
Metab. 32, 102-109. Chim. Acta 100, 301-305.
5. Chard, T., Forsling, M. L., James, M. A. R., Kitau, M. J. & 10. Tamagna, E., Hershman, J., Premachandra, B. N. (1979)
Landen, J. (1970) J. Endocrinol. 46, 533-542. Clin. Chim. Acta 93, 263-268.
By C. Valet, L. Rüssmann
Max-Planck-Institut ßr Biochemie, Martinsried, FRG and
R. Wirsching
Chirurgische Klinik Großhadern der Universität München, München, FRG
Summary: A new method for the automated flow-cytometric identification of colo-rectal tumour cells was
developed. Fresh tissue is cut mechanically to obtain single cell suspensions. The cells are then incubated with
antibodies in an indirect immunofluorescence assay for CEA (carcino-embryonic antigen) on the cell surface,
and counterstained with the DNA stain propidium iodide. Monosized latex particles are added äs internal
Standard, then cell volume, antibody fluorescence and DNA are measured simultaneously in a FLUVO-
METRICELL flow cytometer. A FORTRAN IV Computer program was used to determine whether aneu-
ploid cells or cells with high density of CEA on their surface were present in the sample. All relevant data
were stored automatically in a seif updating data base, which is important for quality control and automated
thresholding. The samples were taken from 120 different patients. A tumour sample and a sample of healthy
adjacent mucosa of the same patient were available in 88 patients. 97.5% of all tumours and 88.6% of the
normal mucosa samples were correctly identified. This shows for the first time that the majority of colo-rectal
tumour samples can be identified by a flow cytometric measurement with automated data evaluation. The
identification of tumour samples was substantially better when based on the measurement of the three pa-
rameters, compared with identification by aneuploidy (59%) or by the CEA antibody alone (91%). It will be
possible to automate the measurement of the samples.
nen. Die Identifizierung der Tumorproben durch die Dreiparametermessung war wesentlich besser als durch
Aneuploidie (59%) oder CEA-Antikörper (91%) allein. Die Probenmessung kann in der Zukunft ebenfalls
automatisiert werden.
quot of fresh cells was centrifuged for 5 min at 300 g, resuspended beyond a threshold in the FITC-antibody versus propidium io-
to the original cell concentration in albumin/Tris buffered saline dide-DNA histogram (fig. 4a, b). The antigen surface density of
and stained according to the same protocol s fixed cells. 85% of the antigen positive cells was calculated for each cell from the cell
the samples were stained s fixed cells and the remainder s fresh, volume and the intensity of the FITC-antibody fluorescence, as-
unfixed cell preparation. suming a spheroid shape of the cell. To determine the aneuploidy
index l (AN1), the product of % cells in S+G 2 /M phase times
Jmmunofluoresccnce their mean DNA-fluorescence was divided by the product of %
cells in Go/Gi phase times their mean DNA-fluorcscence. The
Aliquots (50 μ!) of fixed or vital cell Suspension were incubated aneuploidy index 2 (AN2) was calculated, when a sample of nor-
for 12 h at 0°C in 96 well microtiter plates (250 μΐ welis), either mal mucosa from the same patient was also available. AN2 is the
with 10 μΐ of an antibody dilution in albumin/Tris buffered saline ratio of AN1 of the tumour divided by AN1 of the mucosa. AN2
or with albumin/Tris buffered saline alone s a control. Diluted was a very sensitive indicator of abnormalities because it indicated
(1/100) mouse monoclonal anti-CEA antibody (Hybritech, Pae- minor differences between tumour and mucosa. A sample was
sel, Frankfurt, FRG. l g/l IgG), or diluted (1/100) rabbit-anti- judged aneuploid above an AN l or AN2 of 1.2. All calculated
CEA monospecific antiserum (DAKO, Hamburg, FRG) ren- data were automatically stored in a seif updating data base which
dered free of anti-NCA (non specific cross reacting antigen) an- was installed for long time quality control and automated optima-
tibodies by absorption with human spieen and Jung tissue (serum tion of the decision thresholds. A cell sample was automatically
kindly provided by Dr. Lamerz, Klinikum Gro hadern, Munich, judged malignant by the Computer classifier program either when
FRG, 5.3 g/l IgG) were used to detect cell surface CEA. The it was aneuploid or when the surface density of CEA-positive cells
assays were washed twice by centrifugation (10 min, 300g) with exceded the normal r nge.
200 μΐ albumin/Tris buffered saline and reincubated with either a
fluoresceine isothiocyanate (FITC)-labelled rabbit-anti-mouse or
a FITC-labelled goat-antirabbit IgG (bolh antisera: Paesel,
Frankfurt, FRG, 10 g/l IgG, fluoresceine/protein ratio 3.71 Results
(mg/g) and 12.0 g/1 IgG, fluoresceine/protein ratio 3.95 (mg/g))
for another 12h at 0°C. Both antisera were 1/40 diluted with The identification of samples containing tumour cells
albumin/Tris buffered saline. The cells were washed twice with was easily possible when aneuploid cells were pres-
albumin/Tris buffered saline and finally resuspended in 200 μΐ
Tris buffered saline containing 40 mg/1 propidium iodide. Resus-
ent. They were visible s a separate peak (fig. l a)
pension of the cells after each wash was effected by a Titertek which did not occur in cell samples from the healthy
Vibration mixer (Flow-Laboratories, Gro meckenheim, FRG). A adjacent mucosa (fig. Ib). 71 out of 120 malignant
sample (5 μΐ) of porous, NHa group-containing, monosized (6 μπι
diam.) latex particles (kindly provided by Prof. J. Ugelstad, SIN-
tumour samples (59%) were aneuploid with DNA-
TEF and University of Trondheim, Norway) were prestained with indices mostly in the hyperdiploid region (1.15—
FITC and added at a final concentration of 2.5 x 105/ml to each 1.90).
assay s internal Standard.
The Identification of euploid tumour cells was not coefficients of Variation (CV = 100 · Standard devia-
possible with one-parameter measurements alone. tion/mean value) in the order of 8 to 10%. The CV
This is apparent from figure 2 where the DNA distri- of the DNA distribution curves was lower (6 to 8%)
bution (fig. 2a, b), the antibody distribution (fig. 2c, for fresh cells. The high CV's were due to the intesti-
d) and the volume distribution curves (fig. 2d, e) of nal cells and to formaldehyde fixation, but not to in-
cells of the tumour (fig. 2a, c, d) and the normal mu- strumental Variation because CV's of 1.5 to 1.9%
cosa (fig. 2b, d, e) of a patient with a euploid tumour were obtained for ethanol-fixed rat thymocytes.
are shown. All curves begin with an exponentially Ethanol fixation caused, however, celi clumping.
decreasing background in the left part. The respec- The diploid peaks of the DNA distribution curves
tive curves of tumour sample and normal mucosa were often left skewed after formaldehyde fixation
were quite similar. The shape of the diploid peak of because the large epithelial cells stained slightly
the DNA distributions (fig. 2a, b) was broad with higher with propidium iodide s compared to the
1.00
Ο.ΘΟ
0.60
0.40
0.20
aoo
10 20 30 40 50 10 20 30 40 50 60
U
DNA [arbitrary units] DNA [arbitrary units]
o>
1.00
Q80
σ
X 0.60
o
0.40
o 0.20
o
α 0.00
10 20 30 40 50 60 10 20 30 40 50 60
FITC-antibody [arbitrary units] FITC-antibody [arbitrary units]
Fig. 2. DNA, FITC-antibody and cell volume distribution of an euploid colon cancer (left) and of the adjacent healthy mucosa (right).
All three curves begin with an exponentially decreasing experimental background on the left side of the plot. It is most pro-
nounced in the antibody (c, d) and cell volume distribution (fig. 3e, f).
Between 10600 and 18700 cells per curve were measured.
a) DNA, euploid colon cancer; maximal frequency 1906.
b) DNA, adjacent healthy mucosa; maximal frequency 1547.
c) FITC-antibody, euploid colon cancer; maximal frequency 6286.
d) FITC-antibody, adjacent healthy mucosa; maximal frequency, 9496.
e) Cell volume, euploid colon cancer; maximal frequency 2969. One class on the logarithmic volume scale corresponds to 30 fl.
f) Cell volume, adjacent healthy mucosa; maximal frequency 3120.
small inflammatory leukocytes. The left skew is vis- of granulocytes that react with NCA-antibodies. The
ible in figure 2a, b. Since the identification of euploid cluster of calibration particles is also visible. It is sit-
tumour cells by the one parameter measurements of uated where no interference with stained cells oc-
figure 2 was not possible one could conclude that curs. The particles serve äs internal Standard for the
flow cytometry is not a suitable method for this pur- calculation of the cell concentration. They are also
pose. useful for checking Instrument function with regard
to cell volume and fluorescence. They allow a precise
This was, however, not true, when a simultaneous recalibration of the Instrument from day to day,
measurement of the same three parameters was per- which is important in automated Operation for main-
formed. The measurement resolved additional fea- taining Standard thresholds over a long period of
tures of the different cell populations (fig. 3a, b). time. The cube display is useful for a quick visual
The three parameter measurement distinguishes be- judgment of the three parameter measurement, but
tween cell debris and morphologically intact cells. not suitable for quantitative evaluation. The quantit-
Only particles with DNA and volume are morpho- ative evaluation is performed on two parameter his-
logically intact cells. Cell debris i.e. enucleated celis tograms obtained by projecting the content of the
or broken cells give rise to volume Signals but not to cube onto the antibody versus DNA plane (fig. 4a,
DNA signals, and bare nuclei show DNA Signals but b). The calibration particles were not projected to
only very small volume Signals which do not appear simplify the distributions. The solid lines of the
on the volume scale. Cell debris is significantly pres- graph separate the area of antigen negative and anti-
ent in the tumour sample (fig. 3a) and also in the gen positive cells used by the Computer program for
normal mucosa sample (fig. 3b). Intact, antigen posi- the calculation of cell parameters. The substantial
tive cells are visible amongst the cells with large vo- amount of cell debris which is strongly positive for
lume in the tumour sample (fig. 3a). This is reasona- the CEA-antibody is again visible. The quantitation
ble because tumour cells occur amongst the large would be significantly influenced if the debris were
epithelial cells. Some CEA-antigen positive cells not distinguished from the intact cells by the DNA
were also present in the normal mucosa sample of stain of the cell nuclei. The evaluation of the tumour
the same patient (fig. 3b). The intact inflammatory samples and of the normal mucosa cells of two pa-
cells at the lower edge of the volume scale are not tients (figs. l and 2, 3) is given in table 1. The aneu-
antigen positive, indicating that the antiserum is free ploidy of the tumour sample of the first patient is
31 26 21 16 11 6
Antibody [arb.UJ
*<* 31 26 21 16 11 6
Arvtibody [arb.U]
1
Fig, 3. Three dimensional representation of a simultaneous cell volume, DNA and CEA-antibody measurement of colon cancer ceils (a)
and cells of the adjacent healthy mucosa (b). The cells are derived from the same samples äs those represcntcd in the one
parameter distribution curves of figure 2. The increased number of morphologically intact CEA-positive cells in the tumour cell
sample (a) is visible. The contour lines surround the areas where particles and cells are located. The channcl contenis are
standardized to the maximum logarithmic channel content and plotted for the 10% levcl. Channels with 2 and 3 cells are already
contoured which means that the location of most of the measured cells is indicated. The calibration particles are uscd äs internal
concentration Standard and also for day to day standardisation of the fluorescence measurement. One class on the logarithmic
volume scale corresponds to 30 fl. 19419 (a) and 11948 particles (b) were measured. The maximum channel Contents are 256 and
245 particles respectively. GO/G1, S and G2/M represent the cell cyclc phases.
60 60
50 50
-40 40
30
l
JQ
o
20 20
10 10
1 Debris
1 10 20 30 40 50 60 1 10 20 30 40 50 60
CEA antibody [arb.U] CEA antibody [arb.UJ
Fig. 4. CEA-antibody versus DNA histogram of colon cancer cells (a) and cells of the adjacent healthy mucosa (b). The graphs were
obtained by projecting the respective cube diagrams of figure 3 onto the antibody/DNA plane. The solid lines represent the areas
used for the Computer evaluation. To the left is the antibody negative and to the right the antibody positive compartment. 16.1%
CEA positive cells were found in the tumour sample and 7.9% in the normal mucosa. The graphs were standardized to the
maximum logarithmic channel content and contour lines are plotted in 10% linear increments. To simplify the calculation of
antibody positive cells the calibration particles of figure 3 were not projected onto the antibody/DNA plane. 18574 (a) and 10665
particles (b) were measured. The maximum channel Contents are 523 and 395 particles respectively.
Tab. 1. Calculated parameters from simultaneous CEA-anti- lymph-node material was obtained by abdominal
body, DNA and cell volume measurement of samples surgery. The mean antigen density on the antigen
from an aneuploid (fig. 1) and an euploid colo-rectal
tumour (fig. 2 to fig. 4). positive cells of most tumour samples was higher
than on the antigen positive cells of the adjacent nor-
CEA- Relative Aneu- Aneu- mal mucosa. 109 (91%) of the tumors were recog-
positive antigen ploidy ploidy nized by the CEA-antibody alone. Of the remaining
cells (%) density index 1 index 2 11 tumours, 8 were aneuploid and thus could be ad-
ditionally identified. 3 tumours i.e. 2.5% of all tum-
Aneuploid
ours were not recognized. The metastatie cells be-
Rectum carcinoma 15.13 0.653 1.35 3.75
Normal mucosa 4.24 0.406 0.36 haved similarly to the tumours. Table 2 contäiiis the
quantitative vaiues. The conventional anti-CEA
Euploid
Colon carcinoma 16.12 0.759 0.842 1.00
Normal mucosa 7.89 0.389 0.840
Tab. 2. Flow-cytometric classification of colorectal tumour and
mucosa cells by CEA-antibodies and DNA-aneuploidy.
Monospecific Monoclonal
correctly recognized by the AN2 (>1.2). The DAKO-antibody Hybritech
antibody *
number of antigen positive cells is abnormally high Tumour Mucosa Tumour Mucosa
in both patients and the mean antigen density/cell is FN(%) FP(%) FN(%) FP(%)
substantially increased in the tumour samples. A to-
tal of 120 patients with colo-rectal tumours and 88 Aneuploidy +
normal mucosa samples from the same patients have % CEA-positive 8.3 13.7 6.1 27.5
cells
been screened so far by this method. All samples
Aneuploidy +
were measurable. The lower number of mucosa sam- rel. CEA-äntigen 2.5 11.4 4.9 18.3
ples is due to the fact that some of the tumours were surf ace density
taken from patients prior to cryotherapy without a
normal mucosa sample. Also included in the tumour FN = false negative (n = 120 tumour samples)
cases are 11 patients from which only metastatie FP = false positive (n = 88 mucosa säniples)
speed (30 to 60 s/sample) and simplify the Operation diation damage in bone marrow and blood samples
of flow cytometers. An important requirement for for biological radiation dosimetry (32). Fully mi-
automation are monosized calibration particles of croprocessor-controlled flow cytometers are com-
suitable size, which became available only recently paratively cheap and will also be accessible to small-
(28). They can be used äs internal Standard for cell er hospitals and to specialized private praetice.
concentration but also for the continuous monitoring Although the prospects for a broatjier application of
of the correct sample flow by the microprocessor da- flow-cytometry in diagnostic medicine are substan-
ta analysis System. The Software was adapted for au- tially increasing at the present time^ it is obvious that
tomated Operation. The relevant pararneters of each one is still at the beginning of a development, Much
measurement are automatically stored in a data bank further work is needed to elaborate a spectrum of
file which assures the long term stability of the mea- diagnostic methods for cells, comparable to the large
surements. It will be possible to use automated flow number of common clinical chemistry assays. Des-
cytometers in the same way äs äs photometers, thus pite the improvements one has to see the lirnitations
greatly extending the possibilities for cellular work. of the method. The tissue architecture has to be de-
In addition to the identification of tumour cells it is, stroyed for the preparation of single cell süspensions.
for example, of interest to count blood cells and to Flow cytometry can, therefore, not replace the histo-
determine simultaneously their functional state (29), pathological examination. Nevertheless, the possibil-
to measure cellular assays for cytostatic drug testing ity of performing fast and quantitative biochemistry
on patient tumour cells (30), to partially differen- in singie cells is of great interest for the characteriza-
tiate bone marrow aspirates (31) and to measüre ra- tion of the alterations of cell metabolism in disease.
References
1. Kachel, V., Schneider, H., Bauer, J. & Malin-Berdel, J. 18. Kachel, V., Glossner, E., Kordwig, E. & Ruhenstroth-Bauer,
(1983) Cytometry 5, 244-250. G. (1977) J. Histochem. Cytochem. 25, 804-812.
2. Kachel, V., Glossner, E. & Schneider, H. (1982) Cytometry 19. Valet, G. (1980) Flow Cytpmetry IV, Universitetsforlaget,
3, 202-212. Oslo, p. 125-129.
3. Haskill, S., Becker, S., Johnson, T., Marro, D., Nelson, K. & 20. Frankfurt, O. S., Greco, W. R., Slocum, H. K., Pavelic, S. A.,
Propst, R. H. (1983) Cytometry 5, 359-366. Arbuck, S. A., Pontes, E. J., Hüben, R. P., Petrelli, N., Piver,
4. Valet, G., Raffael, A., Moroder, L., Wünsch, E. & Ruhen- S. M. & Rustum, Y. M. (1983) Climcai Cytometry II, Am.
stroth-Bauer, G. (1981) Naturwiss. 68, 265-266. Engineering Found. Conferences, Sea Island, p, 61, Abstr.
5. Shapiro, H. M., Natale, P. J. & Kamentsky, L. A. (1979) 21. Hiddemann, W., Wörmann, B., Bassewitz, D., Müller, K. M.,
Proc. Natl. Acad. Sei. USA 76, 5728-5730. Ritter, J., Roessner, A., Hauss, J. & Büchner, Th. (1983)
6. Lamerz, R. & Burtin, P. (1983) Br. J. Cancer 47, 823^832. Clinical Cytometry II, Am. Engineering Found. Conferences,
7. v. Kleist, S. & Hohneck, A. (1982) Internist 25, 10-12. Sea Island, p. 67, Abstr.
8. Lamerz, R. & Fateh-Moghadam, A. (1975) Klin. Wo- 22. Böhm, N. & Sandritter, W. (1975) In: Current topic in pa-
chenschr. 55, 193-203. thology, Springer Verlag, Berlin pp. 151—217.
9. Rognum, T. O., Fausa, O. & Brandtzaeg, P. (1982) Scand. J. 23. Barre«, D. L., Jensen, R. H., King, E. B., Dean, Ph. N. &
Gastroenterol. 17, 341-348. Mayall, B. H. (1979) J. Histochem. Cytochem. 27,573-578.
10. Rognum, T. O., Thorud, E., Elgjo, K., Brandtzaeg, P., Orja- 24. Stöhr, M. & Goerttler, K. (1979) J. Histochem. Cytochem.
saeter, H. & Nygaard, K. (1982) Br. J. Cancer 45, 921-934. 27, 564-566.
11. Barlogie, B., Drewinko, B., Schumann, J., Göhde, W., Dosik, 25. Habbersett, M. C., Shapiro, M., Bunnag, B., Nishiya, I. &
G., Latreille, J., Johnston, D. A. & Freireich, E. J. (1980) Herman, Ch. (1979) J. Histochem. Cytochem. 27, 536-544.
Am. J. Med. 69, 195-203. 26. Valet, G., Bamberger, S., Hofmann, H., Schindler, R. & Ru-
12. Barlogie, B., Raber, M. M., Schumann, J., Johnson, T. S., henstroth-Bauer, G. (1979) J. Histochem. Cytochem. 27,
Drevinko, B., Swartzendruber, D. E., Göhde, W., Andreeff, 342-349.
M. & Freireich, E. J. (1983) Cancer Res. 43, 3982-3997. 27. Herlyn, M., Steplewski, Z., Herlyn, D. & Koprowski, H.
13. Klein, F. A., Herr, H. W., Sogani, P. C, Whitmore, W. F. & (1979) Proc. Natl. Acad. Sei. USA 76, 1438-1442.
Melamed, M. M. (1982) Cancer 50, 389-395. 28. Ugelstad, J., Mork, P. C., Herder Kaggerud, K., Elingsen, T.
14. Baisch, H., Otto, U., König, K., Klöppel, G., Köllermann, M. & Berge, A. (1980) Adv. Coll. Interf. Sei. 75, 101-140.
& Linden, W. A. (1982) Brit. J. Cancer 45, 878-886. 29. Valet, G. (1984) Blut 49, 83-90.
30. Valet, G., Warnecke, H. H. & Kahle, H. (1984) Blut 49, 37-
15. Valet, G., Ormerod, M. G., Warnecke, H. H., Benker, G. & 43.
Ruhenstroth-Bauer, G. (1981) J. Canc. Res. Clin. Oncol. 31. Valet, G. & Kahle, H. (1984) Blut submitted.
102, 177-184.
32. Valet, G. & Kahle, H. (1984) Biological Radiation Dosime-
16. Dukes, C. E. (1932) J. Pathol. 55, 323-332. try, Konferenz Bundesgesundheitsamt, Schloß' Reisenburg,
17.r Morson, B. C. & Sobin, L. H. (1976) WHO Bull. Nr. 15, p. Dez. 1983. BGA-Schriften, MM V Verlag München, in
1956, Geneva. press.
Prof. Dr. G. Valet
Max-Planck-institut
für Biochemie
Am Klopferspitz
D-8033 Martinsried ·*
Abteilung für Innere Medizin IV (Direktor: Prof. Dr. M. Eggstein), Medizinische Universitätsklinik Tübingen
Summary: The paper presented deals with the general potentialities of the immunological determination of
enzymes, using selected examples to describe the most important variants of the immunoassay for clinical
chemical enzyme diagnostics. The principle of each test and the respective possibilities of interference are
described. The analytical efficiency and applicabilities of these immunoassays are assessed critically.
!) Presented at the Kleinkonferenz „Immunologische Diagnostik** der Deutschen Gesellschaft für Klinische Chemie, Hamburg, Juni
?
1983.
) Detailed specialized literature is available on request dir;ectly from the authors.
silent products of mutated structure genes ("silent Determination of Enzyme by Catalytic Activity or
genes") (3, 4). by Mass
In the immune complex, the catalytic activity of an
enzyme can be maintained unaltered; however often
steric or allosteric effects lead to varying degrees of
Inhibition but also less frequently rto an increase in
Polyclonal and Monoclonal Anti-Enzyme Antibo- enzyme activity. In which way and to what extent the
dies catalytic properties of an enzyme are changed by an
immune reaction depends primarily on the amount
Even if a highly purified enzyme or isoenzyme is and quality (e.g. specificity, affinity, polyclonal or
available äs an antigen, immunization leads to the monoclonal) of the anti-enzyme antibody used. In
formation of anti-enzyme antibodies of varying spe- this connection it is also extremely important wheth-
cificity and affinity. The quality of these convention- er this antibody reacts with the enzyme in soluble
al i. e. polyclonal antisera can however be improved form or — äs in a solid-phase immunoassay — in an
either by enriching the specific antibodies through imiiiobilized form. Moreover, the catalytic activity of
affinity chromatography or by removing the unspe- an antibody-bound enzyme can be influenced by the
cific antibodies by means of immune absorption, äs size of the Substrate. It is known that söme enzymes
shown in the example of a polyclonal antiserum di-
— after binding on the antibodies — convert sub-
rected against the intestinal isoenzyme of alkaline
strates less effectively, the larger the Substrate mo-
phosphatase (5). lecular weight becomes (10, 11). On the other hand,
Monoclonal antisera (6) were introduced for the enzymes can be inhibited in their activity coiisidera^·
decisive improvement of the specificity of immuno- bly more by pre-incubation with the antibody than
logical enzyme assay. It was shown that monoclonal they are if reaction with the antibody does not occur
antibodies are even able to differentiate clearly be- until after addition of the Substrate. Here the sub-
tween the very similar allelozymes of alkaline phos- strate quasi "proteets" the enzyme from the effect of
phatase from human placenta (7, 8). the antibody (12, 13, 14).
The choice of the type of immunoassay to be used
for a particular enzyme depends firstly on the cata-
lytic activity or mass concentration of this enzyme
and cross-reacting antigens (e. g. isoenzymes) in the
Competitive or Non-Competitive Immunoassay material to be examined and secondly on the preci-
sion, speed and practicability required of the assay in
A polyclonal antiserum is best suited for competitive reaching its diagnostic objective. Immunoassays
assays such äs the classical radioimmunoassay which utilize the antigenic äs well äs the catalytic
(RIA), äs antiserum is diluted to such a high degree properties of an enzyme for its quantification are
in these assays, that only the highly affine i. e. specif- suitable for the assay of enzymes with easily measu-
ic antibodies still react with the desired enzyme and rable activity. After reaction with the specific anti-
the concurrent reaction of unspecific antibodies is to enzyme antibodies (Separation step) the enzyme is
a large extent suppressed. In comparison, in the non- detected via its own catalytic activity. Precipitation,
competitive assays, (e.g. immunometric proce- Inhibition and adsorption procedures can be distin-
dures), which work under conditions of an antibody guished with respect to the Separation techniques
excess, the risk of such undesired cross reactions is used. For the measurement of inactive enzyme fornis
considerably greater. It is therefore especially im- (e. g. proenzymes) these methods are just äs unsuita-
portant here to use a qualitatively high-grade i.e. ble äs they are for enzymes which are quickly inacti-
purified polyclonal or monoclonal antiserum. In con- vated in diagnostically relevant body fluids or whose
trast to the RIA, a labelled enzyme Standard is not activity is difficult to measure for technical reasons.
needed for the non-competitive immunoassay. This Such enzymes can only be qüantified by means of
is a considerable advantage äs radio-iodination can their antigenic properties, i.e. their protein mass.
change the immunological reactivity of an enzyme to For this purpose, besides the RIA, immiunometric
a high degree. As was shown using the RIA for pros- assays in particular come into coiisideration.
täte acid phosphatase for example, this principal
source of error can be overcome by the careful selec- The most important types of immunoassay which
tion and control of the radio-iodination technique have proved successful in clinicai enzyme diagnostics
(9). are listed in table 1. They are e^emplified and de-
scribed in more detail choosing creatine kinases and the supernatant, the precision of the method is par-
phosphatases. ticularly unsatisfactory in the case of low enzyme ac-
tivity. Interferences in the immunoprecipitation can
be caused by the occurrence of macromolecular
Modifications of the Immunoassay creatine kinase variants in the serum (21). These are
Immunoprecipitation not precipitated by the antisera (macro-creatine ki-
nase type 2) or are only partially precipitated (ma-
In figure l the immunological differentiation of the cro-creatine kinase type 1). They remain in the su-
dimerous cytoplasmic creatine kinase isoenzymes by pernatant and lead to false results.
means of precipitating antibodies is shown schemati-
cally. In the first step of the reaction, a specific an-
tiserum directed against the M subunit of the enzyme Immunoinhibition
precipitates the isoenzymes MM and MB. The isoen-
zyme BB remains in the supernatant after centrifu- By contrast to immunoprecipitation, for which sev-
gation and can be measured by its catalytic activity. eral hours are usually required, the immunoirihibi-
After a second, separate precipitation with an anti-B tion of enzyme catalytic activity takes only a few
subunit antiserum, the activity of the creatine ki- minutes. The "CK-MB Inhibition test" utilizes this
nase-MM is determined. The catalytic activity of the effect (fig. 2). Within 5 minutes an excess of specific
hybrid isoenzyme MB can only be calculated ma-
thematically; it results from the subtraction of the
activity of both homomeric isoenzymes from the to-
tal creatine kinase activity (15, 16, 17). DD
The immunoprecipitation renders a selective and
quantitative isoenzyme determination possible, if
carried out with reliable antibody excess and if the
anti-M or anti-B subunit antisera used show no cross
reactions with the respective other enzyme subunit.
The sensitivity of this method depends on whether
the catalytic concentration of the isoenzyme is mea-
sured spectrophotometrically (lower detection limit:
approx. 3 U/l (25 °C)) or by bioluminescenee (lower Fig. 2. Determination of the creatine kinase isoenzyme MB by
immunoinhibition (22). The catalytic activity of the M
detection limit: approx. 0.3 U/l (25 °C)) (18, 19, subunits is selectively blocked by polyclonal goat antibo-
20). dies (ABi), creatine kinase-MB is detected by its residual
B subunit catalytic activity.
As the creatine kinase isoenzymes are determined @: M subunit of creatine kinase (inhibited)
indirectly, i. e. by means of the activity remaining in D: B subunit of creatine kinase (active).
1stStep 2^ Step
Fig. 1. Differentiation of creatine kinase isoenzymes by immunoprecipitation (17). Catalytic activities of the BB (first step) and MM
(second step) isoenzymes are measured in the supernatants; the catalytic concentration of isoenzyme MB can be calculated by the
formula:
MB[U/1] = Total creatine kinase [U/l] - (BB[U/I] + MM[U/1]).
O: M subunit of creatine kinase
D: B subunit of creatine kinase
ABr. Antibody specific for M subunit
AB2: Antibody specific for B subunit
5 i 1 ί . ί
s'i-S ^-
.2"
ίο| •
*Q
«
>^ -C
O 3*
^*,
,' fj
·*·
S ^ ^ 3 ^ ^ Ό
!^! U
ΐί «
V3 ι flj·
κ> Ό
Sw ς>
·§·§ s
| § ς^ffi
Λ O ^> ^^ V^ ^^ ^ς< ·—] ^J ·^
«c i c
^
*> je. ° g
S .ts >* 5
1111 Illl Illl a aa 1111 illllll ss s
S
c.»
wo
(S
c
υ
ςΟ
s1 oo
vo
1
-^
;5i
°i
ο
CN
1
*-«
c*-
1
co
r-
„
σ\
wo
|
τ— O)
'~l r^ r-
Ο
*^> w- u-
CQ ffl
CQ PQ £ u 'S "c
"Verylow"
Cross reacti
2
•2o 'S5 o'S -g
= K
U C^J r r j r ^ o1·§1
ί· SoS
!i
iS S ΙΓΞ Λ « Λ Α O t C i S
^
Ο «Λ
" § Ci^ <Λ3 °£
οO^ Oδ ^ Ρv>? £^ «
S
<υ£ ο^00^00
δ** <L> w > 0) v>
1. c / 5 * a cQ,^-
Q.«
/ 3 ^5
Z ° ° r ^ 5
»-Hr-ivJZ .5
Z 3
Z i-i Ο^Γ^ Ο-*
^coUcoCJ
0 0 2
l
0«
Co*
ι 7
-L 00
2r^ οο5»η
^ ^ ^ S r - s
| "·:ίο^*~* *^
T
Ci
S ^^
Γ ^ 2 ζ
Λ5
oo o\
>· "**" 1 ^ v o l V r ^ c o — I V \ co ( N V I r4 CN
CJ
c
.2 0 ^ 0
"P ^. »0 "*. wo V ^2 ^ V ON wo
0. ^: ι
sq ΓΟ c*^ c o r - ^ O N -—. o o ^ J ^ ' —" ^ ι w o « —« ^ J, c^
Jiz wo oioovd 1 r^ONcoV τ—ι ^- - ^ V ^ T uS
-j
%c
1
c £?
•2 > ^
o 1*-
,22
4) ϊτ
«Λ
_ ι—ι
^- o
•^ ^5
5
co
^—
~^* 00
w^ .
S
^
(u
"ob
—^
w^i
"ob
—*· '
c*l
i
—^
* b *"^
^ y^j
—
"ob
^^
!>co
Qco ι ι 1 co 1 ^ » r ) I ^ H ^ ,_; , ^ ^ ^ 1
FP
X1^^ X"^ ^*~N >*"N \J X^
'S
U UU U °o,y .
•S o r* Γ**· W"> f* w^> ON t~~
o o .ti co co
CD ε
C *~"
CO
_
(NJ CO OJ CS CO
_p
—
_ _ - ^
Λ "5h
t- """"
«4ΪΪ
0 O
c D5 3 5 3 3 33 "^^ "w)^ "ob "ob D =2.
_o υ
S w^ O ^i O wo O wo Γ**· O co o O ^t" CN
^^
vO =L
to
."2
υ
£ £
ω
·- «υ v7 ~ V V V V
V V V V V V V I V V ί! *?
15 o
& C σ\ IX
^
i "^
c
1 3u. Tfr
5J •^ CN CO i/^ »^ VO Γ^ ^^ OO ^\ ζ^ \φ QQ ««M <S 0
ω
3
j
l
D
.9-
£ - cu ι—ι ϊH-« <
S et δ ·—· | 53 <i
2w
«
o
p
Λ
j s
"^
Cfl O ^_ «j
C U. — *g CQ «Λ ^
8
D
^ ^ 'C .£ S c CQ
*~i S Si ' c ' ^ P J e S^ g ^.
c - ""J
ca <Λ« _«
^ &
IG
f S * 3 y X 2 C r ^ > > o C*^^»
£j
00 DD
CQ 73
1 3
<υ 3 0 <
Χ) Q o 3
§
Q i 0
Σ Q
§
Vi O es
IS· 00 00 ON ON
Ι | | 1
VO O\ O* «Λ fo es vo c*· r-l
l
t^ 00 ΓΟ OO 00 00 OO C3N
0
2
d 3S.
3<
ii
L, US
ogy A
day.
28
thfiel
orris
*7 CQ
uΓ «
»5 *-
τ •c |
day
°i 10 |V» ^- \£5 ff) ε
^ ?^ oo ro oo ι Γ*»
J^
8 2
II
νο 1
| ~ O| ir> ^ ej\ ·*^. r»* cn
tt Lab.
*
within
i * - *o es vo 1 es
P C
03
B ε
es =3-8
P <υ
Ι
o2 »o ^ vo es 2 CQ
ί^ 3 C2 ^ t*·· t ^^ Os Ό oo N
Ι ^-* o^ T •o" — r^· r·^· <o· oo es
es es es —
es 1 es eo ΤΓ.* ι
ι oo c*i r*·· co
O
JD
3. «_
^
1
"g'wi^ Tip ^ cd
Τ
es is —« ^n es w"> £
T3
0 1 p o oo »o
σ
o
r*·
s~\
•»«^ TT <
1
g~* _ f-m
«. "^3
—L
~+^
—a- i/-j
oes ^^ 11
·*· ^ «o Q
es O 0 vO 1 ^ ^ o oo
es r-5 o «o cn es r* TJ-
ι V V V ^ V V V 1
1—1
1
0 o o
es
es
ΟΝ
Τ
(^ fO »H o \ es V> o m
>ο" es *^ τί-< es r-< iH
< <
< ^^
S < S <; <
§ c* <
H* »—·
' E 2
§
ώ
Ό
Ο
3
α>
c Ζ 2 2
l
Acid phosphat
S *"&
m r-l ·—
^' ? e
EC 3, 1.3.2
1 2 S|5|
« ^ i τχ
j|
prostate
ί H U uisl 8
antibodies inhibits all creatine kinase M subunits procedures; however if they occur in a high concen-
in a serum sample. The activity of the B subunit of tration and cross react with the antiserum, they may
creatine kinase-MB remains virtually uninfluenced. cause interferences in the immune reaction of active
As the isoenzyme BB only very rarely occurs in enzymes. As is shown in figure 3, such cross reac-
blood in spectrophotometrically measurable activity tions, e. g. between inactive creatine kinase-MM and
(i.e. >3 U/l), this test enables the isoenzymes MM inhibitirig anti-creatine kinase-M antibodies, can be
and MB to be differentiated quickly aind easily. After verified in the displacement experiment and their
total Inhibition of creatine kinase-MM, creatine ki- order of magnitude estimated.
nase-MB can be detected by means of its still active
B subunit without a Separation stage (e.g. centrifu-
gation) (22). Monoclonal antibodies are also able to
Immunoadsorption
inhibit the activity of the creatine kinase M subunit
selectively and totally, however they appear to pos- The immunoadsorption assay comprises three reac-
sess no definite advantages over polyclonal antibo- tion stages: the binding of the desired enzyme by
dies in immunoinhibition tests (23). specific antibodies, the subseqUent Separation of the
resulting enzyme-antibody-complexes and the final
In the determination of creatine kinase-MB in the
quantification of the complex associated enzyme ac-
immunoinhibition test, interferences, i. e. false posi-
tivity. Only those antibodies are suitable which do
tive results, are caused by macromolecular creatine
not inhibit (26, 27) or only slightly inhibit (28, 29)
kinases äs is also the case with immunoprecipitation
the enzyme catalytic activity. Antibodies which lead
and furthermore by increased creatine kinase-BB
to a stabilization (30, 31) and/or reactivation or acti-
activities (21). In spite of this disadvantage the im-
vation (32, 33) of the enzyme are especially desira-
munoinhibition test was proved especially successfül
ble for the detectiqn of catalytically unstable en-
in cardiac infarction diagnosis due to its rapidity and
zymes such äs acid phosphatase. The Separation of
easy application (24, 25).
the enzyme-antibody-complexes is carried out by
Catalytically inactive enzyme molecules are not de- means of precipitation with ammonium sulphate
tectable with the immunoprecipitation and Inhibition (34) or polyethylene glycol (35). After centrifuga-
tion aiid washing it is possible to resuspend the en-
zyme complexes and to measure their activity. Solid-
phase assays in which the enzyme is bound to immo-
bilized antibodies are methodically more refined
(fig-4).
The immunoadsörption test detects an enzyme di-
rectly and thus offers some considerable advantages
over the precipitation and Inhibition methods. In ad-
dition its sensitivity can be increased by augmenting
the volume of the test sample: the enzyme activity is
enriched by the immunoadsorbent before it is mea-
sured (29). The obligatory Separation Step offers ad-
ditional advantages. It eliminates all potential inter-
1:501:100 1:150 1:200 1:300 1:500
Antiserum dilution ference factors in the test matrix before the actual
Fig. 3. Displacement of active creatine kinase-MM from a specif- enzyme determination and thus improves the speci-
ic anti-creatine kinase-M antibody by inactive creatine ki- ficity of the assay.
nase-MM. Creatine kinase-MM was inactivated at 37 °C
in a pH-controlled serum matrix (pH 7.4 ± 0.1). Varying Immunoadsorption assays are distinguished by a
concentrations of inactivated creatine kinase-MM were wide measuring ränge (28, 38, 39) and a remarkably
mixed with a stepwise diluted antiserum containing inhib-
iting anti-creatine kinase-M antibodies. The mixtures
high analytical sensitivity. As is shown in the pros-
were pre-incubated for 20 h at 4 °C followed by addition tate acid phosphatase tests, they are able tö measure
of catalytically active creatine kinase-MM (520 U/l). Af- catalytic concentrations of less than 0.1 U/l. This
ter a second incubation for 3 h at room temperature en-
zyme catalytic activities were measured in triplicates.
corresponds to the enzyme mass concentration also
Y-axis: Ratio of residual to initial catalytic activity. considered to be the lowest detectiori limit for ra-
Molar ratio of inactive to active creatine kinase-MM: dioimmunological and immunometric procedures
O-O-O: 0.0 (active enzyme only)
O-O-O: 4.8 (tab. 1). As the immunoadsorption test is always car-
- - : 12.1 ried out with an antibody excess, interferences can
- - : 24.2 be caused by unspecific antibodips if polyclonal an-
Fig. 4. Solid-phase immunoadsorbent assays for prostatic acid phosphatase (a) or placental alkaline phosphatase (b) (36, 37). A polysty-
rene-attached polyclonal antibody (AB, ABi) reacts directly or mediated by a monoclonal antibody (ABi) with the appropriate
enzyme (E). The amount of immunoreactive phosphatase is determined by its catalytic activity in the immune complex.
S: Substrate
P: product of catalytic activity
Radioimmunoassay 00
Problems associated with the determination of the
concentration of enzymes can be seen from the de-
scription of radioimmunoassays used to detect crea-
tine kinase MB (tab. 1).
It is not possible to obtain isoenzyme specific anti-
Fig. 5. Detection of creatine kinase-MB by radioimmunoassay.
creatine kinase antisera by traditionäl immunization, Labelled creatine kinase-BB and unlabelled creatine ki-
but only those which are specifically directed against nase-MB compete for the binding sites of a limited
B or M subunits of creatine kinase. For this reason amount of an anti-creatine kinase-B antibody (AB).
O: M subunit of creatine kinase
only creatine kinase-B RIAs (assaying BB and MB) D: B subunit of creatine kinase
or creatine kinase-M RIAs (assaying MM and MB) I: I25l-labelled B subunit
are available (24, 40-44). The possibilities of inter-
ference in a radioimmunological creatine kinase-MB
determination in human seruni are thus already
predetermined: the creatine kinase-M RIA is gener- hardly reflect the current clinical condition of the pa-
ally unsuitable due to its cross reaction with the crea- tient. The analytical sensitivity of most creatine ki-
tine kinase-MM which occurs in a concentration nase-B RIAs lies in the ränge l to 5 §/1 (tab. 1). For
about 10 times greater; the creatine kinase-B RIA active creatine kinase-BB or -MB with a specific ac-
(fig. 5) will only be uiiaffected by physiological crea- tivity of ^400 U/mg protein (45), radioimmunoas-
tine kinase-BB concentrations if the creatine kinase- says of this kind have a lower detection limit of ^0.4
MB concentration to be measured is considerably U/l. If a lower specific activity (e.g. 10 U/mg) is tak-
higher than BB, i.e. if MB is clearly within the pa- en äs the basis, a test sensitivity which is too high will
thological ränge. Due to this insufßcient specificity a inevitably be simulated (46). Thus, although these
creatine kinase-B RIA, in spite of its greater sensi- RIAs are 10 times äs sensitive äs the immunoinhibi-
tivity, is not äble to detect the increase of creatine tion, they are by no means more sensitive than lumi-
kinase-MB in the serum of an infarction patient ear- nometric creatine kinase-B assays (18, 19, 20).
lier than the immunoinhibition test. An interesting variant is a radioimmunoassay which
Another deeisive disadvantage of the radioimmu- works with creatine kinase-BB binding autoantibo-
noassay is the long tixne it requires. Especially in the dies, isolated from patients' serum containing these
diagnostics, e.g. of an acute cardiac infarction, it will autoantibodies (47, 48). These highly affine antibo-
dies (association constants: 1.4 x l O111/mol) show In figure 6 an immunometric creatine kiiiase-MB as-
no cross reactions with the isoenzymes MB and MM say is represented. In a first reaction phase the isoen-
under test conditions even when they are present in a zymes MB and BB are bound to immobilized crea-
l O4 or l O5 times greater concentration than creatine tine kinase-B antibodies. After a Separation or wash-
kinase-BB. This unparalleled isoenzyme specific ing step they are separated from the remaining crea-
creatine kinase RIA is remarkably sensitive (detec- tine kinases in the serum (MM, .macromolecular
tion limit: l §/ creatine kinase-BB), but can only creatine kinases). In the second reaction phase the
detect catalytically active enzyme. differentiation of both the antibody associated isoen-
zymes occurs: only creatine kinase-MB can bind la-
The detection of inactive enzyme forms would be
belled creatine kinase-M antibodies.
particularly important in the case of an unstable en-
zyme such äs creatine kinase BB, which has more- Such an assay can be very specific and the creatine
over been assigned a tumour associated marker (49). kinase-MB in a serum sample can be measured with-
Although cross reactions have been observed with out interference even in the case of a 1000-fold mo-
products of in vivo and in vitro enzyme degradation lar excess of the isoenzymes BB and MM (55). How-
in some creatine kinase-B RIAs, up to the present all ever, with a detection limit of 10 g/l of enzyme pro-
pinpointed attempts to quantify inactive creatine ki- tein, the assay does not match the sensitivity of the
nase-B protein in human serum with an immunoas- radioimmunoassay (tab. 1), even though it is just äs
say have failed (40, 43, 50). Here, the excessively time and labour consuming. By shortening the reac-
high concentrations (15—198 mg/1 (!)) of inactive tion times and dispensing with the Separation stage
creatine kinase-B protein measured in the serum of between both reaction phases, the immunometric as-
healthy persons appear to be very doubtful (51, 52). say is made more acceptable for clinical require-
ments, but at the same time, its änalytical specificity
and sensitivity are reduced (56). The extent to which
the introduction of monoclonal creatine kinase-B
I m m u n o m e t r i c assay
and creatine kinase-M antibodies (57—59) is able to
For the immunometric procedure, two antisera are overcome the weaknesses of the immunometric as-
needed. Their antibodies must be capable of reacting say has yet to be clarified through further investiga-
with the different respective epitopes of the enzyme tion.
to be detected without impeding each other sterically
in the process. The antibodies of one of the antisera
are immobilized and separate the enzyme in the test
sample. The antibodies of the second antiserum are Perspectives
labelled (radio iodine (IRMA), marker enzyme The trend in clinical enzyme diagnostics away from
(ELISA)) and identify the enzyme. the "indirect" assay (e.g. immunoprecipitation) to-
wards the "direct" assay (e.g. immunoadsorption)
will continue and lead to a further improvement in
the specificity and sensitivity of immunological en-
zyme assays. For the same reasons the non-competi-
tive immunometric methods will replace the classical
DO competitive irnmunoassay.
The use of monoclonal antibodies should play a deci-
sive role in both these developments. Monoclonal
labour consuming assays (tab. 1) are at present reactions by means of sonication (acceleration factor
available. It remains to be seen whether this dilem- > 100(!)), äs has been demonstrated just recently
ma can be resolved by an acceleration of immune '{60).
References
1. McGee, J. & Udenfriend, S. (1972) Biochem. Biophys. Res. 34. Choe, B., Rose, N., Korol, M. & Pontes, E. (1979) Proc. Soc.
Commun. 46, 1646-1653. Exp. Biol. Med. 762, 396-400.
2. Rush, R., Kindler, S. & Udenfriend, S. (1974) Biochem. Bio- 35. Davies, S. & Griffiths, J. (1982) Clin. Chim. Acta 722, 29-
phys. Res. Commun. 67, 38-44. 38.
3. Kahn, A., Cottreau, D. & Boivin, P. (1974) Humangenetik 36. Gericke, K., Kohse, K., Pfleiderer, G., Flüchter, S. & Bichler,
25, 101-109. K. (1982) Clin. Chem. 25, 596-602.
4. Tedesco, T. & Mellman, W. (1971) Science 772, 727-728. 37. McLaughlin, P., Gee, H. & Johnson, P. (1983) Clin. Chim.
5. Lehmann, F. (1975) Clin. Chim. Acta 65, 257-269. Acta 730, J 99-209.
6. KöhJer, G. & Milstein, G. (1976) Eur. J. Immunol. 6, 511- 38. Lim, M., Lee, C. & Chu, T. (1983) Clin. Chim. Acta 730,
519. 263-267.
7. Millän, J., Stigbrand, T., Ruoslahti, E. & Fishman, W. (1982) 39. Lee, C, Killian, C., Murphy, G. & Chu, T. (1980) Clin.
Cancer Res. 42, 2444-2449. Chim. Acta 707, 209-216.
8. Slaughter, C, Coseo, M., Cancro, M. & Harris, H. (1981) 40. Fang, V., Cho, H. & Meltzer, H. (1977) Clin. Chem. 23,
Proc. Natl. Acad. Sei. USA 78, 1124-1128. 1898-1902.
9. McCarthy, R. & Markowitz, H. (1983) Clin. Chim. Acta 722, 41 v. Steirteghem, A., Zweig, M. & Schechter, A. (1978) Clin.
277-286. Chem. 24, 414-421.
10. Haines, A. & Lepow, J. (1964) J. Immunol. 92, 479-490. 42. Roberts, R. & Parker, C. (1981) Meth. Enzymol. 74, 198-
11. Shapira, E. & Arnon, R. (1967) Biochemistry 6,3951-3956. 209.
12. Michaelides, M., Chennan, R. & Helrareich, E. (1964) J. Bi- 43. Neumeier, D., Hofstetter, R. & Gluck, B. (1977) Clin. Chim.
öl. Chem. 239, 4171-4186. Acta 79, 107-113.
13. Owen, R. & Marken, C. (1955) J. Immunol. 74, 257-269. 44. Thompson, R., Rubery, E. & Jones, H. (1980) Lancet 77,
14. Füller, T. & Marucci, A. (1971) J. Immunol. 706,110-119. 673-675.
15. Jockers-Wretou, E. & Pfleiderer, G. (1975) Clin. Chim. Acta 45. Ritter, C., Mumm, S., Roberts, R. (1981) Clin. Chem. 27,
58, 223-232. 1878-1887.
16. Neumeier, D., Knedel, M., Würzburg, U., Hennrich, N. & 46. Roberts, R., Parker, C. W., Sobel, B. E. (1977) Lancet 77,
Lang, H. (1975) Klin. Wochenschr. 53, 329-333. 319-321.
17. Würzburg, U., Hennrieh, N„ Orth, H., Lang, H., Prellwitz, 47. Urdal, P. & Kierulf, P. (1981) Clin. Chem. 27, 83-87.
W., Neumeier, D., Knedel, M. & Rick, W. (1977) J. Clin. 48. Urdal, P., Urdal, K. & Stromme, H. (1982) Scand. J. Clin.
Chem. Clin. Biochem. 75, 131-137. Invest. 42, 621-625.
18. Tarkkanen, P., Körner, S., Cornely, C, Hacke, W. & Greil- 49. Silverman, L., Derman, G., Zweig, M., van Steirteghem, A.
ing, H. (1979) Clin. Chem. 25, 1644-1648. & Tökes, Z. (1979) Clin. Chem. 25, 1432-1435.
19. Lundin, A., Jäderlund, B. & Lövgren, T. (1982) Clin. Chem. 50. Bayer, P., Hotschek, H., Köhn, H., Wider, G. & Baumgarten,
28, 609-618. K. (1983) J. Clin. Chem. Clin. Biochem. 27, 863-864.
20. Willig, K., Stein, W. & Bohner, J. (1983) J. Clin. Chem. Clin. 51. Burnam, M., Barstis, J., Stern, C., Rose, D., Crouch, M.,
Biochem. 27, 583-588. Haskell, C. & Singh, B. (1981) Clin. Chem. 27, 1724-1728.
21. Stein, W., Bohner, J., Eggstein, M. & Lang, H. (1983) J. Clin. 52. Bumam, M. & Shell, W. (1981) Clin. Chem. 27, 353-354.
Chem, Clin. Biochem. 27, 859-876. 53. Dods, R. (1984) Clin. Chem. 30, 439-441.
22. Würzburg, U., Hennrich, N., Lang, H., Prellwitz, W., Neu- 54. Fenton, J., Brunstetter, S., Gordon, W., Rippe, D. & Bell, M.
meier, D. & Knedel, M. (1976) Klin. Wochenschr. 54, 357- (1984) Clin. Chem. 30, 1399-1401.
360. 55. Willson, V., Jones, H. & Thompson, R. (1981) Clin. Chim.
23. Würzburg, U. & Ströbel, R. (1981) J. Clin. Chem. Clin. Bio- Acta 773, 153-163.
chem. 79, 543-544. 56. Usategui-Gomez, M., Wicks, R., Farrenkopf, B., Hager, H.
24. Lang, H. (ed.) (1981) Creatine kinase isoenzymes. Springer- & Warshaw, M. (1981) Clin. Chem. 27, 823-827.
Verlag Berlin, Heidelberg, New York. 57. Myrtle, J., Shimizu, L, Varga, M., Kotler, H. & Barthlomew,
25. Gerhardt, W., Waldenström, J., Hörder, M., Hofvendahl, S., R. (1983) Clin. Chem. 29, 1232.
Billström, R., Ljungdähl, R., Berning, H.. & Bagger, P. 58. Winston, P. & Peele, J. (1984) Clin. Chem. 30, 1002.
(1982) Clin. Chem. 28, 277-283. 59. Chan, D., Frye, R., Taylor, E., Bitzer, R., Rayburn, B. &
26. Lee, C., Wang, M., Murphy, G. & Chu, T. (1978) Cancer Pieta, K. (1984) Ciin. Chem. 30, 1003.
Res. 38, 2871-2878. · 60. Chen, R., Weng, L., Sizto, N., Osorio, B., Hsu, C., Rodgers,
27. Sussman, H., Small, P. & Cotlove, E. (1968) J. Biol. Chem. R. & Litman, D. (1984) Oak-Ridge-Conference (Abstract).
243, 160-166. 61 Usategui-Gomez, M., Wicks, R. & Warshaw, M. (1979) Clin.
28. Lehmann, F. (1975) Clin. Chim. Acta 65, 271-282. Chem. 25, 729-734.
29. Usategui-Gomez, M., Yeager, F. & deCastro, F. (1973) Ali, M., Braun, E., Laraia, S., Fayemi, A., Nalebuff, D. &
Cancer Res. 33, 1574-1577. Palladino, P. (1981) Am. J. Clin. Pathol. 76, 426-429.
30. Fernstein, R., Haroslow, B., Howard, J. & Taulhaber, J.
ö3 Fogh-Anderson, N., Sorenson, P., Moller-Petersen, J. &
(1971) J. Immunol. 706, 1316-1322. '
31. Michaeli, D., Pinto, J., Benjamin, E. & de Buren, F. (1969) Ring, T. (1982) J. Clin. Chem. Clin. Biochem. 20,291-294.
64 Gerhardt, W., Hofvendahl, S., Ljungdähl, L., Waldenström,
Immunochemistry 6, 101-109. ·
32. Suzuki, T., Pelchova, H., Cinader, B. (1969) J. Immunoi. J., Tryding, N., Petterson, T. & Ohlson, O. (1983) Clin.
703, 1366-1376. Chem. 29, 1057-1060.
33. Zimmerman, S., Brown, R., Curtis, B. & Massey, V. (1971) 65. Wada, H., Teranishi, H. & Kagamiyama, H. (1978) Med. J.
Biochim: Biophys. Acta 229, 260-270. Osaka Univ. 29, 181-189.
66. Inoue, M., Hori, M., Nishimoto, X., Fukui, S., Aba, H, Wada, 80. Bauer, H. & Hackenberg, H. (1982) TumorDiagnostik 3,
H. & Minamino, T. (1978) Brit. Heart. 40, 1251-1256. 138-142.
67. Panteghini, M., Falsetti, F., Chiari, E. & Malchiodi, A. 81. Keller, H. (ed.) Methodik und diagnostische Bedeutung der
(1983) Clin. Chim. Acta 128, 133-140. sauren Prostataphosphatase. GIT Verlag Darmstadt (1983).
68. Panteghini, M., Malchiodi, A., Calarco, M. & Bonora> R. 82. Cooper, E., Glashan, R., Robinson, M., Morgan, D. &
(1984) J. Clin. Chem. Clin. Biochem. 22, 153-158. Trautner, K. (1981) Clin. Chim. Acta 113, 27-34.
69. Wicks, R., Usategui-Gomez, M., Miller, M. & Warshaw, M. 83. Griffiths, J., Rippe, D. & Panfili, P. (1982) Clin. Chem. 28;
(1982) Clin. Chem. 28, 54-58. 183-186. ·' (
70. Wu, A. & Bowers, G. (1982) Clin. Chem.'25, 2017-2021. 84. Grenner, G. & Schmidtberger, R. (1979) J. Clin. Chem. Clin.
71. Ali, M., Laraia, S., Angeli, R., Fayemi, A., Braun, E., Davis, Biochem. 17, 156.
E. & Palladino, P. (1982) Am. J. Clin. Pathol. 77, 573-579. 85. Bauer, H., Göttinger, H., Grenner, G. & Dati, F. (1981) Tu-
72. Witherspoon, L., Shuler, S. & Genre, C. (1983) Clin. Chem. morDiagnostik 7, 44—46.
29, 336-339. 86. Bauer, H., Stammel, A., Tauber, R. & Sturm, W. (1984) Tu^
73. Kwong, T., Rothbard, R. & Biddle, T. (1981) Clin. Chem. morDiagnostik 5, 29—34.
27, 828-831. 87. Elias, E., Wood, T. & Redshaw, M. (1977) Lancet 77,66-68.
74. Royse, V., Jensen, D., Schaffner, J. & Payne, J. (1984) Clin. 88. Stagg, B. & Wood, T. (1979) Ann. Clin. Biochem. 16,147-
Chem. 30, 1058. 151.
75. Grenner, G., Deutsch, G., Schmidtberger, R. & Dati, F. 89. Magid, E. & Fahrenkrug, J. (1980) Clin. Chem. 26, 1573-
(1982) J. Clin. Chem. Clin. Biochem. 20, 515-519. 1576.
76. Griffiths, J. (1980) Clin. Chem. 26, 433-436. 90. O'Connor, C, O'Donnell, M. & McGeeney, K. (1981) Cliri.
77. Huber, P., Scholer, A., Linder, E., Hagmeier, V., Vogt, H., Chim. Acta 774, 29-35.
Christen, P., Eppenberger, U. & Rutishauser, G. (1982) Clin. 91. Neumann, S., Gunzer, G., Hennrich, N. & Lang, H. (1984) J.
Chem. 28, 2044-2050. Clin. Chem. Clin. Biochem. 22, 693.
78. Blick, K., Dick, T. & Webb, T. (1982) Clin. Chem. 28, 92. Duswald, K. (ed.) (1983) Zur Pathobiochemie der Leuko-
2373-2377. zyten Elastäse, GIT Verlag Darmstadt.
79. Davies, S. & Gochman, N. (1983) Am. J. Clin. Pathol. 79,
114-119. Privatdozent Dr. Jürgen Bohner
Medizinische Universitätsklinik IV
D-7400 Tübingen
Summary: The introduction of immunohistochemical methods into pathological diagnostics has opened new
possibilities for combining the specificity of immunological methods with the selectivity of morphological
techniques. This considerable expansion of diagnostic possibilities has occurred since the introduction of
monoclonal antibodies. The basic conditions of immunohistochemical reactions (fixation, embedding), funda-
mental differences between the use of monoclonal antibodies and that of polyclonal antisera and possibilities
for increasing the sensitivity of diagnoses are discussed and illustrated by practical examples.
Presented at the Kleinkonferenz „Immunologische Diagnostik" der Deutschen Gesellschaft für Klinische Chemie, Hamburg, Juni
1983.
Fixation
For all research-oriented problems and all known
antigens, the best, most exact and most reliable re-
sults are obtained in cryostat sections after brief fixa- Fig. 1. Immuno-electron microscopic localization of HLA-DR
tion in organic solvents, such s acetone. How well oh an epithelial cell (E) of the thymic cortex. The immune
the structure is preserved depends on the length of reaction is restricted to the outer cell membrane. Lympho*
cyte (L). 5700 x.
fixation time and on the avoidance of artefacts due
to freezing. The shock freezing technique via freon
or arcton s interphase with liquid nitrogen has
proved in practice to be the method that does the
least damage to the tissue. The frozen sections that
are prepared in this manner can be stored at —80 °C
and are fixed with acetone prior to immunohisto- Tab. 1. Comparison of demonstration. of commonly used anti-
chemical staining. This procedure is adequate for gens in paraffin-embedded tissue and in cryostat sections.
most antigens but is not applicable when immunohis-
tochemical procedures are planned for electron mi- Paraffin
Post- stat
croscopy ((5), fig. 1). In this case short-term fixation embedding
with various fixatives, such s glutaraldehyde, para-
formaldehyde and diluted Karnovsky's fixation me- Cell membrane
dium, is applied. This guarantees on the one hand Membrane-antigens and receptors — +
that the structure is preserved quite well, and on the Lectin receptors + +
other hand many of the membrane antigens investi- Cytoplasm
gated so far can be demonstrated. One must, howev- Secretion products
er, expect a loss in sensitivity that varies from anti- Hormones, mucus +— +
gen to antigen. Immunoglobulins + +
Intennediary filaments
Actin, myosin, vimentin, desmin etc. -* -f +
Embedding
Nuclear antigens
Until only a few years ago immunohistochemical e. g. Tdt (Terminal deoxynucleotidyl- ^ +
techniques were held to be unfeasible and unreliable transferase)
ANF (Antinuclear factors) -H· . +
for routine paraffin-embedded material. The dem-
onstration of immunoglobulins on routinely em- Tumour associated antigens
bedded formalin-fixed material (6) was a decisive CEA (Carcinoembryonic antigen) -H +
α-Foetoprotein + -f-
turning point for immunohistochemical diagnostics. etc.
In subsequent years advances were made in diverse
Antibodies
The quality and specificity of immunological demon-
strations depend fundamentally on the type and
quality of antibodies used. The scientific and practi-
cal consequences of the breakthrough achieved with
the introduction of monoclonal antibodies (4) can-
not be appraised yet. There is no doubt that the in-
troduction of these highly specific and pure reagents
has initiated a revolutioü in the field of pathological-
histological and cytological diagnoses. Previously the
naming — recognition and description of the cells of
Fig. 4. Demonstration of the light immunoglobulin chain lambda
a tissue were reserved for a few, particularly expe- in blast and plasma cells of the tonsil on semithin sections
rienced specialists. Now the immunochemical dem- by means of the peroxidase-antiperoxidase (PAP) meth-
onstration of cell-specific, under certain conditions, od. 370 x.
functionally specific, molecules has created possibi- for immunization for the production of monoclonal
lites for bridging the gap between descriptive anato- antibodies are rat and mouse, it is quite conceivable
my and pathology, and the function (fig. 5). Let us that particularly interesting antigenic structures and
briefly discuss a few basic considerations on the anti- determinants in certain experimental Systems, that
genic structure of cell surfaces (14). have already been defined with the aid of polyclonal
antibodies, are not yet demonstrablp with monoclo-
nal antibodies.
Monoclonal antibodies have found particular appli-
cation for the recognition of cell type-specific deter-
minants (16). We can assume that a particular de-
gree of cell type specificity has been achieved when-
ever molecules that are kiiown to be relevant to cell
functions are identified by means of immunohisto-
chemical procedures. When determinant specific
monoclonal antibodies are used, however, we must
expect to find considerable unexpected and func-
tionally irrelevant cross-reactivity and partial anti-
gen associations with other cells and structures. The
reason for this may lie in whät may be called riatüre's
economy principle, in the sense that cellular individ-
uality is not based on one single characteristic anti-
genic determinant, but on a pattern of different anti-
genic structures with variatiöns in their distribution
on the cells (17). This principle is familiär to all of us
from the polyinorphism of the HLA System or the
Kaufmann-White scheme of Salmonella. Why should
nature breach this tested principle when it comes to
cell type specificity?
For the practical demonstration of so-called cell
type-specific determinants by means of monoclonal
antibodies, this means that it is exactly these cross^
reactivities and partial antigen associatons that make
the application of monoclonal antibodies problemat-
Fig. 5. Thymus of a 4 year old boy. T lymphocytes show a posi- ic. Let us explain this briefly in the following diagram
tive immune reaction with the monoclonal antibody
Leu-1. Mature medullar thymocytes react much more (fig. 6). A polyclonal antibody shows definite quan-
strongly than cortical thymocytes do. Some of the latter titative differences in its reactions with cells A, B,
are negative. In the center of the picture a Hassairs body. and C, due to the varying determinant specificity.
Frozen section. 250 x.
These consideratioüs make it clear that the methods
used in conventional immunohistology, naniely, di-
lution to increase specificity, are of no value when
monoclonal antibodies are employed. On the con-
Aetigenic Structure of Cell Surfaces
trary, it is important to recreate the antigen mosaic
When different animal species are immunized, dif- demonstrated here by combining the demonstratiön
ferent antigenic structures are recognized on cell sur- of different antigens via double labelling methods.
faces, depending on which determinants of the cell
surf ace are recognized by the immunized animal spe-
cies äs foreign. If different animal species, e.g., räb-
ImmunohistochemicaE Techniques
bit, sheep, horse and monkey are used for the pro-
duction for antihuman lymphocyte sera, the different Almost äs mumerous äs the available antibodies with
spectra of the antisera reveal a very variable pattern their värying specificities are the immunohistochein-
of reactivity with human lymphocytes and bone mar- ical techniques that are employed; moreover, their
row cells, in spite of the similarity of the immunogen specificity and sensitivity are being constantly in-
and a comparable cytotoxic antilymphocyte titre creased at the same time äs their application is being
(15). Since thus far the only animal species available simplified (18). Fluorescence procedures, which
B
Monoclonal
arvtibody Av
M V
("singte")
Polyclonat
antiserum
("fingerprint")
Fig. 6. Cell type specificity and cross-reactivity äs a problem of immunological cell recognition. In this example of a determinant-specific
reaction the raonoclonal antibody is not able to distinguish between cells A, B, and C, although all 3 cells types have very different
antigen patterns; this is clearly demonstrated by the polyclonal antiserum, which distinguishes the pattern of antigen associations
on the cell membrane.
(Reproducted with permission of Prof. Dr. Dr. W. Müller-Ruchholtz (14)).
were the first to be introduced, are equal to the later followed by a secondary peroxidase-conjugated anti-
peroxidase technique with regard to specificity and body that is directed against the globulin fraction of
sensitivity, but have certain decisive disadvantages. the primary antibody. Further progress was repre-
For instance, specialized microscopy is needed; fresh sented by the peroxidase technique according to
tissues must be used; morphology is poor, and fluo- Sternberger et al. (21), which made peroxidase-anti-
rescent stains are impermanent. For these reasons body conjugation superfluous. In this procedure the
we employ almost exclusively peroxidase and, more sections are incubated with the primary antibody and
recently, alkaline phosphatase immune labelling then with a secondary antibody directed against the
techniques. The evaluations can then be performed globulin fraction of the primary antibody. This Step
under a conventional light microscope, often on pa- is followed by the peroxidase-antiperoxidase com-
raffin sections, and the permanence of the immuno- plex, which must be prepared in the same animal
staining is excellent. Out of the multitude of immu- species äs the primary antibody. For the visualization
nohistochemical techniques let us illustrate here of antigens on frozen sections, we find the indirect
three of the most important methods, which are peroxidase technique to be particularly appropriate,
probably also of the most practical significance and on paraffin sections, the peroxidase reaction ac-
(fig. 7). In the direct peroxidase technique the tissue
is incubated with peroxidase-conjugated antibodies.
The applied antibody combines with the antigen to Pecoxidase.
ant i peroxidase
be demonstrated and, after addition of diaminoben-
zidine äs Substrate, it is visüalized in the form of a
brown reaction product (19). Some disadvantages of Rabbit
antiperoxidase
this simple method are: For each antigen one needs a
Swine
different peroxidase-conjugated antibody. Due to anti- rabbit IgG
the conjugation reaction between antibody and per-
oxidase, some of the antibody denatures and is thus Rabbit ant i-A
less specific for the antigen to be demonstrated. The A B
binding of antibody and peroxidase is never com- Direct Indirect Peroxidase-
antiperoxidase
plete, so that free excess antibody and free peroxi- (PA P)
dase can lead to nonspecific reactions. An increase in
Fig. 7. Diagrammatic representation of antigen demonstration by
specificity, and thus a reduction of background stain- means of the direct immunoperoxidase method, the indi-
ing is made possible by the indirect peroxidase meth- rect immunoperoxidase method and the peroxidasc-an-
od (20). In this method a primary antibody is applied tiperoxidase (PAP) method. antigen.
References
1. Lennert, K. (1983) Verh. Dtsch. Ges. Pathol. 67, XIII- 15. Vogel, S. (1983), Immunmorphologische Untersuchungen an
XXXI. menschlichen Knochenmarkzellen. Darstellung der Antigen-
2. Coons, A. H., Creech, H. J. & Jones, R. N. (1941) Proc. Soc. muster mit verschiedenen Xenoantiseren. Dissertation, Kiel.
Exp. Biol. 47, 200-202. 16. Zola, H. (1980) Pathology 72, 539-557.
3. Coons, A. H. & Kaplan, M. H. (1950) J. Exp. Med. 97, l- 17. Anderson, M. J. D., Müller-Hermelink, H. K. & Müller-
13. Ruchholtz, W. (1984) submitted.
4. Köhler, G. & Millstein, C. (1975) Nature 256, 495-497. 18. Taylor, C. R. (1978) Arch. Pathol. Lab. Med. 702,113-121.
5. Kuhlmann, W. D. (1977) Progress in Histochemistry and 19. Graham, R. C. & Karnovsky, M. J. (1966) J. Histochem.
Cytochemistry, Vol. 10. Nr. l, 1-57. Cytochem. 14, 291-302.
6. Taylor, C. R. & Burns, J. (1974) J. Clin. Pathol. 27, 14-20. 20. Nakane, P. K. & Pierce, G. B., jr. (1966) J. Histochem. Cyto-
7. Taylor, C. R. (1980) J. Histochem. Cytochem. 28, 777-787. chem. 14, 929-931.
8. Mason, D. Y. & Biberfeld, P. (1980) J. Histochem. Cyto- 21. Sternberger, L. A., Hardy, P. H., jr., Cuculis, J. J. & Meyer,
chem. 28, 731-745. H. G. (1970) J. Histochem. Cytochem. 18, 315-333.
9. DeLellis, R. A., Sternberger, L. A., Mann, R. B., Banks, P. 22. Mepham, B. L., Frater, W. & Mitchell, B, S. (1979) Histo-
M. & Nakane, P. K. (1979) Am. J. Clin. Pathol. 77, 483- chem. J. 77, 345-357.
488. 23. Hsu, S. M., Raine, L. & Fänger, H. (1981) J. Histochem.
10. Steinmann, G. & Müller-Hermelink, H. K. (1983) Klin. Pä- Cytochem. 29, 577-580.
diat. 795, 230-233. 24. Falini, B. & Taylor, C. R. (1983) Arch. Pathol. Lab. Med.
11. Kohler, T. (1983) Nachweis der Antigenreaktivität spezifisch 707, 105-117.
absorbierter Antilymphozyten- und Antimakrophagenseren 25. Feller, A. C., Panvaresch, M. R., Waekef, H. H., Radzun, H.
an verschiedenen Geweben bei Ratte und Mensch. Disserta- J. & Lennert, K. (1983) Histochem. J. 75, 557-562.
tion, Kiel. 26. Petrusz, P., Ordronneau, P. & Finley, J. C. W. (1980) Histo-
12. Rodning, C. B., Erlandsen, S. L., Coulter, H. D. & Wilson, I. chem. J. 72, 333-348.
D. (1978) J. Histochem. Cytochem. 26, 223.
13. Stein, H., Bonk, A., Tolksdorf, G., Lennert, K., Rodt, H. &
Gerdes, J. (1980) J. Histochem. Cytochem. 28, 746-760. Prof. Df. H. K. Müller-Hermelink
14. Müller-Ruchholtz, W. (1983) Verh. Dtsch. Ges. Path 67 Pathologisches Institut der Universität Kiel
32-53. Hospitalstraße 42
D-2300 Kiel l >;
By K. Wonigeit
Klinik für Abdominal- und Transplantationschirurgie, Zentrum Chirurgie, Medizinische Hochschule Hannover
Summary: Immunological rejection is still the most important problem in clinical organ transplantation re-
quiring the lifelong immuno-suppressive treatment of the allograft recipient. The clinical success rate however
can be improved by a variety of diagnostic procedures:
a) The reduction of the histocompatibility barrier between donor and recipient by HLA-typing and organ
exchange in order to obtain the best possibie match;
b) posttransplant monitoring of donor specific immune responsiveness towards donor antigens;
c) monitoring of T-cell subsets by monoclonal antibodies and cytofluometry.
T-cell subset monitoring is a rapidly developing new technique with great potential. With the presently availa-
ble first generation reagents already a detailed analysis of the major T-cell population in circulation is possi-
bie, which can markedly facilitate the diagnosis of rejection and viral infection. New monoclonal antibodies,
defining certain activation stages of T-cells or permitting a more refined differentiation of functionally distinct
subsets will leäd to increased relevance of this diagnostic approach. A particulary interesting aspect of mono-
clonal antibodies against T-cell differentiation antigens is their potential therapeutic use äs immunosuppres-
sive drugs with a highly selective action on defined T-cell subsets.
J
) Presented at the Kleinkonferenz „Immunologische Diagnostik" der Deutschen Gesellschaft für Klinische Chemie, Hamburg, Juni
1983.
eine gute Differenzierung zwischen Zellen mit Helferfunktion und zytotoxischen/supprimierenden T-Zellen
möglich. Die Bestimmung des relativen Anteils dieser T-Zell-Subsets im Blut kann die Differentialdiagnose
zwischen Abstoßung und Virusinfektion wesentlich erleichtern. Das zunehmende Verfügbarwerden von mo-
noklonalen Antikörpern, die bestimmte Aktivierungsstadien von Lymphocyten erfassen oder zu einer Ver-
feinerung der Subset-Differenzierung führen, dürfte diesen diagnostischen Ansatz schon bald weiter an Be-
deutung gewinnen lassen. Ein besonders interessanter Aspekt der monoklonalen Antikörpep gegen T-Zell-
Differenzierungsantigene ist ihr therapeutischer Einsatz als Immunsuppressiva mit hochselektiver Wirkung
gegen definierte Lymphocytenuntergruppen.
the cause for the association of certain diseases with For a long time it has been difficult to prove the
particular HLA antigens (4, 5). These aspects of the beneficial effect of matching in unrelated donor re-
HLA System have raised a general interest in the sys- 'dpient combinations. Important reasons for this
tem going far beyond the transplant problem, but were the incomplete knowledge of the HLA System
have also contributed to a better insight into its par- and its enormous polymorphism, rendering it very
ticular role in organ transplantation. difficult to find combinations with füll identity. Only
The technical problems of HLA typing can be re- by an extensive organ exchange between transplant
garded äs essentially solved. The antigens coded for centers has it become possible to achieve a sufficient
by the three class I loci and the DR and DC class H number of good matches and to collect enough data
antigens are typed for by complement-dependent cy- to confirm the beneficial effect, even for the trans-
totoxicity with lymphocytes äs target eells and de- plantation of cadaver kidneys (8—10). In this coun-
fined monospecific typing sera (2). The antisera are try this has been achieved with the help of the Euro-
obtained from immunized human individuals (multi- transplant Organization, in which all transplant cen-
ters in central Europe cooperate. According to the
parous women, transfused patients and transplant
Eurotransplant data, the difference in one year graft
recipients). By this means in many instances com-
survival between fullhouse matches and complete
plete antigen patterns can be obtained. Besides HLA
mismatches is about 20% (8). This means that pa-
typing, histocompatibility testing includes typing for
tients with a fully compatible graft derive true bene-
ABO blood group antigens and screening for the
fit from tissue typing. Because of the enormous po-
presence of cytotoxic antibodies (tab. 1). Before the
lymorphism, however, such excellent matches are
transplantation is actually performed a cross-match
achieved only for a minority of patients, which very
with recipient serum and donor lymphocytes is nec-
much limits the overall influence of HLA matching
essary. In the presence of a positive cross-match with
on the clinical outcome.
a recent serum of the patient the transplantation
should not be performed because hyperacute rejec- The fact that in most patients füll compatibility can-
tion is impending (2). not be achieved raises the question äs to whether
there is a hierarchy in the clinical relevance of anti-
Despite the advanced state of HLA typing the influ-
gens coded for by different loci. For nonsensitized
ence of tissue matching on transplant results is limit-
recipients of first cadaver kidney grafts there is
ed. Nevertheless it is worthwhile to consider what
strong evidence that the HLA-DR antigens are par-
HLA typing can contribute and what the reasons for ticularly important (fig. 1). Therefore matching for
its limited impact are. Clear evidence for the domi- HLA-DR is now generally accepted to rank over
nant role of the HLA System in organ transplanta- matching for HLA-ABC (8, 11). Of particular im-
tion has been derived from kidney transplants per-
formed in living related combinations particularly in
siblings. If siblings share all HLA antigens (two hap-
lotype identity) the organ graft survival is about
1.00
90%, if there is identity for antigens coded for by
one chromosome (orie haplotype identity) this is
75—80% and if there is a two haplotype mismatch it
is the same äs in unrelated combinations (6, 7). 0.80 HLA-DR
mismatches
a>
Tab. 1. Tissue typing for organ transplantation. 1 ( n = 15)
0.60
2 ( n = 167)
1. Recipient
o
a) Typing for ABO
b) Typing for HLA atthetimeofentry
.
c) Screening for HLA antibodies in the waiting list
(indicating presensitization)
2. Donör
t [a]
a) Typing for ABO
b) Typing for HLA Fig. 1. Effect of matching for HLA-DR antigeos on renai allo-
graft survival in 827 patients transplanted under the auspi-
3. Cross-match ces of Eurotransplant (8). All patients received a kidney
(complement-dependent cytotoxic assay with recipient serum from an unrelated cadaveric donor. Compatibility at the
DR löcus (group with 0 mismatches) clearly improves the
and donor lymphocytes)
graft prognosis.
portance are tissue typing and organ exchange for In vitro techniques determining the reactivity of iso-
patients who are sensitized from a previous graft or lated T lymphocytes of allograft recipients against
after blood transfusions. If broadly cross-reactive cultured cells of the graft donor are a suitable tool
antibodies are present it can be very difficult to find for this purpose. By this means it is possible to test
a cross-match negative graft at all. For all available whether the patient's T cell population contains anti-
grafts in an organ exchange network it always has gen-reactive clones against the dojjor antigens and
first to be clarified whether or not the graft can be whether these clones have been stimulated or not.
given to one of the highly immunized patients on the Relevant techniques are the mixed lymphocyte cul-
waiting list. With a suitable transplant the results in ture (MLC) and the direct and indirect cell-mediated
these patients are äs good äs in unsensitized recip- cytotoxicity assay (direct and indirect CMC), In the
ients of first grafts (10). MLC test the proliferative reactivity of recipient T
cells indicates the presenee of T cell clones predomi^
The fact that even HLA identical living related kid-
nantly directed against donor HLA-DR antigens. In-
ney transplants can be immunologically rejected
formation on the state of sensitisation of these clones
clearly points to the relevance of other antigenic Sys-
can be obtained from the kinetics of the prplifefätive
tems in addition to HLA. With the exception of the
response. The indirect cytotoxicity assay demon-
ABO system these antigens are not typed for be-
strates the presence of cytotoxic precursör cell clones
cause they clearly rank below the HLA System in
to donor HLA-A, B, C antigens. Upon Stimulation
clinical relevance. Nevertheless a clear statistical ef-
these precursor cells differentiate in vitro into effec-
fect has been shown for the Lewis antigens (12, 13)
tor cells and can be measured in a cell-mediated cy-
and for accumi^lated differences in other blood
totoxicity assay (51Cr release assay). In vivo sensit-
group Systems (10). On the basis of animal experi-
ments in the mouse it has to be assumed that the ized cells can be measured without previous in vitro
number of non-HLA loci which can function äs his- Stimulation in a direct cell-mediated cytotoxicity as-
tocompatibility loci is very high and probably ex- say using donor target cells.
ceeds one hundred. For the detection of acute rejection the direct cyto-
For the clinical transplantation of heart and liver toxicity assay caii be expected to be the appropriate
even matching for HLA is extremely difficult be- test. Indeed this assay has been demöiistrated to in-
cause these organs cannot be preserved sufficiently dicate the occurrence of differentiated effector cells
long to allow enough time for HLA typing of the in blood in close correlation with the development of
donor before transplantation. In contrast to kidneys acüte rejection episodes (15, 16). However it is dis-
which can be preserved for up to 50 hours the con- puted whether the occurrence of these cells is early
servation time for heart and liver grafts has to be enough to predict impending rejectipn before clinical
below 4 hours. Because there is no artificial Substitu- Symptoms are present. Severe limitations are the re-
tion for these organs such äs haemodialysis for pa- quirement for donor target cells which are difficult to
tients with chronic renal failure, these transplanta- maintain in the cadaver donor Situation, and the
tions always have to be performed urgently. There- complicated nature of the assay which renders it not
fore it is not possible to wait for a well matched do- very useful for routine purposes. Most attempts to
nor. detect activated cells by spontaneous blastogenesis
of peripheral blood lymphocytes have been unsuc-
cessful (17). A promising new approach however is
the use of monoclonal antibodies, which detect dif-
ferentiation antigens present only on activated T
Monitoring of Antigen-Specific T Cell Responses cells (see below).
Since practically all organ grafts are transplanted During periods of clinical quiescence precursor cell
across some major histocompatibility barrier, graft assays are of particular interest because they can
success depends on a delicate balance between im- provide Information about the risk of the patient de-
pending rejection on one side and drug-mediated veloping T cell-mediated immune reactions. Üsing
immunosuppression on the other. Disturbances of the indirect CMC assay it has been possible to show
this balance will either lead to graft damäge by rejec- that a number of patients possessing cytotoxic pre-
tion processes or overimmunosuppression with the cursor cell clones against donor antigens before
risk of severe or even fatal infection. In this Situation transplantation loose these clones several months af-
there is an urgent need for methods monitoring the ter transplantation (18, 19, tab. 2). Interestingly this
reactivity of the recipient's immune System towards does not happen with proliferating helper cell clones.
the antigens of the graft. It is not clear whether this represents clonal deletiön
Tab. 2. Loss of donor-specific cytoioxic prccursor cells in pa- It is now clear that these subsets represent distinct
tients with well tolerated kidney or liver allografts (dcvcl-
opcd by about 50% of patients with a good long tcrm re- differentiation lines of T cells and differ not only in
sult). • function but also in a number of cell surface proteins
which can be used äs subset specific markers. Mo-
T cell response T cell response noclonal antibodies against such "differentiation an-
to donor cells tothirdparty cells tigens" have become the most important tools for
Prolif- Cyto- Prolif- Cyto- the definition of subsets, their quantitative analysis
eration toxicity eration toxicity
and physical Separation (21, 22). Furthermore it is
Before transplantation likely that at least some T cell specific differentiation
After transplantation +++ 0 antigens are involved in the mediation of subset spe-
cific functions (23).
The chemical and functional features of six human T
of the cytotoxic cells, representing some type of par- cell differentiation antigens defined by mouse mo-
tial tolerance, or selective Inhibition of the cytotoxic noclonal antibodies are summarized in table 3. In-
clones by suppressor cells. In any case this antigen- cluded are antigens present only on intrathymic pre-
specific defect shows that the recipient's immune cursors of peripheral T cells (T6), antigens presented
System can adapt to the continued presence of for- on all peripheral T cells but not B cells (T3, TU,
eign histocompatibility antigens. Whereas assays for T12) and finally true subset specific antigens (T4 and
rejection indicate when an increase in immunosup- T8). Originally T4 and T8 were thought to charac-
pressive treatment is required, studies of precursor terize T cells strictly on the basis of function. Recent-
cell activity may indicate whether treatment can be ly it has become clear that they define the class of
reduced or even withdrawn. MHC antigens which restricts antigen recognition by
the particular subset. T4 positive cells are restricted
by class II antigens, T8 positive cells by class I anti-
Monitoring of T Cell Subsets by Monoclonal Anti- gens (24). Since the majority of class II restricted
bodies cells belongs to the helper cell pool and most class I
The analysis of T cell subsets by monoclonal antibo- antigen restricted cells are cytotoxic, the original as-
dies approaches the problem of monitoring T cell sociation with function holds true in most instances.
reactivity at a different level. This most recent diag- A schematic representation of the complex associa-
nostic concept assumes that the development of a re- tion between the specificity of MHC restriction and
jection episode and the effects of immunosuppres- the function of the T4 and T8 subsets is given in fig-
sion are reflected in the T subset composition of the ure 2. Against these and several other T cell antigens
blood. The subset model of the immune System orig- a variety of monoclonal antibodies have been pro-
inally has been based on functional tests which duced in many different laboratories. The availabili-
showed that different T cell functions, such äs helper ty of multiple antibodies detecting the same mole-
or suppressor activity or the capability to kill other cule but reacting with different epitopes and possess-
cells, are mediated by distinct populations of T cells. ing different functions is very useful for analytical
Tab. 3. Human T lymphocyte surface antigens defined by monoclonal antibodies (adapted from Reinherz et al. (23).
against HLA-A, B, C antigens. The aim of post presently in a state of rapid development and can be
transplant monitoring of the immune response is the expected to become increasingly important. Since
diagnosis of rejection by immunological means and the presently available immunosuppressive proce-
the recognition of states of overimmuno-suppression dures to some degree have differential effects on T
and infection. This will render the necessary immu- subsets, this diagnostic approach deals with the im-
no-suppressive therapy both more efficient and less mune System on a level which lendß itself to thera-
dangerous. Relevant procedures are follow up stud- peutic Intervention. T subset-speciric monoclonal
ies of donor-specific immune responses and T sub- antibodies are likely to become therapeutically rele-
set monitoring in peripheral blood using T cell-spe- vant and to permit true subset engineering for the
cific monoclonal antibodies. The latter technique is manipulation of the immune response.
References
1. Bodmer, W. (ed.) (1980) B., Albert, F. W., Ewald, R. W., Sprenger-Klasen, J., Fischer,
The HLA System. M. & Goldmann, S. F. (1981)
Brit. Med. Bull. 34, No. 3. Significance of Lewis and HLA System in kidney transplanta-
2. Albert, E. (1981) tion: A multicenter study in Gerfnany.
Histokompatibilitätstestung und ihre klinische Relevanz, In: Transplant. Proc. 13, 930-933.
Transplantationschirurgie (Pichlmayr, R., ed.). 14. Wonigeit, K. (1981)
Berlin, Heidelberg, New York, pp. 171-203. In: Tränsplantationsimmunologie. (Pichlmayr, R., ed.)
3. Zinkernagel, R. M. & Doherty, P. C. (1979) Berlin, Heidelberg, New York, pp. 29-121.
MHC-restricted cytotoxic T cells: Studies on the biological 15. Stiller, C. R., Sinclair, N. R., Abrahams, S., McGirr, D.,
role of polymorphic major transplantation antigens determin- Singh, H., Howson, W. T. & Ulan, R. A. (1976)
ing T cell restriction specificity and responsiveness. Anti-donor immune responses in prediction of transplant re-
Adv. Immunology 27, 51-177. jection.
4. Benacerraf, B. & Germain, R. N. (1978) N. Engl. J. Med. 294, 978-982.
The immune response genes of the major histocompatibility 16. Grunnet, N. & Kristensen, T. (1978)
complex. Antibody and lymphocyte-mediated Immunologie recipient
Immunol. Rev. 38, 70—119. versus donor reactioris before and after human renal trans-
5. Svejgaard, A., Platz, P. & Ryder, L. P. (1983) plantation — A prospective study.
HLA and Disease 1982 - A Survey. Transplant. Proc. 10, 531-534.
Immunol. Rev. 70, 193-218. 17. Stiller, C. R., Dossetor, J. B., Carpenter, C. B. & Myburgh, J.
6. Brynger, H., Brunner, F. P., Chantier, C., Donckerwolcke, R. A. (1977)
A., Jacobs, C, Kramer, P., Seiwood, N. H. & Wing, A. J. Immunological monitoring of the transplant recipient.
(1979) Transplant. Proc. 9, 1245-1254.
Combined report on regulär dialysis and transplantation in 18. Wonigeit, K. & Pichlmayr, R. (1978)
Europe, X, 1979. In: Dialysis, transplantation, nephrology. Posttransplant monitoring of donor-specific T-cell reactivity
Proc. EDTA, Pitman Medical, London. at the precursor cell level.
7. Opelz, G., Mickey, M. R. & Terasaki, P. L (1977) Transplant. Proc. 10, 563—567.
Calculations on long term graft and patient survival in human 19. Thomas, J., Thomas, F. & Lee, H. M. (1978)
kidney transplantation. Considerations in immunological monitoring of long term
Transplant. Proc. 9, 27—30. transplant recipients.
8. Rood, van J. J., Persijn, G. G., Cohen, B., Landsbergen, Q. & Transplant. Proc. 10, 569—572.
Schurman, R. K. B. (1981) 20. Goulmy, E., Persijn, G., Blokland, E., D'Amaro, J. & van
Eurotransplant-Report 1981, Leiden Niederlande. Rood, J. J. (1981)
9. Festenstein, H., Sachs, J. A., Butterfield, K., Yeatman, N. & Cell-mediated lympholysis studies in renal allograft recip-
Holmes, J. (1981) ients.
Collaborative scheme for tissue typing and matching in renal Transplantation 31, 210-217.
transplantation. XL Role of HLA-A, B, DR and D-matching 21. Kung, P. C, Goldstein, G., Reinherz, E. L. & Schlossman, S.
and other factors on 899 cadaver kidney grafts. F. (1979)
Transplant. Proc. 13, 934-937. Monoclonal antibodies defining distinctive human T-cell sur-
10. Opelz, G. & Terasaki, P. I. (1980) face antigens.
International histocompatibility workshop study on renal Science 206, 347-349.
transplantation. In: Histocompatibility Testing 1980 (Terasa- 22. Reinherz, E. L., Krug, P. C, Goldstein, G. & Schlossman, S.
ki, P. L, ed.) F. (1979)
Los Angeles, p. 592. Further characterization of the human inducer T-cell subset
11. Persijn, G. G., Gabb, B. W., van Leeuwen, A. A., Nagtegaal, defined by monoclonal antibody.
A., Hoogeboom, J. & van Rood, J. J. (1978) J. Immunol. 725, 2894-2896.
Matching for HLA antigens of A, B and DR loci in renal 23. Reinherz, E. L., Meuer, S. C. & Schlossman, S. F. (1983)
transplantation by Eurotransplant. The human T cell receptor: Analysis with cytotoxie T cell
Lancet /, 1278-1281. clones.
12. Oriol, R., Opelz, G., Chun, C. & Terasaki, P. I. (1980) Immunol. Rev. 74, 83—112.
The Lewis System and kidney transplantation. 24. Meuer, S. C., Schlossman, S. F. & Reinherz, E. L. (1982)
Transplantation 29, 397-400. Clonal analysis of human cytotoxic T lymphocytes: T4+ ahd
13. Lenhard, V., Roelcke, D., Dreikorn, K., Wernet, P., Müller, T8+ effector T cells recognize products of different major his-
G., Bockhorn, H., Dorn-Zachertz, D., Wilms, H., Fassbind- tocompatibility complex regions. 4
er, W., Fetta, R. F., Jansen, A. M., Halbfass, H. J., Gümbel, Proc. Natl. Acad. Sei. USA 79, 4345^-4399.
25. Bernard, A., Boumsell, L. & Hill, C. (1984) 31. Mohanakumar, T., Ellis, T. M., Mendez-Picon, G., Goldman,
Joint Report of the First Workshop on Human Leucocyte M. H., Lee, H. M., Muakkassa, W. & Lower, R. (1983)
Differentiation Antigens. Monitoring Human T-cell Subpopulations: Effect of Immu-
In: Leucocyte Typing - Human Leucocyte Differentiation nosuppressicc Therapy and Blood Transfusion on OKT4+/
Antigens Detected by Monoclonal Antibodies. OKT8+ Ratios.
(Bernard, A., Boumsell, L., Dausset, J.t Milstein, C. & Transplant. Proc. 75, 1978-1979.
Schlossman, S. F., eds.) 32. Guttmann, R. G. & Paulsen, R. S. (1983)
Berlin, Heidelberg, New York, Tokyo, pp. 9—142. FACS analysis of lymphocyte subsets after renal transplanta-
26. Melamed, M. R., Mullaney, P. F. & Mendelsohn, M. L., eds. tion: Clinical correlations and evidence for reduced expres-
(1979) sion of antigen density associaled with chronic immunosup-
Flow Cytometry and Sorting. pression.
New York, Toronto. Transplant. Proc. 75, 1962-1965.
27. Valet, G. (1984) 33. Williams, J. M., Christensen, L., Aranjo, J. L., Carpenter, C.
Automated flow-cytometric Identification of colo-rectal tu- B., Milford, E. L., Shapiro, H. M. & Strom, T. B. (1983)
mour cells by simultaneous DNA, CEA-antibody and cell vo- A new Approach to the Monitoring of Kidney Transplant Pa-
lume measurement. tients Via Flow Cytomctric Analysis of T-cell Subsets, Acti-
J. CHn. Chem. Clin. Biochem. 22, 935-942. vation Antigens and DNA Content.
28. Lanier, L. L., Engleman, E. G., Gatenby, P., Babcock, G. F., Transplant. Proc. 75, 1957-1961.
Warner, N. C. & Herzenberg, L. A. (1983) 34. Van Es, A., Baldwin, W. M., Oljans, P. J., Tanke, H. J.,
Correlation of functional properties of human lymphoid cell Ploem, J. S., Van Es, L. A. (1984)
subsets and surface marker phenotypes using multiparameter Expression of HLA-DR on T lymphocytes following renal
analysis and flow cytometry. transplantation, and association with graft rejection episodes
Immunol. Rev. 74, 143—160. and cytomegalovirus infection.
29. Cosimi, A. B., Colvin, R. B., Burton, R. C, Rubin, R. H., Transplantation 37, 65—69.
Goldstein, G., Kung, P. C., Hansen, W. P., Delmonico, F. L. 35. Tilney, N. (1983)
& Russell, P. S. (1981) Treatment of acute rejection with T12 monoclonal antibody.
Use of monoclonal antibodies to T-cell subsets for Immuno- In: Modern Trends in Clinical Immunosuppression (Weimar,
logie monitoring and t reatmen t in recipients of renal allo- W., Marquet, R. L., Bijnen, A. B. & Ploeg, R. J., eds.).
grafts. University Hospital Rotterdam.
New Engl. J. Med. 505, 308-314. 36. Takahashi, H., Okzaki, H., Terasaki, P. L, Iwaki, Y., Kimika-
30. Cosimi, A. B., Burton, R. C, Colvin, R. B., Goldstein, G., wa, T., Taguchi, Y., Chia, D., Hardinidjaja, S., Miura, K.,
Delmonico, F. L., LaQuaglia, M. P.,Tolkoff-Rubin, N., Rub- Ishizaki, M. & Billing, R. (1983)
in, R. H., Herrin, J. T. & Russell, P. S. (1981) Reversal of transplant rejection by monoclonal antiblast anti-
Treatment of acute renal allograft rejection with OKT3 mo- body.
noclonal antibody. Lancet 77, 1155-1158.
Transplantation 32, 535-539.
Dr. med. Kurt Wonigeit
Klinik für Abdominal- und
Transplantationschirurgie
der Medizinischen Hochschule Hannover
Konstanty-Gutschow-Str. 8
D-3000 Hannover 61
By C. Wagener
Summary: The meaningful use of tumour markers for cancer diagnosis depends on the nature of the diagnos-
tic problem, on an adequate definition of positive and negative test results, and on the correct choice of the
patient group. Potential diagnostic applications lie in screening studies, diagnosis in patients with Symptoms,
staging and prognosis, diagnosis of local recurrence and distant metastases, and the monitoring of radio- and
chemotherapy. In quantitative tests, a positive or negative test result may be obtained by the establishment of
reference ranges in control groups, or by longitudinal studies in single patients. Usually, the monitoring of
therapy and the diagnosis of tumour progression are performed by following the concentration pattern of the
marker. When tumour marker determinations are performed in conjunction with other diagnostic tests, the
diagnostic sensitivity or specificity may be increased, depending on the particular test combination. The deter-
mination of tumour markers with limited diagnostic specificity should be performed in groups of patients with
a high prevalence of the disease, e.g. in the postoperative follow-up of patients with a high risk of tumour
recurrence. Tumour markers with high diagnostic specificity are also useful in differential diagnosis.
Diagnostische Empfindlichkeit, diagnostische Spezifität und prädiktiver Wert der Bestimmung von Tumor-
markern
Zusammenfassung: Der sinnvolle Einsatz des Tumormarker-Nachweises im Rahmen der Tumor-Diagnostik
hängt von der Fragestellung, einer adäquaten Definition des positiven bzw. negativen Testergebnisses sowie
von der richtigen Wahl der uiitersuchten Patientengruppe ab. Unter den potentiellen Fragestellungen lassen
sich Screening-Untersuchungen, die Diagnose nach Auftreten von Symptomen, Stadieneinteilung und Pro-
gnostik, Erkennung von lokalen Tumorrezidiven und Fernmetastasen sowie die Überwachung einer Radio-
oder Chemotherapie voneinander abgrenzen. Der Definition eines positiven bzw. negativen Testergebnisses
kann bei quantitativen Tests eine Transversal- und eine Longitudinal-Beurteilung zu Grunde liegen. Die
Abschätzung des Therapieerfolgs und die Diagnose der Progredienz einer malignen Erkrankung beruht in der
Regel auf einer Beurteilung des Konzentrationsverlaufs beim Einzel-Patienten. Durch eine sinnvolle Kombi-
nation des Marker-Nachweises mit anderen diagnostischen Tests lassen sich, je nach Art der Test-Verknüp-
fung, diagnostische Empfindlichkeit oder diagnostische Spezifität erhöhen. Die Bestimmung von Tumor-
markern mit begrenzter diagnostischer Spezifität ist nur in Personengruppen mit hoher Krankheitsprävalenz,
so z.B. im postoperätiven Verlauf von Patienten mit hohem Rezidiv- bzw. Metastasen-Risiko, angezeigt.
Tumormarker mit hoher diagnostischer Spezifität besitzen hingegen auch in der Differentialdiagnose einen
Stellenwert.
luation of a diagnostic test. For any test, data are ciency, and it is given by the proportion of the total
required on diagnostic sensitivity and specificity, on test results that are correctly positive or negative.
the positive and negative predictive values, together These diagnostic test parameters depend strongly on
with the exact conditions under which the data are the known medical history of the investigated group
obtained. In the absence of such Information, it is of subjects. Diagnostic sensitivity is influenced main-
not possible to define those clinical situations in ly by the stage of the malignancy. If fthe stage defini-
which the determination of tumour markers is mean^· tions of a malignancy are well established, then the
ingful, or to recognize those cases in which tumour diagnostic sensitivity can serve äs a üseful test criter-
markers yield no more Information than already pro- ion. Diagnostic specificity, however, can vary be-
vided by established procedures. In the present ac- tween wide limits, depending on the type and com-
count, the diagnostic value of various tumour Position of the control group.
markers is critically evaluated, taking account of the The predictive value of positive or negative resülts is
above test criteria. In this connection, particular at- of particular importatice in screening and in follow-
tention is paid to published investigations, in which up investigations. Predictive values are derived from
the diagnostic test criteria were considered, and the the probability that a positive test result will truly be
exact conditions of the study were reported. associated with a case of illness, or the absence of
illness will be accompanied by a negative result (1).
Since the prevalence of the illness is included in the
Diagnostic Test Criteria, with Special Consideration calculation of the predictive value (fig. 1)^ the latter
of Tumour Markers depends on the ratio of ill to non-ill in the investigat-
ed group. Predictive values calculated from the
The value of a diagnostic test depends on its ability
"Vierfelder table" are only generally applicable if
to differentiate between the clinically normal and
the investigated population is a repräsentative sam-
abnormal, and between different groups of illnesses
ple of the whole. For example, this may be a suffi-
or stages of an illness. The diagnostic relevance of a
ciently large sample of patients, iii which a tümour
test is based on the criteria of sensitivity, specificity
marker is determined postoperatively for the detec-
and efficiency (1) (fig. 1). For a qualitative test, diag-
tion of tumour recurrence. In such investigations
nostic sensitivity represents the probability that the
care müst be taken to ensure that the respective
presence of an illness will result in a positive test re-
stages of the malignancy are correctly recorded.
sult, while diagnostic specificity represents the prob-
ability that the result will be negative in the absence In quantitative methods for the determination of
of a particular clinical condition. The probability of tumour markers, the definition of a positive test re-
achieving a correct test result in a mixed group of sult may be based on a transverse or a longitudinal
normal and ill subjects is called the diagnostic effi- evaluation. For the transverse evaluation, it is neces-
TD P(D) · P(T/D)
Test positive T true positive = TD false positive = TD P(D/T) ·.
TD + TD" pos. Test P(D) - P(T/D) + P(D) · P(T/D)
TD
TD + TD" P(T/D)
. . PfT/r>\
P(T/D)
TD + TD
Sensitivity
TD TD
nf/Dl
1(T/D) P(T/ß)
TD + TD TD + TD
Specificity
Fig. 1. Results matrix and definitions of a qualitative test. Positive and negative predictive values are calculated with the aid of Bayes*
theorem (48).
D: illness present D: illness absent T: test result positive T: test result negative (according to Blittner (1)).
sary to establish a reference ränge within a control other hand, if all possibly affected individuals are to
group. The resulting diagnostic parameters depend be detected, followed by invasive diagnosis, then the
on the composition of the control group and on the ' test combination should possess maximal sensitivity.
Position of the cut-off point. If the cut-off point is Examples of both cases are described below.
raised, the positive predietive value increases, and
there is a decrease in the proportion of false positive
test results; at the same time there is a decrease in
the negative predietive value, and an increased pro- Screening
portion of false negatives. In choosing the reference
Figure 2 shows how diagnostic sensitivity and speci-
ränge, it must be decided whether a false positive or
ficity are influenced by the choice of patient and con-
a false negative test result presents the greater risk
trol groups. This example shows the changes in the
for the patient. The risk depends primarily on the
sensitivity and specificity of the carcinoembryonic
extent to which the therapeutic decision is influenced
antigen (CEA) determination in the course of var-
by the result of the individual test. For example, a
ious investigations between 1969 and 1972. In this
"second look" Operation may be performed if the
particular case, the upper limit of the reference
concentration of a tumour marker increases postop-
ränge corresponds to the normal ränge of 2.5 g/l.
eratively.
According to the data of Thompson et al. (3), the
A quantitative test also becomes a binary test when sensitivity and specificity of the CEA determination
it is used for the longitudinal evaluation of a tumour are almost perfect. During subsequent investiga-
marfcer in individual patients. In this case, a signifi- tions, the sensitivity of the test for colorectal carcino-
cant increase in concentration is recorded äs a posi- ma decreased continually, but there was an increase
tive test result. In contrast to benign illnesses, which in the proportion of elevated CEA values associated
can lead to false positive test results, the malign neo- with non-malignant complaints of the gastrointesti-
plasia shows progressive behaviour. This progression nal tract. It is very apparent that the reason for this
is manifested äs a sustained increase in the serum phenomenon lies in the selection of the patient
concentration of a tumour marker. A longitudinal groups. Advanced colorectal carcinomas almost al-
evaluation therefore permits an earlier recognition ways lead to elevated CEA values. As a rule, howev-
of tumour development than is possible by a trans-
verse study. As a rule, a change in the concentration
of a tumour marker in one patient has greater diag-
nostic sensitivity and specificity than positive ör neg- 100
ative results obtained with the aid of a cut-off point.
The problem lies in the definition of a "significant
concentration increase". so
In the literature there are frequent reports of the B
measurement of various tumour parämeters in cer- Cn
60
tain groups, and the result is considered to be posi-
tive if one of these test results is positive. If the cor-
relation coeffident between the individual tests is
less than unity, then such a linkage of test results in- "
deed leäds to iacreäsed diagnostic sensitivity, where-
as the diagnostic specificity is decreased. Conversely, S 20
the sensitivity is decreased and the specificity in- l
creased if the declaration of a positive result requires 0,0|
that each of the individual tests be positive. Finally, Thomson et öl., Lo Gert o et ., Ohor et öl., Cotloborotive
the combined test results may be considered positive 1969 (3) 1971 (50) 1972 (51) study,
1972 (52)
or negative when eäch of the tests yields a positive or
negative result. The remaining cases are classified äs Fig. 2. Results of the CEA test from various investigations of pa-
inconclusive. In these cases, the final diagnosis must tients with colorectal carcinomas, non-enteric cancers and
non-malignant diseases of the gastrointestinal tract (ac-
be confirmed by invasive procedures, or by further cording to Bodansky (49)).
continuous observations (l, 2). The choice of test
Q colorectal cancer
coinbination depends on the clinical problem. If an
important therapeutic decision rests on the test re- R>3 non-enteric cancer
sult, then maximal specificity is required. On the the [/2 non-malign g^strointestinaJ disease.
er, non-malignant diseases of the gastrointestinal concentration then decreases with a half life of 5—6
tract, e.g. liver cirrhosis, are accompanied by ap- days, which corresponds to the normal half life of
preciable increases of CEA only during the active serum AFP. In contrast, patients with liver carcino-
phases of the illness. ma show a further increase. A positive test result can
therefore be defined äs follows: the AFP concentra-
Consideration of the data on the diagnostic sensitivi-
tion must either exceed 2000 ^/ ^ lie above 50
ty and specificity of the CEA determination, togeth-
g/l with subsequent increases in the course of the
er with the relatively low prevalence of colorectal
disease. Thus, Lehmann & Wegener (10) reported
carcinomas in the normal population, leads to the
that 24 out of 27 cases of hepatocellular carcinoma
conclusion that the CEA determination is not suita-
in a patient collective were diagnosed by AFP deter-
ble for screening purposes. This was confirmed in an
mination (89%), 17 of these before the appearance
Australian field study, which formed part of the
of Symptoms (63%).
"Busselton study" (4). In 1969, serum samples were
taken from about 3500 inhabitants. Ninety percent
of these persons continued to take part in clinical in-
vestigations at regulär intervals. In 1973/74, the
Differential Diagnosis after the Appearance of
CEA concentrations were determined in the sera of
Symptoms
2372 inhabitants, aged 40 and older. The sensitivity
of the CEA determination, i. e. the frequency of pos- For various reasons, CEA determination plays a se^
itive results for patients with malignant tumours, was condary role in the differentiation of malignant tum-
27%, while the specificity was 97%. Since the pre- ours. Colorectal carcinoma must inost frequently be
valence was 1.4%, a positive predictive value of differentiated from benign illnesses of the gastroin-
0.4% can be calculated, i.e. only one in 250 persons testinal tract; but these same benign illnesses are ac^
with a positive test result actually had a malignant companied by a relatively high frequency of false
tumour. Since the CEA determination detects ad- positive increases in CEA concentration (11). This
vanced rather than early tumour stages, it is doubtful means that the CEA test is not sufficieiitly specific to
whether a positive CEA result could have been fol- serve äs a basis for differential diagnosis. By increas-
lowed by effective curative therapy. In summary, the ing the upper limit of the refereiice ränge, the speci-
CEA determination is therefore not suitable for ficity of the diagnosis can be increased, but the de-
screening for malignancies in a normal population. tected tumours are thän predominantly in an ad^
Similar considerations apply to other tumour vanced stage. The CEA test is too insensitive for the
markers, whose diagnostic sensitivity and specificity detection of localized carcinoma of the stoinach,
are comparable to those of CEA. The CEA determi- mammary gland, bronchial tract, ovary and cervix
nation is also unsuitable in a risk group, e. g. hospital (H, 12).
patients (5) or subjects with polyps of the large intes-
Despite the relatively low diagnostic sensitivity of
tine (6) or with colitis ulcerosa (7). This is because
the CEA determination, it may be of value in the
an increased prevalence of disease with a possible
differential diagnosis of those tumours that are slow
increase in diagnostic sensitivity is accompanied by a
to produce Symptoms, and which caniiot be recog-
decrease of diagnostic specificity.
nized by present diagnostic procedure until a late
The only tumour marker that can possibly be consi- stage of development. This is the cäse for carcinoma
dered äs suitable for screening purposes is alpha-foe- of the pancreas. The fange of CEA concentrations in
toprotein (AFP). Taking into account the time diagnosed pancreatic carcinoma is significantly dif-
course of the concentration, and by choosing a suita- ferent from that found in non-maligriant diseases of
ble cut-off point, AFP measurement is relatively the pancreas and gastrointestinal tract (13). For the
specific for liver cell carcinoma (8). In addition, pa- CEA determination to be of special diagnostic value,
tients with liver cirrhosis represent a risk group in however, its sensitivity and specificity should be
which the prevalence of hepatocellular carcinoma is higher than those of other established procedures. In
about 5% according to clinical studies, or 10^-25% a double blind study, the value of the CEA determi-
according to autopsy studies (9). Diagnosis of liver nation in differential diagnosis was studied in pa-
cell carcinoma by serum AFP measurement is, how- tients with suspected pancreatic carcinoma, where
ever, made difficult by the occurrence of intermit- immediate confirmation of the diagnosis had not
tent, short term concentration increases, which are been possible (13) (tab. 1). In three out of nine cases
unrelated to the presence of carcinomas (10). These with later confirmed pancreatic carcinoma, CEA
short term increases do not, however, normally ex- concentrations were markedly eleväted on admission
ceed 2000 §/1. In patients without hepatoma, the to hospital. In these three cases, however, the diag-
Tab. l. Initial plasma CEA level and interval before definite di-
agnosis, in patients suspected of carcinoma of the pan- -, 100
creas (according to the MRC Tumour Products Commit-
tee (13)).
Definite diagnosis
Pancreatitis Carcinoma of Othcr Other non-
or gallstones the pancreas malignancy malignant
disease
Days Initial Days Initial Days Initial Days Initial
to CEA to CEA to CEA to CEA v
(pg/l) diag- ftig/l) diag- ( /1) diag-
nosis nosis nosis nosis
ca.
c
1 13 3 100 7 17 2 23
11 21 7 50 7 82 14 14
120 17 8 191 461 26 23 33
123 8 18 32 un- 36 379 9
164 11 28 14 known Chorio- Invasive Hydatidiform
193 6 28 10 carcinoma mole mole
215 11 90 21
230 11
Fig. 3. Ratio of serum pregnancy specific ßi-glycoprotein to hu-
956 12 man ß-chorionic gonadotropin in patients with chorion-
carcinoma, invasive mole and hydatidiform mole. The
quotient was calculatecl from the concentrations in §/1
(according to Sakuragi (17)).
n = Total patients
nosis was confirmed within a week by other estab- Staging, Diagnosis of Metastases, Prognosis
lished procedures. In those cases that were not diag-
Determination of the stage of neoplastic develop-
nosed until they were more advanced, the CEA de-
ment and the diagnosis of metastases may be based
termination was not sensitive enough for a signifi-
on the result of one type of test, or on a combination
cantly earlier diagnosis. In contrast, the measure-
of various diagnostic procedures. In addition, the
ment of CEA is relatively sensitive for the diagnosis
time course of the concentration of a tumour marker
of medullary thyroid carcinoma, although the deter-
following therapeutic Intervention provides a matrix
mination of calcitonin is riiore sensitive and more
of results. The use of tumour markers for staging and
specific. Since there is a good correlation between
for the diagnosis of metastases is closely related to
these two tests, the CEA determination does not ap-
their importance in prognosis.
pear to be capäble of yielding any essentially new
Information (14). In patients with colorectal carcinoma, there is a sig-
As already mentipned, the determination of AFP is a nificant positive correlation between the preopera-
useful aid to the diagnosis of hepatocellular carcino- tive CEA concentration and the spread of the carci-
ma. On the other band, germ cell tumours of the noma. Between Dukes' stages -D, there is an in-
testes are diagnosed clinically by the local swelling. crease in the concentration of CEA and an increase
The specific determination of human chorionic go- in the proportion of cases showing elevated CEA.
nadotropin (HCG) has long been used for the diag- Thus a relationship exists between preoperative
nosis of hydatidiform mole and chorioncarcinoma CEA concentrations and the prognosis. The higher
(15). These two malignancies can be differentiated the concentration ränge, the higher the proportion of
from one aiiother by the determination of pregnan- patients with tumours in an advanced stage of devel-
cy-specific ß-1 glycoprotein (SP-1) and HCG (16) or opment (20—22). According to recent studies, how-
the fcsubimit of HCG (17) (fig. 3). In chorioncarci- ever, CEA concentrations within each Dukes' stage
noma, the cpnceiitration of HCG-ß- is higher than have little or no additional prognostic importance
that of SP-1, whereas the converse is true for hydati- (23—25). By determination of the time course of
diform mole. The fact that the SP-1/HCG-ß ratio in- CEA concentrations directly after surgical removal
creases during pregnancy indicates that the change in of colorectal carcinomas, we were able to distinguish
ratio is the result of an altered differentiation of the between patients with CEA-secreting residual tum-
cells of the trqphoblast (17). ours and those in which CEA-producing tissue had
been removed, or in which no preoperative CEA in- the diagnostic sensitivity of such a combination will
crease had been found (26). It was shown that CEA be lower than that of the single test. Thus, the diag-
concentrations greater than 20 \ig/l can also be nostic sensitivities are 42.1% + 14.0% = 56.1% for
caused by the resectable primary tumour. We eon- the CEA determination, and 42.1% + 36.8% =
cluded from this that, after elimination of patients 78.9% for liver scintigraphy, but only 42.1% for the
with CEA-producing residual tumours, even a high test combination (fig. 4). The consequence of com-
CEA serum concentration need not mean a poor bining individual tests in this way is that fewer fälse
prognosis. This relationship has meanwhile been diagnoses are made, but the diagnosis at first re-
confirmed by Persijn & Hart (24). If cases revealing mains uncertaui for a larger number of patients.
a residual tumour during Operation are excluded These uncertain diagnoses must then be resolved by
from the follow up, there is no longer a significant further time course observations and/or alternative
correlation between the preoperative CEA concen- diagnostic procedtires.
trations and the frequency of tumour recurrence. For Preoperative measurement of AFP and HCG makes
tumours sited away from the rectum or colon, how- a decisive contribution to the clinical staging of jion^
ever, CEA concentrations 8—10 fold higher than the seminomatoüs germ cell tumours of the testes (30).
upper limit of the normal ränge indicate, with a high The importance of the determination of these tu-
degree of certainty, the presence of an extensive, mour markers is, however, relative, if staging is based
non-operable residual tumour or distant metastases on pathological-anatomical criteria (31). This rela-
(27, 28). tionship is shown in täble2, where it is seen that
Measurement qi CEA can serve äs a valuable sup- staging was improved by the determination of
plement to other procedures for the diagnosis of me- markers only in stage A. As the tumour progressed
tastases. In this connection, one study shoüld be not- further, all cases showed tumour-associated in-
ed in which the combination of CEA measurement creases in the conceiiträtion of the tumour markers.
and liver scintigraphy, showed a markedly higher On the other hand, the AFP and HCG concentra-
positive predictive value than the single test (29) tions are relatively insensitive indicators in the early
(fig. 4). The result was counted äs positive if both stages of lymph gland metastasis.
tests were positive. The positive predictive value of The existence of residual tumours and/or distant me-
scintigraphy was 75%, and that of the CEA determi- tastases, following therapeutic Intervention, can also
nation was 64%, whereas the combination of the two be diagnosed by moiiitoring the time course of the
resulted in a value of 100%. It is to be expected that concentration of a tumour marker, providing the
45/60 == 75%
S (60) D (45)
32/50 = 64%
CEA (50)
24/57 = 42,1% 24/24 = 100%
D (57) - S, CEA (24)
8,(3 (36)
Not classified
S, CEA (26)
30
S(317) ^7'^. 6(305)
Fig. 4. Diagnosis of liver metastases by liver scintigraphy (S) and CEA measurement (CEA). The iipper limit of the CEA reference
ränge was 3.6 times higher than the upper limit of the normal ränge. The presentation is according to Büttner (2), using data from
McCartney & Hoffer (29).
D: liver metastases confirmed in course of the illness. D: no liver metastases in follow-üp period. Si.positive scintigram S:
negative scintigram CEA: positive CEA test CEA: negative CEA test.
Tab. 2. Frequency of elevated levels of human chorionic gonado- Diagnosis of Tumour Recurrences
tropin (HCG) and alpha-foetoprotein (AFP) in serum
samples obtained after orchiectomy but immediately be- After resection of a carcinoma, the rationale of rec-
fore any other therapy in 142 patients with non-semi- ognizing renewed tumour growth is similar to that of
nomatous germ cell tumoursa (according to Skinner &
Scardino (31)). a screening investigation in a highly selected popula-
tion with a high frequency of illness; in patients with
Stageb No.of HCG AFP Either resectioned colon carcinoma, for example, this fre-
patients (%) (%) (%) quency is 30 to 40%. On the basis of this high fre-
quency of illness, the predictive value of a positive
A 67 7 9 10
Bl 15 29 33 50 tumour marker test is markedly higher than in a nor-
B2 23 52 43 64 mal population or in patients with questionable diag-
B3 6 83 75 100 noses. The result may be based on an individual test
C 31 84 60 93 or a combination of different tests, depending on the
clinical problem and the therapeutic consequences.
8
These figures represent data collected since 1973 ftom a com- In both cases, the decision äs to whether a result is
bined group of patients treated at the Walter Reed Army Medi- positive or negative depends on the reference ränge,
cal Center, the National Cancer Institute and UCLA.
b
Stage A: disease confined to the scrotum. which is established by a transverse study. Alterna-
Stage B1: metastases to <6 retroperitoneal nodes with no node tively, a result may be designated negative or posi-
>2cm in diameter. tive on the basis of the time course of the marker
Stage B 2: metastases to ^6 retroperitoneal nodes or any me-
tastases >2cm in diameter. concentration in one particular patient. In this con-
Stage B 3: bulk abdominal disease. nection, for the purpose of comparing different in-
Stage C: metastases above the diaphragm or to the viscera (liv- vestigations, it is essential to establish the exact crite-
ria for a concentration increase.
The technique used by Martin et al. (38) for the de-
termination of a CEA increase takes into account
the variance of the method. Intra- and interassay
variance of the CEA determination were determined
same marker was elevated before the onset of ther- in 9 different concentration ranges between l and 10
apy. For tumour markers with a known biological |ig/L These values were recorded on a nomogram
half life and a uniform pattern of elimination, a de- with calibration marks for the average value and the
layed decrease can be distinguished from a non-de- 95% confidence interval. If a significantly increased
layed decrease in concentration. At the moment this value is measured, then both samples are analysed
is possible only for AFP (32). For other markers, a again in a single assay. Thus, alterations of concen-
complete fall in concentration is generally consi- tration due to methodical variance are largely ex-
dered to be a negative result, and an incomplete de- cluded. Alterations of CEA concentration caused by
crease is counted äs positive. non-malign conditions are not, however, excluded
by this method.
Contradictory data have been reported for the speci-
ficity of the post-therapy diagnosis of residual tum- Steele et ai. (25) estimated the CEA increase by a
ours and/or distänt metastases by monitoring the slope analysis, using at least four determiiiations to
time course of tujnqür markers. Many authors con- calculate the slope. The logarithms of CEA concen-
sider a complete or -delayed decrease in marker trations are plotted against time, and the average
concentration tö be relatively certain evidence for monthly concentration increase can be calculated
the complete elimination of tumour cells (32-34). from the slope of the regression line. This method
According to other stüdies, however, the diagnostic permits an exact retrospective, statistical evaluation,
specificity of a non-delayed ör complete concentra^ and provides a. quantitative assessment of malignant
tion decrease is relatively low (35—37). growth. For diagnostic purposes and for therapeutic
A decrease in CEA concentration to a stable but ele- decision making, however, a relatively long time is
vated level may be observed when a non-malign ill- required to obtain the positive test result. Other
ness is also present (36). The absence of any de- workers regard the result äs positive if at least two
crease, or an incomplete decrease of CEA with a suecessive analyses show concentrations outside the
subsequent rise is, on the other hand, relatively cer- normal ränge (39), or if one value is several fold
tain evidence of a residual tumour (33). There is a higher than the upper limit of the normal ränge (40).
lack of agreement on the diagnostic value of an ex- More complicated definitions of a concentration in-
tended AFP half life (32, 35). crease are also used (21, 24).
The diagnostic value of a postoperative CEA in- tively low, especially if the possibility of a second-
crease can be assessed from the results of two colla- look-operation is considered. In the quoted study,
borative studies using a large number of cases, the positive predictive value was, however, markedly
shown figure 5. Despite different working definitions decreased by basing a positive test result on a single
for the positive test result, the results of the two stu- CEA concentration, instead of ä concentration in-
dies compare well with each other. The study repre- crease. The predictive value was decreased, eveii if
sented in figure 5a was based on the äverage month- the elevated concenträtion was more than four fold
ly increase in CEA (25), and was limited to patients higher than the upper limit of the normal ränge.
at Dukes' stages B2 and C, i.e. a high risk group for
tumour recurrence. A positive test result was re- In the study represented in figure 5b, the test result
corded if the average CEA increase was greater than was positive if at least one postoperative CEA value
3% per month. The diagnostic parameters are calcu- was 3.2 times higher than the upper limit of the nor^
lated from the "Vierfelder table". At 66.4%, the mal ränge (40). The number of cases is similar to
positive predictive value of the CEA increase is rela- that in the previpus investigation. Here also, the pre-
Recurrence Np recurrence
104
Monthlyrise>3% 104 52 P(D/T) 66,7%
"156"^
388
Monthlyrise^3% 55 388 P(D/f) 87,6%
443
104
P(T/D)= — = 65,4%
——
—
388
88,2%
Recurrence No recurrence
TD + TD 398
N -468~ 85 ' 0/ ° !
P(T/D) = ^ = 54%
Fig. 5. Diagnostic sensitivity, specificity and efficiency, and the predictive value of the CEA concentration rise for the recognition of
tumour recurrence in patients with colorectal carcinoma.
a) Data from Steele et al. (25) for patients with colorectal carcinoma at Dukes* stages B2 and C. .
b) Data from Täte (40). .-
dictive value of the positive test result is lower than sult becomes a factor of major importance in the es-
70%, whereas the predictive value of the negative timation of the diagnostic value. In this case, the pro-
test result is approximately 90%. For more than half ' portion of false positive test resuits is critical. If,
the patients with tumour recurrence, the elevated however, a test or test combination is required that
CEA concentration was the first indicator that the will detect the greatest possible proportion of pa-
disease was still present. tients with tumour recurrence, then the negative pre-
There is no disagreement that the increase of CEA dictive value is critical. In the latter Situation, the
in a certain percentage of the patients is an earlier Proportion of false negative test resuits should be
indicator of relapse than other diagnostic measures kept äs low äs possible. On the other hand, the false
or subjective Symptoms. With few exceptions, no positive resuits can be tolerated, because the diagno-
causal therapy is so far available for distant metasta- sis can be confirmed by invasive procedures, or by a
ses of colorectal carcinoma. The time between an in- more exact monitoring of the patient. This is demon-
crease of CEA concentration and the diagnosis of a strated below by an example (tab. 3; (44)). A test
local recurrence is therefore of special importance. combination is required for the detection of distant
A local recurrence is more amenable to surgery than metastases, following the Operation for mammary
distant metastases. According to the data of Persijn carcinoma. The tests should impose äs little strain äs
& Hart (24), about one quarter of local tumour re- possible on the patients, and be capable of the earli-
currences were first detected by an increased CEA est possible detection of the highest possible percen-
concentration. tage of distant metastases. Table 3 shows the resuits
of individual tests in cases of diagnosed distant me-
The question arises äs to whether a second-look-op- tastases. With respect to diagnostic specificity, the
eration should be performed with the aim of resec- CEA determination is superior to all other methods.
tioning the residual tumour, solely on the basis of an At least one of the tests marked with an asterisk was
increased CEA concentration. In other words, what positive for 46 out of 47 patients with distant meta-
is the predictive value of the CEA concentration in- stases. In one half of the cases, the positive test result
crease äs the first objective indication of a local tu- was obtained 3 months or more before the conclu-
mour recurrence in the absence of distant metastases? sive clinical diagnosis. The and/or linkage of individ-
The most optimistic study reported so far is by Min- ual tests should result in a relatively low specificity
ton & Martin (41). In 40 patients showing preopera- for the positive test result. Nevertheless, false posi-
tive elevated CEA concentrations, which became tive resuits were recorded for only 3.5% of the pa-
normalized after surgery, a second-look-operation tients. There are two reasons for this:
was subsequently performed solely on the basis of an
increased CEA concentration. CEA was determined 1. the upper limit of the CEA reference ränge was
three times higher than the normal ränge, and
at three monthly intervals in 22 patients, and at
monthly intervals in 18 patients. The concentration 2. the group in question is a very high risk group
increases were confirmed by use of the previously with a metastasis prevalence of 33%.
mentioned nomogram. The positive predictive value
of a CEA increäse for a local relapse was 48%. In Tab. 3. Abnormal biochemical and physical tests of first presen-
tation with metastases in 47 patients with breast cancer
other studies, the predictive values for a local relapse (according to Coombes et al. (44)).
are, however, much lower. The value of 7% from the
No. abnormal
investigations of Mach et al. (42) is comparable with Test
the resuits of Persijn & Hart (24). In the latter study, Biochemical tests
an increäse of CEA at least 200 days before diagno- Erythrocyte Sedimentation rate 5/31(16%)
sis of a local relapse showed a predictive value of -Glutamyl transpeptidase 9/30 (30%)*
5%. The positive predictive value for a local relapse AJkaline phosphatase 15/46(32%)'
16/36(44%)*
CEA
may possibly be increased by slope analysis (43). Hydroxyproline 8/32 (25%)
Distant metastases are more frequently accompan- Physical tests
ied by steep cöncentration increases, whereas the in- Clinical examination 19/47(40%)*
crease for a local relapse tends to be more graduaL Chest X-ray 19/44 (43%)'
Bone scan 15/44 (34%)
In a cömparison of patients with slow and steep CEA 3/30(10%)
Liver scan
concentration increases, Wood et al. (39) reported Liver ultrasound 4/26(15%)
twice äs many cases of relapse in the former group. Skeletal survey 13/38(34%)
Bone-marrow aspirate 7/34(21%)
If, äs in the last example, a serious therapeutic deci-
sion must be made on the basis of a single diagnostic * Combination of these tests would have detected metastases in
test, then the predictive value of the positive test re- 46/47 patients.
10 12
t[months]
Fig. 6. Time course of serum concentrations of alpha-foetoprptein and human chorionic gonadotropin in a pätient with non-seminomat-
ous germ cell tumour (from Lange et al. (47)).
(1) Radical orchiectomy,
(2) retroperitoneal lymphadenectomy,
(3) start of chemotherapy,
(4) change of chemotherapeutic regime
References
1. Büttner, J. (1977) J. Clin. Chem. Clin. Biochem. 75, 1-12. 26. Wagener, C., Müller-Wallraf, R., Nissen, S., Gröner, J. &
2. Büttner, J. (1982) J. Clin. Chem. Clin. Biochem. 20, 477- Breuer, H. (1981) J. Natl. Cancer Inst. 67, 539-547.
490. 27. Myers, R. E., Sutherland, D. J., Meakin, J. W., Kellen, J. A.,
3. Thomson, D. M. P., Knipey, J., Freedman, S. O. & Gold, P. Malkin, D. G. & Malkin, A. (1978) Cancer 42,1520-1526.
(1969) Proc. Natl. Acad. Sei. USA 64, 161-167. 28. Braun, P., Hildenbrand, G., Izbicki, J. & Leyendecker, G.
4. Cullen, K. J., Stevens, D. P., Frost, M. A. & Mackay, I. R. (1981) Arch. Gynecol. 230, 263-273.
(1976) Aust. N. Z. J. Med. 6, 279-283. 29. McCartney, W. H. & Hoffer, P. B. (1976) J. Am. Med. As-
5. Frost, M. A. & Coates, A. S. (1976) Med. J. Aust. /, 950- soc. 236, 1023-1027.
953. 30. Scardino, P. T., Cox, H. D., Waldmann, T. A., Mclntire, K.
6. Doos, W. G., Wolff, W. L, Shinya, H., DeChabon, A., R., Mittemeyer, B. & Javadpour, N. (1977) J. Urol. 118,
Stenger, R. J., Gottlieb, L. S. & Zamcheck, N. (1975) Cancer 994-999.
36, 1996-2003. 31. Skinner, D. G. & Scardino, P. T. (1980) J. Urol. 723, 378-
7. Rule, A, H., Goleski-Reilly, C, Sachar, D. B., Vandevoorde, 382.
J. & Janowitz, H. D. (1973) Gut 14, 880-884. 32. Kohn, J. (1979) In: Carcino-Embryonic Proteins, Vol. II
8. Ruoslahti, E. & Seppälä, M. (1979) Adv. Cancer Res. 29, (Lehmann, F. G., ed.), pp. 383-386. Elsevier/North-Hol-
275-346. land Biomedical Press, Amsterdam/New York/Oxford.
9. Lehmann, F. G. & Wegener, T. (1979) In: Carcino-Embry- 33. Mach, J.-P., Jaeger, P., Bertholet, M.-M., Ruegsegger, C.-H.,
onic Proteins, Vol. I (Lehmann, F. G., ed.) pp. 233-245. Loosli, R. M. & Pettavel, J. (1974) Lancet 77, 535-540.
Elsevier/North-Hoöand Biomedical Press, Amsterdam/New 34. Mann, K., Lamerz, R., Hellmann, T., Kümper, H. J.,
York/Oxford. Staehler, G. & Karl, H. J. (1980) Oncodev. Biol. Med. 7,
10. Lehmann, F. G. & Wegener, T. (1979) In: Carcino-Embry- 301-312.
onic Proteins, Vol. I (Lehmann, F. G., ed.) pp. 219-231. 35. Willemse, P. H. B., Sleijfer, D. T., Schraffordt Koops, H., De
Elsevier/North-Holland Biomedical Press, Amsterdam/New Bruijn, H. W. A., Oosterhuis, J. W., Brouwers, T. M., Ock-
York/Oxford. huizen, T. & Marrink, J. (1981) Oncodev. Biol. Med. 2,
11. Hansen, H. J., Snyder, J. J., Miller, E., Vandevoorde, J. P., 129-134.
Miller, O. N., Hines, L. R. & Burns, J. J. (1974) Hum. Pa- 36. Sorokin, J. J., Sugarbaker, P. H., Zamcheck, N., Pisick, M.,
thol. 5, 139-147. Kupchik, H. Z. & Moore, F. D. (1974) J. Am. Med. Assoc.
12. Hirai, H. (1977) Cancer Res. 37, 2267-2274. 225; 49-53.
13. MRC Tumour Products Committee (1980) Br. J. Cancer 41, 37. Reynoso, G. & Keane, M. (1979) In: Immunodiagnosis of
976-979. Cancer, Vol. I (Herberman, B. R. & Mclntire, K. R., eds.),
14. Calmettes, C, Talbot, J.-N., Moukhtar, M. S. & Milhaud, G. pp. 239-254, Marcel Dekker, New York/Basel.
(1979) In: Carcino-Embryonic Proteins, Vol. II (Lehmann, 38. Martin, E. W., James, K. K., Hurtubise, P. E., Catalano, P. &
F. G., ed.) pp. 787-790. Elsevier/North Holland Biomedical Minton, J. P. (1977) Cancer 39, 440-446.
Press, Amsterdam/New York/Oxford. 39. Wood, C. B., Ratcliffe, J. G., Burt, R. W., Malcolm, A. J. H.
15. Goldstein, D. P. (1976) Cancer 38, 453-459. & Bluragart, L. (1980) Br. J. Surg. 67, 46-48.
16. Lee, J. N., Salem, H. T., Al-Ani, A. T. M., Chard, T., Huang, 40. Täte, H. (1982) Br. J. Cancer 46, 323-330.
S. C., Ouyang, P. C, Wei, P. Y. & Seppälä, M. (1981) Am. J. 41. Minton, J. P. & Martin, E. W. (1978) Cancer 42, 1422-
Obstet. Gynecol. 139, 702-704. 1427.
17. Sakuragi, N. (1982) Gynecol. Oncol. 13, 393-398. 42. Mach, J.-P., Vienny, H., Jaeger, P., Haldemann, B., Egely, R.
18. Goslin, R., Steele, G., Macintyre, J., Mayer, R., Sugarbaker, & Pettavel, J. (1978) Cancer 42, 1439-1447.
P., Cleghorn, K., Wilson, R. & Zamcheck, N. (1980) Ann. 43. Staab, H. J., Anderer, F. A., Stumpf, E. & Fischer, R. (1978)
Surg, 792, 747-751. Amen J. Surg. 736, 322-327.
19. Zamcheck, K, Doos, W. G., Prudente, R., Lurie, B. B. & 44. Coombes, R. C., Gazet, J.-C., Ford, H. T., Powles, T. J.,
Gottlieb, L. S. (1975) Hum. Pathol. 6, 31-45. Nash, A. G., McKinna, A. & Neville, A. M. (1980) Lancet 7,
20. Wanebo, H. J., Rao, B., Pinsky, C. M., Hoffcnan, R. G., 296-298.
Stearns, M., Schwarte, M. K. & Oettgen, H. F. (1978) N. 45. Lokich, J. J., Zamcheck, N. & Lowenstein, M. (1978) Ann.
Engl. J. Med. 299, 448-451. Intern. Med. 89, 902-906.
21. Chu, T. M., Lavin, P., Day, J., Evans, J. T., Mittleman, A., 46. Lamerz, R., Leonhardt, A., Ehrhart, H. & v. Lieven, H.
Holyoke, E. D. & Vincent, R. (1979) In: Carcino-Embryonic (1980) Oncodev. Biol. Med. 7, 123-135.
Proteins, Vol. I (Lehmann, F. G., ed.) pp. 55—64. Eisevier/ 47. Lange, P. H., Mclntire, K. R., Waldmann, T. A., Hakala, T.
North-HoJland Biomedical Press, Amsterdam/New York/ R. & Fraley, E. E. (1976) N. Engl. J. Med. 295,1237-1240.
Oxford. 48. Bayes, T. (1763) Philos. Trans. R. Soc. London 53, 370-
22. Staab, H. J,, Anderer, F. A., Briimmendorf, T., Stumpf, E. & 418.
Fischer, R. (1981) Br. J. Cancer 44, 652-662. 49. Bodansky, O. (1974) Cancer 33, 364-370.
23. Beatty, J. D., Romero, C., Brown, P. W., Lawrence, W. & 50. Lo Gerfo, P., Krupey, J. & Hansen, H. J. (1971) N. Engl. J.
Terz, J. J. (1979) Aren. Surg. 114, 563-567. Med. 285, 138-141.
24. Persijn, J. P. & Hart, A. A. M. (1981) J. Clin. Chem. Clin. 51. Dhar, P., Moore, T., Zamcheck, N. & Kupchik, H. Z. (1972)
Biochem. 19, 1117-1123. · J. Am. Med. Assoc. 227, 31-35.
25. Steele, G., Ellenberg, S., Ramming, K., O'Connell, M., 52. A collaborative study of a test for carcinoembryonic antigen
Moertel, C-* Lessner, H„ Bruckner, H., Horton, J., Schein, (CEA) in the sera of patients with carcinoma of the colon and
P., Zamcheck, N., NoVak, J. & Holyoke, E. D. (1982) Ann. rectum (1972) Can. Med. Assoc. J. 107, 25-33.
Surg. 796, 162-169.
Priv.-Doz. Dr. C. Wagener
Institut für Klinische Biochemie
der Universität
Sigmund-Freud-Straße 25
D-5300 Bonn l